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2ABSTRACT
ABSTRACT
Natriuretic peptides are a family of vasoactive hormones that play important roles in 
cardiovascular  homeostasis.  These  peptides  exert  biological  effects  primarily  via 
activation  of guanylate  cyclase  (GC)-coupled  natriuretic  peptide  receptors  (NPR) 
that  generate  the  intracellular  messenger  cyclic  guanosine  3',5'-monophosphate 
(cGMP).  Activation  of the  cytosolic  GC  by  NO  is  well-established  to  mediate 
cGMP-dependent,  anti-atherogenic  effects;  however,  an  analogous  cytoprotective 
role  for  natriuretic  peptides  has  yet  to  be  fully  elucidated.  Since  many 
cardiovascular  disorders  (e.g.  atherosclerosis,  septic  shock)  are  now  accepted  as 
inflammation-based diseases, identification of potential roles for natriuretic peptides 
in regulating vascular inflammation might assist in the prevention and treatment of 
cardiovascular pathology.
The  studies  described  in  this  thesis  investigated  the  hypothesis  that  natriuretic 
peptides  (i.e.  atrial  natriuretic  peptide  [ANP],  C-type  natriuretic  peptide  [CNP]) 
affect pro-inflammatory protein expression (i.e.  inducible NO synthase, iNOS) and 
cell proliferation via activation of GC-linked NPR.
Herein, it is demonstrated that in NPR-A knockout mice, iNOS expression and NO 
production in response to intravenous administration of bacterial lipopolysaccharide 
is significantly reduced compared to wild-type controls; this difference is mirrored in 
the  ex  vivo  functional  reactivity of vessels  from  such  animals.  However,  neither 
ANP  nor CNP  were  able  to  alter  iNOS  expression  or NO  production  in  vitro  in 
RAW264.7 murine macrophages or primary rat aortic smooth muscle cells.  CNP, 
but not ANP, transiently enhanced phosphorylation of extracellular signal-regulated 
kinase  (ERK)l/2.  CNP-induced  ERK  1/2  phosphorylation  was  blocked  by  the 
selective ERK  1/2  inhibitor PD98059, the Gj-protein inhibitor Pertussis toxin,  and 
the  selective  NPR-C  antagonist  M372049.  Accordingly,  CNP  inhibited  vascular 
smooth muscle proliferation in a PD98059- and M372049-reversible manner.
These  observations  suggest  that  part  of  the  anti-atherogenic  profile  of  CNP  is 
mediated  via  NPR-C,  Gj-dependent  ERK  1/2  phosphorylation  and  inhibition  of 
vascular smooth muscle proliferation.  Moreover,  my findings  identify a potential 
pro-inflammatory role for ANP/NPR-A-dependent signalling in vivo.
3ACKNOWLEDGEMENTS
ACKNOWLEDGEMENTS
This thesis maiks the end of a long and inquisitive journey, for which there are many 
people  that  I  wish  to  acknowledge  for  their  support  along  the  way.  First  and 
foremost I would like to thank my supervisor Dr Adrian Hobbs who has provided me 
with  guidance,  encouragement  and  an  endless  resource  of ideas,  especially when 
things were not going to plan.  His patience, despite my many, many questions, is 
greatly appreciated.  Adrian, I could not have imagined having a better advisor and 
mentor for my PhD, I would have been lost without you.  Thanks  for sharing your 
wealth of knowledge with me.  I would also like to thank my second supervisor, Prof 
John Garthwaite, to whom I am very grateful  for his ideas and support throughout 
the course of this work.
I thank a11 the people, past and present,  in the pharmacology wing at the Wolfson 
Institute for being my friends, advising and encouraging me  for the best part of 4 
years.  Special thanks to Neale Foxwell for all his technical support and advice, and 
to the Wellcome Trust for providing the financial backing for this project.
A big thank you to Carl Boadu-Seddoh for his endless love and surviving this trial 
with me.  I would not have made it without you to make me laugh  and keep me 
happy.
Finally I would like to thank my family.  My brother, Matthew, who kept reminding 
me that it was my own choice to do a PhD and for being my last minute proof reader, 
dropping  everything at a moments notice to  cross  out,  slash and comment on this 
manuscript.  My Godparents, Koulla and Stelios Pantazides, for opening their door 
to me and being my surrogate parents when I was  far away from the comforts of 
home.  Without you I would not have survived my time in London.  Lastly, but not 
least my parents,  George and Yiola,  for instilling in me the  importance of a good 
education.  Their support has been unconditional all these years at each turn of the 
road and they have given up many things for me to be where I am today.  Much of 
my life I have been to them like this thesis has been to me, troublesome.  I love you 
both very much.
4PUBLICATIONS
PUBLICATIONS
Work described in this thesis has given rise to the following manuscripts:
1.  Inmaculada  C.  Villar,  Catherine  M.  Panayiotou,  Adil  Sheraz,  Melanie 
Madhani,  Ramona S.  Scotland,  Muriel Nobles, Barbara Kemp-Harper, Amrita 
Ahluwalia  &  Adrian  J.  Hobbs  (2007).  Definitive  role  for  natriuretic  peptide 
receptor-C in mediating the vasorelaxant activity of endothelium-derived C-type 
natriuretic peptide.  Cardiovasc. Res., 74:515-525
2.  Catherine M.  Panayiotou & Adrian J.  Hobbs (2007).  Regulation of vascular 
smooth muscle proliferation by C-type natriuretic peptide: Key role for NPR-C 
mediated ERK 1/2 phosphorylation.  (In preparation for publication).
3.  Martin  L.  Marro,  Concepcion  Peiro,  Catherine  M.  Panayiotou  &  Adrian  J. 
Hobbs  (2007).  Characterisation of human  ai  and  pi  soluble  guanylyl  cyclase 
promoter: key factors regulating expression in human aortic smooth muscle.  (In 
preparation for publication).
4.  Catherine M. Panayiotou, Ray Stidwill, Val Taylor, Mervyn Singer & Adrian 
J. Hobbs (2007).  NPR-A gene deletion reverses vascular dysfunction associated 
with sepsis.  (In preparation for publication)
5TABLE OF CONTENTS
TABLE OF CONTENTS
TITLE___________________________________     1
DECLARATION OF OWNERSHIP_______________________ ...... 2
ABSTRACT..__________________         3
ACKNOWLEDGEMENTS------------------------------------   — ..............4
PUBLICATIONS______________________________________     5
TABLE OF CONTENTS_____________________________________6
LIST OF FIGURES AND TABLES-----------------------------------------10
FIGURES.    ________________________________________ 10
TABLES______________________________________________ 12
TABLE OF ABBREVIATIONS......    _____________    13
CHAPTER 1
1.  Introductloii..................................................................................... 18
1.1. Nitric oxide..................    18
1.1.1.  History................................................................................................................18
1.1.2.  Nitric oxide synthases (NOS).........................................................    20
1.1.2.1.  Neuronal nitric oxide synthase (nNOS/NOS I).....................................21
1.1.2.2.  Endothelial nitric oxide synthase (eNOS/NOS HI)..............................21
1.1.2.3.  Inducible nitric oxide synthase (iNOS/NOS II)....................................23
1.2. Mitogen-activated protein kinases (MAPK).........................................................25
1.2.1.  Extracellular signal-regulated kinases (ERK 1/2)........................................26
1.2.2.  p38   ...........................................................................    28
1.2.3.  c-Jun N-terminal kinases/stress activated protein kinases (JNK/SAPK) ..29
1.3. LPS and septic shock.......................................    30
1.3.1.  LPS and its signalling.......................................................................................30
1.3.2.  LPS and the MAPK pathway..........................................................................36
1.3.3.  Septic (endotoxic) shock............................................      37
1.4. Guanylate cyclase (GC) and cGMP........................................................................40
1.5. Natriuretic peptides..................................  40
1.5.1.  Introduction..............................................................    40
1.5.2.  History of natriuretic peptides.........................................................................41
1.5.3.  Natriuretic peptide synthesis, processing and expression...........................42
1.5.3.1.  ANP......................................................................;..................................... 42
1.5.3.2.  BNP...................................................................................    43
1.5.3.3.  CNP......................................    44
1.5.4.  Natriuretic peptide structure and homology..................................................45
1.5.5.  Natriuretic peptide receptors (NPRs).............................................................46
1.5.5.1.  NPR-A.........................    47
1.5.5.2.  NPR-B    ............................................................................................48
1.5.5.3.  NPR-C................        49
1.5.6.  Natriuretic peptide clearance..................................    50
1.5.7.  Natriuretic peptide signalling..........................................................................51
1.6. Functions of natriuretic peptides in the cardiovascular system..........................52
1.7. Functions of natriuretic peptides in the immune system......................................57
6TABLE OF CONTENTS
1.8. Role of natriuretic peptides in atherosclerosis......................................................58
1.8.1.  Introduction........................................  58
1.8.2.  Role of natriuretic peptides in the pathogenesis of atherosclerosis.......... 60
1.8.2.1.  ANP.............................................................................................................61
1.8.2.2.  BNP..................................................................      63
1.8.2.3.  CNP....................................................    64
1.9. Role of natriuretic peptides in cellular growth......................................................65
1.9.1.  ANP.....................................      65
1.9.2.  BNP.................................................................................................................... 66
1.9.3.  CNP......................             67
1.10. Current study    .........        68
CHAPTER 2
2.  Materials and Methods........................................................... 71
2.1. Reagents.....................................................................................................................71
2.2. Cell culture.................................................................................................................72
2.2.1.  RAW 264.7 -  Murine macrophage cell line.......................................  72
2.2.2.  Rat aortic smooth muscle cells (RAoSMC)..................................................73
2.2.2.1.  Isolation......................................................................................................73
2.2.22.  Characterisation.........................................................................................74
2.2.2.2.1. Immunocytochemistry........................................................    74
2.2.2.2.2. Hill and valley morphology................................................................74
2.2.3.  Freezing and thawing cells..............................................................................75
2.2.3.1.  Freezing cells ...........................................................................................75
2.2.3.2.  Thawing cells............................................    75
2.3. Determination of iNOS activity and expression in vitro..................  76
2.4. Determination of MAPK phosphorylation in vitro.............................................. 76
2.5. Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) 
and Western blotting........................................................................................................77
2.5.1.  Sample preparation for SDS-PAGE...............................................................77
2.5.2.  SDS-PAGE........................................................................................................78
2.5.3.  Western blotting................................................................................................78
2.5.3.1.  Wet transfer................................................................................................78
2.5.3.2.  Immunoblotting.........................    79
2.6. Chemiluminescence..................................................................................................80
2.7. Assessment of cell proliferation..............................................................................81
2.8. RNA isolation and reverse transcriptase polymerase chain reaction (RT-PCR) 
  .................................................82
2.8.1.  RNA isolation.............................    82
2.8.2.  RT-PCR.............................................................................................................. 83
2.9. Ex vivo animal studies..................        83
2.9.1.  Genotyping NPR-A knockout mice    .......    84
2.9.2.  Determination of iNOS activity and expression in vivo.............................. 84
2.9.3.  Functional reactivity of isolated thoracic aorta...........................  85
2.10. Data Analysis........................................................................................................... 85
7TABLE OF CONTENTS
CHAPTER 3
3.  Results 1 .............................................................................................88
3.1. Introduction........................................................................  88
3.2. Effect of NPR-A gene deletion on LPS-induced iNOS expression and activity 
in vivo...................................................      89
3.3. Effect of NPR-A gene deletion on vascular function induced by LPS in vivo .96
3.3.1.  Responses to U46619.......................................................................................96
3.3.2.  Responses to acetylcholine..............................................................................96
3.3.3.  Responses to ANP............................................................................................ 97
3.3.4.  Responses to spermine NONOate..................................................................97
3.4. Summary of key results.......................................................................................... 104
CHAPTER 4
4.  Results 2 .......................................................................................... 106
4.1. Introduction..............................................................................................................106
4.2. Optimisation of LPS-induced activation of RAW264.7 macrophages............107
4.3. Effect of ANP or CNP on LPS-induced iNOS in RAW264.7 macrophages.. 109
4.4. Characterisation of primary rat aortic smooth muscle cells..............................113
4.4.1.  Morphology.....................................................................................................113
4.4.2.  Optimisation of primary rat aortic smooth muscle cell activation...........118
4.4.3.  Timecourse of iNOS expression in primary rat aortic smooth muscle 
cells in response to activator cocktail.......................................................................121
4.5. Effect of ANP and CNP on activator cocktail-induced iNOS expression in 
primary rat aortic smooth muscle cells........................................................................123
4.6. Summary of key results..........................................................................................126
CHAPTER 5
5.  Results 3 ...........................................................................................128
5.1. Introduction..............................................................................................................128
5.2. Effect of MAPK phosphorylation inhibitors on activator cocktail-induced 
iNOS expression and activity in primary rat aortic smooth muscle cells...............129
5.3. Activation of MAPK pathway phosphorylation in primary rat aortic smooth 
muscle cells......................................................................................................................131
5.4. Effect of CNP on MAPK phosphorylation (ERK 1/2 and p38) in primary rat 
aortic smooth muscle cells.............................................................................................134
5.5. Effect of PD98059 on CNP-induced ERK 1/2  phosphorylation in primary rat 
aortic smooth muscle cells.............................  140
5.6. NPR-A, NPR-B and NPR-C mRNA is present in primary rat aortic smooth 
muscle cells......................................................................................................................142
5.7. Effect of the NPR-C antagonist, M372049 on CNP-induced MAPK 
phosphorylation (ERK 1/2 and p38) in primary rat aortic smooth muscle cells.... 144
5.8. Effect of Gj-protein inhibitor, Pertussis toxin on CNP-induced MAPK 
phosphorylation (ERK 1/2 and p38) in primary rat aortic smooth muscle cells.... 149
5.9. Effect of 8-Bromo-cGMP on MAPK phosphorylation (ERK 1/2 and p38) in 
primary rat aortic smooth muscle cells........................................................................ 152
8TABLE OF CONTENTS
5.10. Effect of ANP on MAPK phosphorylation (ERK 1/2 and p38) in primary rat 
aortic smooth muscle cells.............................................................................................155
5.11. Effect of CNP on cell proliferation in primary rat aortic smooth muscle cells 
............................................................................................................................................158
5.12. Summary of key results.........................................................................................161
CHAPTER 6
6.  Discussion and Conclusions...........................................................163
6.1. Background and aim of current study.................................................................. 163
6.2. Summary of key results...........................................................................................164
6.3. Effect of ANP on iNOS expression and vascular reactivity in vivo................ 165
6.4. Effect of ANP and CNP on iNOS expression in vitro.......................................172
6.5. iNOS expression and the MAPK pathway...........................................................175
6.6. Effects of ANP and CNP on  MAPK pathways..................................................177
6.7. MAPK, CNP and proliferation.............................................................................. 178
6.8. Conclusions..............................................................................................................184
REFERENCES......................................................................................186
9LIST OF FIGURES AND TABLES
LIST OF FIGURES AND TABLES 
FIGURES
Figure 1  -  MAPK cascades..................................................................................................26
Figure 2 -  Structural organisation of LPS..........................................................................31
Figure 3 -  LPS-triggered signalling cascades....................................................................38
Figure 4 -  Natriuretic peptide synthesis............................................................................42
Figure 5 -  Amino acid sequence and primary structure of mammalian natriuretic
peptides...........................................................................................................................45
Figure 6 -  Natriuretic peptide receptors NPR-A, NPR-B and NPR-C, showing
homology between the three structures......................................................................47
Figure 7 -  Early development of an atherosclerotic plaque.............................................60
Figure 8 -  Chemical structure of M372049.......................................................................72
Figure 9 -  Blotting setup using mini trans-blot electrophoretic transfer cell................79
Figure 10 -  Reactions underlying chemiluminescence analysis of nitrate/nitrite
concentration................................................................................................................. 81
Figure 11 -  Rat NPR-A, B and C gene specific primers.................................................83
Figure 12 -  Genotyping of wild type and NPR-A knockout mice................................. 90
Figure 13 -  LPS-induced iNOS expression in the heart of wild type and NPR-A
knockout mice...............................................................................................................91
Figure 14 -  LPS-induced iNOS expression in the lung of wild type and NPR-A
knockout mice............................................................................................................... 92
Figure 15 -  LPS-induced iNOS expression in the aorta of wild type and NPR-A
knockout mice...............................................................................................................93
Figure 16 -  LPS-induced plasma NOx in wild type and NPR-A knockout mice  94
Figure 17 -  Survival rates of wild type and NPR-A knockout mice following
treatment with LPS.......................................................................................................95
Figure 18 -  Effect of LPS in vivo on responses to U46619 in wild type and NPR-A
knockout mice............................................................................................................... 98
Figure 19 -  Effect of LPS in vivo on responses to acetylcholine in wild type and
NPR-A knockout mice.................................................................................................99
Figure 20 -  Effect of LPS in vivo on responses to ANP in wild type and NPR-A
knockout mice............................................................................................................. 100
Figure 21 -  Effect of LPS in vivo on responses to spermine NONOate in wild type
and NPR-A knockout mice........................................................................................101
Figure 22 -  Effect of LPS in vivo on Em ax and potency (EC50) to U46619 in wild type
and NPR-A knockout mice........................................................................................ 102
Figure 23 -  Effect of LPS in vivo on Em ax and potency (EC50) to acetylcholine, ANP
and spermine NONOate in wild type and NPR-A  knockout mice........................103
Figure 24 -  LPS-induced iNOS expression and activity in RAW264.7 macrophages...
  108
Figure 25 -  Effect of ANP on LPS-induced iNOS expression and activity in
RAW264.7 macrophages...........................................................................................110
Figure 26 -  Effect of CNP on LPS-induced iNOS expression and activity in
RAW264.7 macrophages............................................................................................111
Figure 27 -  Effect of time of administration of ANP on LPS-induced iNOS
expression and activity in RAW264.7 macrophages..............................................112
Figure 28 -  Primary rat aortic smooth muscle cells with nuclear staining..................114
10LIST OF FIGURES AND TABLES
Figure 29 -  Non-homogeneous population of primary rat aortic smooth muscle cells..
........................................................................................................................................115
Figure 30 -  Homogeneous population of primary rat aortic smooth muscle cells.... 116 
Figure 31 -  Primary rat aortic smooth muscle cell culture exhibiting typical hill and
valley morphology.......................................................................................................117
Figure 32 -  Activation of primary rat aortic smooth muscle cells with different
LPS/cytokine cocktails............................................................................................... 119
Figure 33 -  Rat aortic smooth muscle cell activation with LPS {Salmonella
typhimurium) in combination with varying cytokine concentrations................. 120
Figure 34 -  Timecourse of iNOS expression and activity in primary rat aortic smooth
muscle cells in response to activator cocktail.........................................................122
Figure 35 -  Effect of ANP on activator cocktail-induced iNOS expression and
activity in primary rat aortic smooth muscle cells.................................................124
Figure 36 -  Effect of CNP on activator cocktail-induced iNOS expression and
activity in primary rat aortic smooth muscle cells.................................................125
Figure 37 -  Effect of MAPK phosphorylation inhibitors on activator cocktail-
induced iNOS expression and activity in primary rat aortic smooth muscle cells..
....................................................................................................................................... 130
Figure 38 -  Effect of activator cocktail on ERK 1/2 phosphorylation in primary rat
aortic smooth muscle cells........................................................................................ 132
Figure 39 -  Effect of activator cocktail on p38 phosphorylation in primary rat aortic
smooth muscle cells...................................................................................................133
Figure 40 -  Effect of CNP on ERK 1/2 phosphorylation in the presence of activator
cocktail in primary rat aortic smooth muscle cells................................................135
Figure 41 -  Effect of CNP on p38 phosphorylation in the presence of activator
cocktail in primary rat aortic smooth muscle cells.................................................136
Figure 42 -  Effect of CNP on ERK 1/2 phosphorylation in primary rat aortic smooth
muscle cells..................................................................................................................137
Figure 43 -  Effect of CNP on p38 phosphorylation in primary rat aortic smooth
muscle cells..................................................................................................................138
Figure 44 -  Concentration-dependent effect of CNP on ERK 1/2 phosphorylation in
primary rat aortic smooth muscle cells....................................................................139
Figure 45 -  Effect of PD98059 on CNP-induced ERK 1/2 phosphorylation in
primary rat aortic smooth muscle cells....................................................................141
Figure 46 -  mRNA for NPR-A, NPR-B and NPR-C is present in primary rat aortic
smooth muscle cells................................................................................................... 143
Figure 47 -  Effect of the NPR-C antagonist, M372049 (1 pM and 10 pM) on CNP- 
induced ERK 1/2 phosphorylation in primary rat aortic smooth muscle cells . 145 
Figure 48 -  Effect of the NPR-C antagonist, M372049 (10 pM) on CNP-induced
ERK 1/2 phosphorylation in primary rat aortic smooth muscle cells..................146
Figure 49 -  Effect of the NPR-C antagonist, M372049 (1  pM and 10 pM) on CNP-
induced p38 phosphorylation in primary rat aortic smooth muscle cells............147
Figure 50 -  Effect of the NPR-C antagonist, M372049 (10 pM) on CNP-induced p38
phosphorylation in primary rat aortic smooth muscle cells..................................148
Figure 51  -  Effect of Pertussis toxin on CNP-induced ERK 1/2 phosphorylation in
primary rat aortic smooth muscle cells.....................................................................150
Figure 52 -  Effect of Pertussis toxin on CNP-induced p38 phosphorylation in
primary rat aortic smooth muscle cells.....................................................................151
Figure 53 -  Effect of 8-Bromo-cGMP on ERK 1/2 phosphorylation in primary rat 
aortic smooth muscle cells..........................................................................................153
11LIST OF FIGURES AND TABLES
Figure 54 -  Effect of 8-Bromo-cGMP on p38 phosphorylation in primary rat aortic
smooth muscle cells....................................................................................................154
Figure 55 -  Effect of ANP on ERK 1/2 phosphorylation in primary rat aortic smooth
muscle cells..................................................................................................................156
Figure 56 -  Effect of ANP on p38 phosphorylation in primary rat aortic smooth
muscle cells..................................................................................................................157
Figure 57 -  Effect of CNP on basal cell proliferation in primary rat aortic smooth
muscle cells.................................................................................................................. 159
Figure 58 -  Effect of CNP on angiotensin II-stimulated cell proliferation in primary
rat aortic smooth muscle cells....................................................................................160
Figure 59 -  Schematic of established signalling pathways involved in MAPK
activation by G-protein coupled receptors and proposed mechanism by which 
CNP may exert effects on growth inhibition via ERK 1/2 phosphorylation  185
TABLES
Table 1  -  MAPK substrate targets......................................................................................27
Table 2 -  Phenotypes of MEK and MAPK KO mice......................................................30
Table 3 -  Plasma concentrations of natriuretic peptides under physiological and
pathophysiological conditions.....................................................................................53
12TABLE OF ABBREVIATIONS
TABLE OF ABBREVIATIONS
1°  -  Primary
8-pCPT-cGMP  -  8-(4-chlorophenylthio)-cGMP
aa  -  Amino acids
ACh  -  Acetylcholine
Ang II  -  Angiotensin II
ANP  -  Atrial natriuretic peptide
AP-1  -  Activating protein-1
ASK  -  Apoptosis signal-regulating kinase
ATF-2  -  Activated transcription factor-2
ATP  -  Adenosine 5'-triphosphate
BH4  -  Tetrahydrobiopterin
BMI  -  Body mass index
BNP  -  Brain natriuretic peptide
BrdU  -  5-bromo-2'-deoxyuridine
C/EBP  -  CCAAT/enhancer-binding protein
CaM  -  Calmodulin
cAMP  -  Cyclic adenosine 3',5'-monophosphate
cGK  -  cGMP-dependent protein kinase
cGMP  -  Cyclic guanosine 3',5'-monophosphate
CNG  -  Cyclic nucleotide-gated
CNP  -  C-type natriuretic peptide
COX-1  -  Cyclooxygenase-1
COX-2  -  Cyclooxygenase-2
CREB  -  cAMP response element binding protein
CXCR4  -  Chemokine receptor 4
DAPI  -  4',6-diamidino-2-phenylindole
DLK  -  Dual leucine zipper-bearing kinase
DMEM  -  Dulbecco’s modified eagle medium
DMSO  -  Dimethyl sulphoxide
DNA  -  Deoxyribonucleic acid
DNP  -  Dendroaspis natriuretic peptide
dNTP  -  Deoxynucleotide triphosphate
ECL  -  Enhanced chemiluminescence
EDHF  -  Endothelium-derived hyperpolarising factor
EDRF  -  Endothelium-derived relaxing factor
EDTA  -  Ethylenediamine-tetraacetic acid
EGF  -  Epidermal growth factor
EGTA  -  Ethylene glycol-bis(|3-aminoethylether)-N,N,N',N'-tetraacetic
acid
eIF-4E  -  Eukaryotic initiation factor 4E
eNOS  -  Endothelial nitric oxide synthase
ERK  -  Extracellular signal-regulated kinases
FAD  -  Flavin adenine dinucleotide
FCS  -  Foetal calf serum
FDA  -  Food and drug administration
FGF  -  Fibroblast growth factor
FITC  -  Fluorescein isothiocyanate
13TABLE OF ABBREVIATIONS
FMN -  Flavin mononucleotide
g -  Relative centrifugal force
GC-A -  Guanylate cyclase-A
GC-B -  Guanylate cyclase-B
GIRK -  G-protein gated inward rectifying K+ channels
GM-CSF -  Granulocyte-macrophage colony-stimulating factor
gp 96 -  Glycoprotein 96
G-proteins -  Regulatory guanine nucleotide binding proteins
GTN -  Glyceryl trinitrate
GTP -  Guanosine 5’-triphosphate
h -  Hours
HEPES -  N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid
HMG -  High mobility group
HPB -  (3E)-4-(2-hydroxyphenyl)but-3-en-2-one
Hsp -  Heat shock protein
Hsp 1 -  Heat shock factor transcription factor 1
Hsp27 -  Heat shock protein 27
HUVEC -  Human umbilical vein endothelial cells
ICAM-1 -  Intercellular adhesion molecule-1
ICU -  Intensive care unit
IFN-y -  Interferon-y
IKK -  Inhibitors of kB kinase
IL-1R -  IL-1 receptor
IL-lp -  Interleukin-ip
iNOS -  Inducible nitric oxide synthase
IP3 -  Inositol triphosphate
IRAK -  IL-1 receptor associated protein kinase
IRF -  Interferon regulatory factor
IkB -  Inhibitory kB subunit
JAK -  Janus tyrosine kinase
JNK/SAPK -  C-Jun N-terminal kinases/stress activated protein kinases
K atp -  ATP sensitive potassium
KHD -  Kinase homology domain
KO -  Knockout
LBP -  LPS-binding protein
LDL -  Low density lipoprotein
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LPS -  Lipopolysaccharide
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LSP1 -  Lymphocyte specific protein-1
Mai -  MyD88-adaptor-like
MAPK -  Mitogen-activated protein kinase
MCP-1 -  Monocyte chemotactic protein-1
M-CSF -  Macrophage colony stimulating factor
MD -  Myeloid differentiation protein
MEK -  MAPK/ERK kinase
MEKK -  MAPK/ERK kinase kinase
min -  Minutes
MKK -  MAPK kinase
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1. Introduction
The defining clinical features of an inflammatory response were first described by a 
Roman physician, Celsus -  Aulus Cornelius, in De re medicina circa 30 AD, but it 
was only in the late 20th  century that the involvement of nitric oxide (NO) was first 
characterised (Ignarro et al,  1986; Palmer et al,  1987; Ignarro et al,  1987).  In De 
re medicina, the cardinal signs of inflammation were described as calour (warmth), 
dolour (pain), tumour (swelling) and rubour (redness and hyperaemia).  Following 
the establishment of an infection in the body the immune  system acts to fight and 
eradicate it in a multifaceted process involving many mediators.  Blood flow around 
the infected area is increased as a result of vasodilatation, making the tissues red and 
warm.  Capillaries  in  the  area  become  more  permeable  allowing  cell  and  fluid 
infiltration, and thus causing oedematous  swelling.  As a result of the swelling and 
the release of various chemical mediators, the infected area becomes painful as tissue 
expansion causes mechanical pressure on nerve cells.  NO  contributes to  each of 
these cardinal signs of inflammation by causing vasodilatation,  increasing vascular 
permeability and regulating nociception (Moncada and Higgs,  1993  ;  Hobbs et al, 
1999).  Thus,  NO  has  a key role  to  play in  the  development  of an  inflammatory 
response.  More recently, the involvement of natriuretic peptides in the development 
of an  inflammatory  response  has  been  revealed  (Hama  et  al.,  1994;  Kiemer  and 
Vollmar,  1997;  Casco  et  al,  2002;  Scotland  et  al,  2005a)  suggesting  that  these 
complementary  cardiovascular  mediators  might  act  in  concert  to  govern  vascular 
inflammation.  Moreover, this implies that both soluble (sGC) and particulate (pGC) 
isoforms of guanylate cyclase are capable of modulating an inflammatory response.
1.1.  Nitric oxide
1.1.1.  History
In  1818,  Prout  observed  large  amounts  of nitrite  in  the  urine  of a  febrile  patient 
(Prout,  1818) but these findings were not pursued until 1981 when Tannenbaum and 
Green made similar observations and concluded, following work with germ-free rats, 
that the increased nitrite (and nitrate) excretion exceeded the dietary intake and was 
due to the host and not its microbial flora (Green et al,  1981a; Green et al,  1981b).
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Following these observations Stuehr & Marietta identified activated macrophages as 
the predominant nitrogen oxide producers (Stuehr and Marietta,  1985).  But the true 
pioneering work came from the groups of Murad (Arnold et a l,  1977; Murad et al, 
1978), Furchgott (Furchgott and Zawadzki,  1980), Ignarro (Ignarro et al,  1987) and 
Moncada  (Palmer  et  al,  1987)  who  worked  independently  to  conclude  that  NO 
played an important physiological role as a signalling molecule.  In the late  1970s 
and early 1980s Furchgott reported that relaxation of smooth muscle in blood vessels 
by  acetylcholine  (ACh)  required  an  intact  endothelium  and  concluded  that  the 
endothelial  cells  produced  a compound  in  response  to  ACh,  named  endothelium- 
derived relaxing factor (EDRF), which acted on smooth muscle cells to bring about 
relaxation (Furchgott and Zawadzki,  1980).  At the same time, Murad demonstrated 
that  NO  activated  sGC,  the  enzyme  responsible  for  producing  the  secondary 
messenger  cyclic  guanosine  3',5'-monophosphate  (cGMP),  and  that  the  active 
metabolite of glyceryl trinitrate (GTN) and related organic nitrates is NO (Murad et 
al,  1978;  Howlett,  1998).  Following  these  observations  it  was  independently 
concluded  by  Furchgott  and  Ignarro  at  a  conference  (Mayo  Clinic  in  Rochester, 
Minn) in 1986 that EDRF is NO (Howlett, 1998).  The first published evidence came 
from Moncada and Ignarro in  1987 showing that NO produced by endothelial cells 
had the  same biological  activity and chemical properties  as  EDRF  (Palmer et al, 
1987; Ignarro et al, 1987).
Since  its  discovery  as  a  signalling molecule,  NO  has  received  immense  attention 
from the scientific community.  It was described as “Molecule of the year” in  1992 
by  Science  Magazine  (Culotta  and  Koshland,  1992)  and  Robert  Furchgott,  Louis 
Ignarro and Ferid Murad were awarded the Nobel prize in physiology or medicine in 
1998 for their breakthrough work (Howlett,  1998).  NO has now been implicated in 
numerous  physiological  processes  including  smooth  muscle  contractility,  platelet 
reactivity,  central  and  peripheral  neurotransmission  and  the  immune  response 
(Hobbs et al,  1999).  Regulation of this unique signalling molecule has been shown 
to  be  invaluable  in  highly  diverse  pathologies  including  cancer,  impotence  and 
inflammatory diseases like atherosclerosis, sepsis and circulatory shock, asthma and 
colitis (Moncada and Higgs, 1993; Hobbs et al, 1999).
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1.1.2.  Nitric oxide synthases (NOS)
NO  is  a  stable,  hydrophobic,  diatomic  radical  gas,  which  is  both  lipid and  water 
soluble.  It is produced by the catalytic  conversion of L-arginine to L-citrulline by 
one of three nitric oxide synthase (NOS) iso forms (Bredt and Snyder,  1990; Pollock 
et al.,  1991;  Stuehr et al.,  1991a).  Several co-factors have been implicated in the 
reaction  including  nicotinamide  adenine  dinucleotide  phosphate  (NADPH), 
tetrahydrobiopterin  (BH4),  flavin  adenine  dinucleotide  (FAD),  flavin 
mononucleotide (FMN), calmodulin (CaM) and O2 (Knowles and Moncada,  1994). 
The catalytic reaction involves two steps.  L-arginine is initially hydroxylated to NG - 
hydroxy-L-arginine (NOHA;  Stuehr et al.,  1991b) followed by NOHA oxidation to 
equimolar quantities of NO and L-citrulline  (Lirk et al., 2002).
Three  isoforms  of NOS  have  been  identified:  neuronal  NOS  (nNOS),  endothelial 
NOS  (eNOS)  and  inducible NOS  (iNOS).  They all  exist  as  homodimers  in  their 
active form, share 50 -  60 % sequence homology and show 80 -  90 % conservation 
among species (Forstermann and Kleinert, 1995).
The  enzymes  are  composed  of  a  C-terminal  reductase  domain  containing  the 
NADPH,  FAD  and  FMN  binding  sites  and  a  N-terminal  oxygenase  domain 
containing a haem binding domain and binding sites for BH4 and L-arginine (Stuehr, 
1999).  The  two  domains  are joined  by  a  calmodulin  (CaM)  binding  site,  which 
permits the transfer of electrons  from the flavins to the haem iron.  The haem iron 
can  then bind and activate  O2  and  ultimately  synthesise NO  (Stuehr,  1997).  The 
constitutive  isoforms  eNOS  and  nNOS  regulate  NO  synthesis  by  CaM  binding 
giving  a  rapid  on/off  switch,  while  the  inducible  isoform  iNOS  binds  CaM 
irreversibly  (Cho  et  al.,  1992).  Therefore  eNOS  and  nNOS,  the  ‘low  output’
enzymes,  are regulated  by  intracellular Ca2+  fluxes  while  iNOS,  the  ‘high output’
2+ enzyme,  is  Ca  -independent  and  is  controlled  primarily  by  enzyme  expression 
(Forstermann and Kleinert,  1995).  NO cannot be formed from monomeric subunits 
as the transfer of electrons occurs between the reductase and oxygenase regions of 
the opposing monomers in the dimerised active enzyme  (Siddhanta et al., 1998).
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1.1.2.1.  Neuronal nitric oxide synthase (nNOS/NOS I)
Neuronal NOS  is a  160 kDa protein  first cloned and purified  from rat cerebellum 
(Bredt  and  Snyder,  1990).  It  is  expressed  mostly  in  the  central  and  peripheral 
nervous system but it has also been identified in human skeletal muscle (Stamler and 
Meissner,  2001).  NO  synthesised  by  nNOS  acts  primarily  as  a  neurotransmitter 
(Bredt,  1996).  In  the  central  nervous  system  NO  has  been  implicated  in  the 
formation  of memory  via  long-term  potentiation,  since  in  nNOS  knockout  (KO) 
mice or following inhibition of NO, learning behaviour is impaired (Chapman et al., 
1992).  Neuronal NOS-derived NO has also been shown to have a physiological role 
in vision (Venturini et a l,  1991), feeding behaviour (Morley and Flood,  1991), pain 
(Moore et a l,  1991) and olfaction (Breer and Shepherd,  1993),  and pathologically, 
has been implicated in cerebral ischaemia and epilepsy (Dalkara et al,  1994).  In the 
periphery there are numerous organ systems that use NO as a neurotransmitter.  For 
example,  in  the  gastrointestinal  tract  relaxation  and  dilatation  of  the  stomach 
(Schuurkes  and  Meulemans,  1994),  in  addition  to  control  of the  sigmoid  colon 
muscle and sphincter muscle are modulated by NO (Burleigh,  1992).  Furthermore, 
NO  is  responsible  for  penile  erection,  as  its  release  from  nerve  endings  causes 
vasorelaxation  of the  blood  vessels  in  the  corpus  cavemosum  bringing  a  flow  of 
blood to the blood sinuses resulting in an erection (Ignarro et al, 1990; Moncada and 
Higgs, 1993).
1.1.2.2.  Endothelial nitric oxide synthase (eNOS/NOS III)
Endothelial  NOS  was  first  purified  from  native  bovine  aortic  endothelial  cells 
(Pollock et al, 1991) and is a 135 kDa protein (Pollock et al, 1991).  Like nNOS its
^ I
activity  is  regulated  by  intracellular  free  Ca  and  it  is  constitutively  expressed. 
Endothelial  NOS  can  also  be  activated  by  phosphorylation  (in  the  absence  of
^ I
increased Ca  ) by shear-stress  via regulatory guanine  nucleotide  binding  proteins 
(G-proteins; Kuchan et al, 1994).  Activated G-proteins stimulate effector molecules 
including phosphoinositide-3-kinase (PI3K).  PI3K subsequently phosphorylates and 
activates  the  serine/threonine  protein  kinase Akt/protein kinase  B,  which can  then 
phosphorylate eNOS (Fulton et al,  1999).  Endothelial NOS is mostly found in the 
vasculature, being expressed by vascular endothelial cells of both arteries and veins,
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but  this  isozyme  has  also  been  detected  in  both  rodent  and  human  macrophages 
(Hecker et a l, 1992; Reiling et al, 1994).  NO produced by eNOS in the vasculature 
has been shown to have anti-thrombotic  and anti-atherogenic properties as well  as 
being an  inhibitor of platelet adhesion and preventing initiation of the coagulation 
pathway  by  inhibiting  the  expression  of  thrombotic  protein  tissue  factor  (TF; 
Naseem, 2005).  In addition, NO has a role in vascular remodelling and angiogenesis 
and  inhibits  smooth  muscle  cell  proliferation  via  a  protein  kinase  G  (PKG)- 
dependent mechanism  (Assender et al,  1992) as well as cGMP-independently via 
inhibition of ornithine decarboxylase (Ignarro et al, 2001).  It has been shown that 
NO bioavailability is reduced in cardiovascular disease and that normal function of 
eNOS is required for a fully functional and compliant endothelium (Naseem, 2005).
Perhaps the most important role for NO  is  in  controlling systemic blood pressure. 
Under physiological  conditions,  endothelial  cells  lining  blood  vessels  release  NO 
synthesised  by  eNOS,  which  diffuses  into  the  underlying  smooth  muscle  cells 
causing them to relax and thus increasing vessel diameter.  Therefore, aberrant NO 
bioactivity  has  been  implicated  in  hypertension,  characterised  by  endothelial 
dysfunction  and  impairment  of  eNOS  expression  and  activity  (Naseem,  2005). 
Endothelial NOS KO mice also suffer from hypertension, decreased heart rate and 
increased plasma renin concentrations (Shesely et al,  1996).  Thus, NO plays a key 
anti-atherogenic role in maintaining the integrity of blood vessels.  In the immune 
system, and particularly in macrophages, low level NO from eNOS has been shown 
to be essential for obtaining maximal levels of iNOS expression and activity in cells 
stimulated with bacterial lipopolysaccharide (LPS; Connelly et al, 2003) suggesting 
that NO can also expedite host defence.  The importance of eNOS as a regulator of 
iNOS  has  also  been  demonstrated  in  vivo  using  eNOS  KO  mice,  where  iNOS 
expression and activity are reduced,  vascular reactivity to  the NO  donor spermine 
NONOate  (SPER-NO)  is  enhanced,  and  hypotension  is  reversed  following  LPS 
treatment (compared to wild type  (WT)  animals;  Connelly et al,  2005;  Vo et al, 
2005).  PI3K  and  Akt/Protein  kinase  B-dependent  enzyme  phosphorylation  have 
been  shown  to  be  involved  in  eNOS  activation  in  response  to  LPS/inflammatory 
stimuli (Connelly et al, 2005), collectively giving eNOS a role in the pathogenesis 
of sepsis and other inflammatory disorders.
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1.1.2.3.  Inducible nitric oxide synthase (iNOS/NOS II)
In  the  late  1970s  and  early  1980s  it  was  postulated  that  mammals  were  able  to 
produce high levels of urinary nitrate, 4 fold higher than ingested in humans (Green 
et al,  1981a) and 9 fold higher than ingested in Escherichia coli LPS treated rats 
(Wagner et al.,  1983).  In 1985 it was shown that macrophages were responsible for 
most  of this  nitrate  production  (Stuehr  and  Marietta,  1985)  and  later  iNOS  was 
identified  as  the  NOS  isoform  responsible  for  NO  production  in  macrophages 
(Stuehr  et al,  1991a).  Unlike  eNOS  and  nNOS,  iNOS  is  inducible  (Geller  and 
Billiar, 1998) and does not require Ca2+ and CaM for activation (Cho et al., 1992).  It 
is  a  130  kDa  protein  (Stuehr  et  al,  1991a)  expressed  in  numerous  cell  types 
including  chondrocytes,  kupffer  cells,  hepatocytes,  neutrophils,  pulmonary 
epithelium and vascular smooth muscle cells in response to inflammatory cytokines 
and bacterial metabolites (Lirk et al, 2002).
NO  provides  a primary defence  mechanism  against  tumour cells  and  intracellular 
and extracellular microorganisms in macrophages (Moncada and Higgs,  1993).  The 
‘high  output’  NO  from  iNOS  is  cytotoxic  and cytostatic  and  is  thus  important  in 
combating  bacterial  infections.  During  the  course  of an  inflammatory  response, 
stimulated  macrophages  produce  high  levels  of  NO  that  surpass  physiological 
concentrations and this diffuses to target cells (e.g. bacteria, fungi or tumour cells) 
where  it  causes  deoxyribonucleic  acid  (DNA)  damage,  low  density  lipoprotein 
(LDL) oxidation, isoprostane formation, tyrosine nitration and inhibits mitochondrial 
respiration (Guzik et al, 2003).  NO binds with iron-sulphur centres in key enzymes 
involved in the target’s  respiratory chain and DNA synthesis pathway.  NO target 
enzymes include aconitase, which is part of the Krebs cycle, reduced nicotinamide 
adenine  dinucleotide  (NADH)  dehydrogenase,  which belongs  to  complex  I  of the 
mitochondrial  respiratory  pathway,  succinate-NADPH  dehydrogenase  part  of 
mitochondrial  complex  II  and  ribonucleoside-diphosphate  reductase,  which  is 
essential in  DNA  synthesis  (Moncada and  Higgs,  1993).  The high NO  levels  are 
usually  paralleled  with  the  production  of  superoxide  anion  (O2 ).  NO  and  O2' 
combine to give peroxynitrite (ONOO ), which complements the cytotoxic effects of 
NO  (Linares  et  al,  2001).  Animal  models  and  human  clinical  data  have
23CHAPTER 1  -  INTRODUCTION
demonstrated the importance of iNOS and ‘high output’ NO in the development of 
septic  shock,  a heightened  inflammatory response,  as  will  be  discussed  in  greater 
detail in section 1.3.3.
The most prominent mediators involved in iNOS expression are interferon (IFN)-y, 
interleukin (IL)-ip, tumour necrosis  factor (TNF)-a and bacterial LPS  (Lirk et al., 
2002).  The activation of iNOS  expression varies profoundly from one cell type to 
another.  Macrophages activated with LPS alone give a high level of iNOS (Kiemer 
and Vollmar, 1998; Connelly et al., 2001; Connelly et al., 2003) while combinations 
of cytokines and LPS are required in vascular smooth muscle cells, for example, to 
give maximal iNOS expression (MacNaul and Hutchinson,  1993; Matsumura et al., 
2001).  Vascular  smooth  muscle  cells  derived  from  different  species  require 
differential  combinations of LPS  and pro-inflammatory cytokines  to  induce  iNOS 
expression; indeed, it is important to note that induction of iNOS in human cells in 
vitro  is  notoriously  difficult  (MacNaul  and  Hutchinson,  1993).  This  gives  an 
indication  that  different  pathways  are  involved  in  iNOS  regulation,  either 
individually or synergistically.
The nuclear  factor-KB  (NF-kB)  signal  transduction pathway has  been  extensively 
studied and shown to be of major importance in iNOS expression.  iNOS expression 
is blocked by a number of NF-kB inhibitors including salicylates (Wu, 2003), (3E)- 
4-(2-hydroxyphenyl)but-3-en-2-one  (HPB;  Tsao  et  al,  2005),  pyrrolidine 
dithiocarbamate (PDTC; Cuzzocrea et al., 2002) and dexamethasone (Matsumura et 
al.,  2001).  Moreover,  promoter-reporter  studies  have  shown  that NF-kB  binding 
sites on the iNOS promoter are key to its expression (Xie et al.,  1994; Taylor et al., 
1998; Marks-Konczalik et al.,  1998; Ganster et al., 2001).  NO has been shown to 
have  a  biphasic  effect  on  NF-kB  in  murine  macrophages  such  that  it  can  both 
downregulate  and  upregulate  iNOS  expression  and  a  number  of  other  pro- 
inflammatory proteins  (Connelly et al.,  2001) perhaps  explaining why  eNOS  has 
been reported to have both pro- and anti-inflammatory actions.  In addition to NF-kB, 
alternative  pathways  are  involved  in  the  regulation  of iNOS  expression  including 
janus  tyrosine  kinase  (JAK)-signal  transducers  and  activators  of  transcription
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(STAT;  Kleinert  et  al,  1998;  Xuan  et  al,  2001),  and  mitogen-activated  protein 
kinases (MAPK; Guha and Mackman, 2001).
1.2.  Mitogen-activated protein kinases (MAPK)
The MAPK network targets are involved in controlling numerous physiological and 
pathophysiological  processes  including  proliferation,  differentiation,  development, 
inflammatory  responses  and  cell  death  (Pearson  et  al,  2001).  Three  main 
mammalian  MAPK signalling pathways  have been identified;  extracellular signal- 
regulated kinases (ERK), p38 pathway and c-Jun N-terminal kinases/stress activated 
protein kinases (JNK/SARK; although other MAPKs exist including ERK3, ERK5, 
ERK7,  nemo-like  kinase  (NLK)  and  MOK,  but  these  are  less  well  characterised; 
Pearson  et  al,  2001).  These  pathways  involve  the  stimulation  of  extracellular 
receptors,  which  then  transmit  the  signal  to  intracellular  targets  via  a  cascade  of 
consecutive cytoplasmic protein kinases.  Up to six tiers of protein kinases have been 
identified  and  these  assist  in  the  amplification  and  specificity  of the  signalling 
pathway via phosphorylation cascades (Seger and Krebs, 1995).
The distinguishing feature of MAPK is that direct phosphorylation of two sites, one 
threonine and one tyrosine, in the kinase activation loop is required to bring about 
their activation.  MAPK are  activated through the consecutive phosphorylation of 
kinases higher up in the hierarchy.  The first kinase in the phosphorylation sequence 
belongs to the MEK (MAPK/ERK kinase) kinase (MEKK) family, which are subject 
to numerous regulators including G-protein coupled receptors (GPCRs) and multiple 
protein kinases (e.g. protein kinase C (PKC) and Akt; Pearson et al, 2001).  MEKK 
activates  MEK  downstream  by  phosphorylating  two  conserved  adjacent 
serine/threonine residues  in the activation loop (Zheng and Guan,  1994).  MEK in 
turn activates MAPK (Crews et al,  1992) by phosphorylating both serine/threonine 
and tyrosine residues with aliphatic or aromatic side chains (Kosako et al,  1992).  In 
the  case of ERK  1/2,  tyrosine residues  are phosphorylated prior to  threonine,  and 
tyrosine  phosphorylation  must  accumulate  at  a  threshold  before  threonine 
phosphorylation  is  enabled  (Pearson  et  al,  2001).  Once  activated,  MAPK  can 
phosphorylate  targets  and  thus  affect  biological  processes.  The  various  different 
members of each step in the MAPK cascade are shown in Figure 1.
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Figure 1 -  MAPK cascades (Abbreviations: ASK -  apoptosis signal-regulating kinase, DLK -  dual 
leucine zipper-bearing kinase, ERK -  extracellular signal-regulated kinase, JNK -  c-Jun N-terminal 
kinase,  MAPK  -   mitogen-activated  protein  kinase,  MEK  -   MAPK/ERK  kinase,  MEKK  -  
MAPK/ERK kinase kinase, MKK -  MAPK kinase, MLK -  mixed lineage kinase, NLK -  nemo-like 
kinase, TAK -  transforming growth factor (TGF)-(3-activated protein kinase, TAO -  thousand and 
one amino acid kinase, Tpl-2 -  tumour progression locus-2).
1.2.1.  Extracellular signal-regulated kinases (ERK 1/2)
ERK  1   and  ERK 2  (ERK  1/2)  are  43  and 41  kDa proteins respectively  and  show 
85 % homology.  They are ubiquitously expressed but their respective distributions 
vary  with  individual  cell  types.  The  two  phosphorylation  accepting  residues  are 
separated by a single glutamate residue in the enzyme’s active loop  (Payne  et al,
1991).  As shown in Figure 1, ERK 1/2 are activated by MEK 1   and 2 and MEK 1/2 
are phosphorylated by Raf isoforms including A-Raf, B-Raf and Raf-1  (Avruch et al., 
1994; Daum et al.,  1994) or Mos (Pearson et al., 2001).  The downstream activation 
of ERK  1/2 is brought about by activation of either RTKs and Ras or GPCRs at the 
cell  membrane.  Alternatively  the  ERK  1/2  pathway  can  be  activated  through 
heterotrimeric GPCRs.  ERK 1/2 have multiple effector targets both cytoplasmic and 
nuclear  and  these  are  summarised  in  Table  1.  A  number  of  gene  disruption 
experiments have been carried out involving numerous members of each of the three 
main MAPK signalling pathways.  The phenotypes of such animals are summarised 
in Table 2.
26CHAPTER 1  -  INTRODUCTION
MAPK SUBSTRATE TARGETS
MAPK SUBSTRATE TARGETS DOWNSTREAM ACTIONS
PROTEIN KINASES
ERK 1/2 Rsk 1,2,3
Once activated Rsks phosphorylate downstream 
targets  involved  in  transcriptional  regulation 
including  cAMP  response  element  binding 
protein  (CREB),  the  co-activator  CBP,  c-Fos, 
serum response factor and oestrogen receptor.
•
MAPKAP kinase-2 and 3 Phosphorylate  heat  shock  protein  27  (hsp27), 
and  in  human  neutrophils  MAPKAP  kinase-2 
phosphorylates  lymphocyte  specific  protein-1  
(LSP  1).  Hsp27 and LSP  1   are F-actin binding 
proteins  involved  in  cytoskeletal  structure. 
MAPKAP kinase-2 also  phosphorylates CREB 
and ATF-1.
ERK 1/2 and p38
MAP kinase-interacting 
kinase (Mnk) 1   and Mnk 2
Once  activated  they  phosphorylate  the 
eukaryotic  initiation  factor  4E  (eIF-4E) 
enabling  recruitment of ribosomes  and  protein 
synthesis  initiation  factors  to  messenger 
ribonucleic acid (mRNA).
Mitogen and stress activated 
protein kinases (Msk)
Phosphorylates CREB
MEMBRANE AND CYTOPLASMIC SUBSTRATES
ERK 1/2 and p38 Phospholipase A2
ERK 2 Heat shock factor 
transcription factor 1   (hsp 1) 
Topoisomerase Il-b 
Ral-GDS
ZNF-7 (zinc finger protein)
NUCLEAR SUBSTRATES
Nuclear Substrates are regulated indirectly via other protein kinases or MAPKs can translocate to the 
nucleus and phosphorylate transcription factors themselves
ERK 1/2 Ribosomal S6 kinase (Rsk) 2 Phosphorylates histone H3
Mnks Phosphorylates  histone  H3  and  high  mobility 
group (HMG) protein  14, thus controlling DNA 
packaging into chromatin
Transcription factors of the 
activating protein-1  (AP-1) 
family.
c-Jun  (N-terminal  phosphorylation),  c-Fos, 
activating transcription factor (ATF-2)
ERK 2 Steroid receptor coactivator-1  
(SRC-1)
SRC-1  has  histone  acetyltransferase  activity. 
SRC-1  also  interacts  with  CREB  to  enhance 
oestrogen  and  progesterone  receptor-mediated 
gene  activation  and  HAT  protein  p300/CBP- 
associated  factor.  SRC-1  is  involved  in 
chromatin remodelling and gene expression
JNK/SARK
c-Jun (C-terminal 
phosphorylation)
ERK, p38 and 
JNK/SARK
Ternary complex factor (TCF) 
family of transcription factors
Ets  domain  proteins  including  Elk-1,  which 
mediates  transcription  from  serum  response 
elements (SREs).
SAP-1  and SAP-2 (ternary complex factors)
Table 1 -  MAPK substrate targets (Pearson et al., 2001).
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ERK  1/2  is  partly  involved  in  cytokine-induced  iNOS  expression  (without 
modulating  NF-kB)  in  vascular  smooth  muscle  cells  (Doi  et  al,  2000)  and 
cyclooxygenase-2 (COX-2) expression in human tracheal smooth muscle cells (Lin 
et al, 2004).  In human airway epithelial cells, ERK is the major kinase regulating 
prostaglandin E2 (PGE-2) synthesis, and inhibition of ERK phosphorylation with 2 - 
amino-3'-methoxyflavone (PD98059) almost completely abrogates PGE-2 synthesis 
in response to LPS, IL-1 (5  or TNF-a (Petrovic et al, 2006).  Furthermore, it has been 
demonstrated  that  ERK  1/2  signalling  is  important  in  the  regulation  of baseline 
permeability and  cGMP-induced hyperpermeability in endothelial  cells  (Varma et 
al,  2002)  and  in  platelet-activating  factor  (PAF)-induced  microvascular 
hyperpermeability  in  vivo  (Yu  et  al.,  2005),  a  process  that  is  vital  in  the 
inflammatory reaction that characterises vascular disease and wound healing.
1.2.2.  p38
The p38 MAPK pathway is less well defined and unlike ERK  1/2, p38 is activated 
by a variety of environmental stresses and pro-inflammatory signals.  These include 
cytokines, hormones, osmotic shock and heat shock but they can also be activated by 
GPCRs (Pearson et al, 2001).  This 38 kDa protein exists as four analogous family 
members,  p38a,  |3,  y  and  5  (Pearson  et  al,  2001).  All  p38  isoforms  have  the 
sequence TGY in their active  loop thus having a single glycine separating the two 
threonine/tyrosine  phosphoaccepting  residues.  As  shown  in  Figure  1,  the  MEK 
family  members  that  phosphorylate  p38  are  MEK  3  and  MEK  6  and  these  are 
phosphorylated further upstream by TAO  1   and  2, ASK,  TAK and MEKK  1,  2,  3 
and 4.  The downstream effectors of p38 are summarised in Table  1, while Table 2 
shows the phenotypic results of gene disruption.
p38,  like  ERK  1/2 has  been  implicated  in  iNOS  and  COX-2  gene  expression.  In 
glial  cells  p38a  and  P  have  been  shown  to  modulate  iNOS  expression  via 
transcriptional control.  Activated transcription  factor (ATF-2),  CCAAT/enhancer- 
binding  protein  (C/EBP)  and  NF-kB  increase  expression,  while  cyclic  adenosine 
3',5'-rnonophosphate  (cAMP)  response  element  binding protein  (CREB)  decreases 
expression  (Bhat  et  al,  2002).  In  murine  astrocytes  the  p38  pathway  is  partly 
responsible  for  inhibiting  iNOS  expression  (Da  Silva  et al,  1997)  while  in
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human tracheal smooth muscle cells, p38 is involved in regulation of COX-2 (Lin et 
al,  2004).  Akin to  ERK  1/2, p38  is  important  in mediating hyperpermeability  in 
endothelial cells and in PAF-induced microvascular hyperpermeability in vivo (Yu et 
al., 2005).
1.2.3.  c-Jun N-terminal kinases/stress activated protein 
kinases (JNK/SAPK)
JNK/SAPK  are  46  and  54  kDa  proteins  encoded  on  three  genes  producing  10  or 
more  alternative  splice  variants  (Pearson  et  al,  2001).  The  phosphoacceptor 
residues are separated by a single proline in the active loop and they are activated by 
cytokines, certain ligands for GPCRs (e.g. growth factors), agents that interfere with 
DNA  and  protein  synthesis,  serum,  transforming  agents  as  well  as  various  other 
stresses  (Pearson  et  al,  2001).  These  MAPK  are  activated  by  MKK  4 
(phosphorylates  tyrosine)  or  MKK  7  (phosphorylates  threonine),  which  are  MEK 
family members and MEKs are in turn phosphorylated by MEKK family members 
including MLK 3, MEKK 1, 2, 3 and 4, DLK and Tpl-2 (Figure 1).  The phenotypes 
of MEKK  and  MAPK  KO  mice  are  shown  in  Table  2.  Principal  downstream 
effectors of the JNK/SAPK pathway are shown in Table 1.
JNK/SAPK signalling has also been implicated in the regulation of iNOS.  In murine 
macrophages,  LPS-induced iNOS  expression is blocked by the overexpression of a 
JNK/SAPK  dominant  negative  mutant  or  by  the  broad  caspase  inhibitor 
benzyloxycarbonyl-Val-Ala-Asp-fluromethylketone (Z-VAD-FMK;  Chakravortty et 
al,  2001).  This  inhibitory effect is  also  seen with a dominant negative mutant of 
MKK 4, the upstream  MEK for JNK/SAPK (Chan and Riches,  2001).  In insulin- 
producing cells it has been hypothesised that activation of ATF-2 by JNK  1   could 
result in ATF-2  synergising with  N F-kB  and AP-1  to  enhance  iNOS  transcription 
(Welsh,  1996).  In rat glomerular mesangial  cells  IL-ip-induced iNOS  stimulation 
requires  both  p38  and  JNK/SAPK  activation  (Guan  et  al,  1999).  Furthermore 
JNK/SAPK  has  been  shown  to  be  overexpressed  and  activated  in  atherosclerotic 
lesions.  It  has  therefore  been  proposed that  JNK/SAPK  could  play a  key role  in 
mediating cell differentiation and apoptosis during atherosclerosis development  with 
the  possible  involvement  of  the  p53  transcription  factor  (Metzler  et  al,  2000). 
Finally, the JNK/SAPK cascade has been  implicated in the development of cardiac
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hypertrophy and  could therefore  be  pursued  as  a  drug target  for treatment  of this 
condition (Choukroun et al., 1999).
MAPKK/MAPK PHENOTYPE
MEK 1 Defective placental vascularisation
MKK 4 Defective liver development
MKK 7 Embryonic lethality of unknown cause
MEK 3 Defective IL-12 production
ERK 1 Defective T-cell development (positive selection)
JNK1 Defective T-cell differentiation to Th2 cells
JNK2 Defective T-cell differentiation to Thl cells
JNK 1  or JNK 2 Defective T-cell proliferation and IL-1 production
Defective activation induced death of thymocytes
JNK 1  and JNK 2 IL-2 production
Neural tube disclosure
JNK 3 Resistance to excitotoxic neuronal cell death
p38a Placental defect (trophoblast cells)
Insufficient production of erythropoietin
Table 2 -  Phenotypes of MEK and MAPK KO mice (adapted from Chang and Karin, 2001).
1.3.  LPS and septic shock
1.3.1.  LPS and its signalling
LPS  is  a complex  glycolipid  macromolecule  found on  the  outer membrane  of all 
gram-negative bacteria  such as Escherichia coli and Salmonella,  and is one of the 
most potent microbial initiators of inflammation (Schaechter et al.,  1999; Parslow et 
al, 2001).  Each LPS molecule consists of three regions, a core carbohydrate domain 
consisting of a variable and an invariable portion linked on one side by a hydrophilic 
polysaccharide  moiety  (O-Antigen),  and  on  the  other  side  by  hydrophobic 
phospholipids  (Lipid  A),  which  anchors  LPS  to  the  bacterial  membrane  (Raetz, 
1990).  The repeating sugar subunits in the O-Antigen region are highly variable and
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species-specific  giving  rise  to  the  different  antigenic  specificities  among  Gram- 
negative bacteria (Schaechter et al,  1999).  To the contrary, the core polysaccharide 
and Lipid A moieties are essentially invariable thus acting as targets for binding by 
human serum proteins (Parslow et al, 2001).  The common LPS structure is shown 
in Figure 2.
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Figure 2 -  Structural organisation of LPS.
LPS activates monocytes  and macrophages to produce pro-inflammatory cytokines 
including  IL-1,  IL-6  and  TNF-a  (Cohen,  2002)  and  humans  have  developed  a 
complex system to recognise minute amounts of LPS (<101 2  M) to combat infection 
(Guha  and  Mackman,  2001;  Parslow  et al,  2001).  LPS  binds  to  LPS-binding 
protein  (LBP),  first  isolated  from  acute  phase  rabbit  serum  (Tobias  et al,  1986). 
LBP is a 60 kDa serum glycoprotein that binds Lipid A of LPS with high affinity 
and is normally present in serum at <0.5 pg/ml, but levels rise  100-fold to 50 ng/ml 
24 h after induction of an acute phase response (Schumann et al,  1990).  LBP-LPS 
complexes  enhance  LPS-induced  TNF  production  250-fold,  while  levels  are 
unaltered  in  the  presence  of LPS  alone  (Schumann  et al,  1990).  The  LBP-LPS 
complexes  bind  to  CD14,  a  55  kDa  differentiation  antigen  of  monocytes,  as 
determined using CD 14 monoclonal antibodies, which abrogate the binding of these 
complexes to cells (Wright et al,  1990).  CD 14 is  found anchored to myeloid cell 
membrane  (especially  at  the  final  stage  of monocyte/macrophage  maturation  and 
weakly on neutrophils) via a glycosyl phosphatidyinositol tail or as a soluble form 
circulating free in plasma at a concentration of 2 -  6  pg/ml  (Guha and Mackman, 
2001), which enables cells such as endothelial and smooth muscle cells to respond to 
LPS even though they do not possess membrane bound CD 14 (Guha and Mackman, 
2001).  CD14/LPS complexes reduce the concentration of LPS required to activate 
macrophages compared to LPS alone  (Fujihara et al, 2003) and mice lacking CD 14
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are highly resistant to endotoxic shock and almost no secreted TNF-a is detectable in 
the serum of these animals (Haziot et al.,  1996).  Isolated peripheral mononuclear 
cells  from CD14-deficient mice also do not secrete detectable  levels of TNF-a and 
IL-6 (Haziot et al., 1996).  Interestingly, increased levels of circulating soluble CD 14 
(3.23  vs 2.48  pg/ml vs control) are associated with high mortality in patients  with 
gram-negative septic shock (Landmann et al., 1996).
Although CD 14 is anchored to myeloid cells, it does not possess a transmembrane 
domain and can therefore not induce intracellular signalling.  The discovery of Toll­
like receptors  (TLRs)  solved the mystery  of how CD14/LPS  complexes  convey a 
signalling  message  to  the  cytoplasm  (Medzhitov  et al.,  1997).  Studies  involving 
innate  immunity  in  Drosophila  unveiled  a  plasma  membrane  receptor,  Toll,  that 
recognises  pathogens  and  activates  an  innate  immune  response  via  activation  of 
Dorsal, Dif and Relish, transcription factors of the Rel family that are homologous to 
mammalian  N F-kB  (Ghosh  et  al.,  1998).  Mutations  in  Toll  render  Drosophila 
susceptible  to  fungal  infections  as  they  are  unable  to  produce  drosomycin,  an 
antifimgal  peptide  (Lemaitre  et  al.,  1996).  In  Drosophila,  Toll  is  a  plasma 
membrane  receptor  that  possesses  a  cytoplasmic  domain  homologous  to  the 
mammalian IL-1  receptor (IL-1R)  (Medzhitov et al.,  1997).  The Dorsal system in 
Drosophila,  which  is  important  in  the  formation  of dorsoventral  patterning  in  the 
embryo, is paralleled in mammalian species by N F-kB  (Wasserman,  1993).  Dorsal 
and  N F-kB  are  retained  in  the  cytoplasm  by  the  inhibitor  proteins  cactus  and 
inhibitory  kB  subunit  (IkB)  respectively.  Upon  receptor  stimulation  (Toll/IL-IR) 
dorsal and N F-kB are released from cactus and IkB and are free to translocate to the 
nucleus and interact with target promoters bringing about controlled gene expression 
(Wasserman, 1993; Lemaitre et al., 1996).
Sequence homology between  Toll and human  IL-1R was used in a blast search  of 
human  cDNA  libraries.  A  cDNA  clone  with  an  open  reading  frame  of 2523  bp 
encoding a 841 amino acid (aa) chain was found and was termed TLR (Medzhitov et 
al.,  1997).  Five TLRs were originally cloned  (Medzhitov et al.,  1997) but there are 
now known to be at least  10 members in the  family  (Takeda et al., 2003;  Pandey 
and Agrawa,  2006)  and  they are  characterised  structurally  by leucine-rich  repeats 
(LRR) in the extracellular domain and a 7o///IL-lR (TIR) domain in the intracellular
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region (Rock et al.,  1998; Akira et al., 2001; Takeda et al., 2003).  TLR-4 was the 
first mammalian TLR to be identified.  mRNA encoding this protein has been found 
in monocytes, macrophages, T-cells, small intestinal epithelial cells and B-cells and 
activation of the receptor induces expression of inflammatory cytokines (Medzhitov 
et al.,  1997).  In 1998, TLR-4 was established as the receptor for LPS (Poltorak et al., 
1998;  Qureshi  et al.,  1999;  Hoshino  et al.,  1999).  C3H/HeJ  and  C57BL/10ScCr 
mice were known to be hyposensitive to LPS and the group of Poltorak et al showed 
that both had mutations in the Tlr4 gene.  C3H/HeJ mice have a missense mutation 
in the third exon, which replaces a highly conserved proline with histidine at position 
712,  while  C57BL/10ScCr  mice  are  homozygous  for  a  null  mutation  of  Tlr4 
(Poltorak et al.,  1998; Qureshi et al.,  1999).  Subsequently, the involvement of TLR- 
4 in LPS recognition was further confirmed using TLR-2 and TLR-4 deficient mice. 
In  WT  and  TLR-2  deficient  mice,  shock  was  induced  by  day  5  following  LPS 
challenge and only one fifth survived on day 6.  In contrast all the TLR-4 deficient 
mice  were alive  on day  6  showing that TLR-4  but not  TLR-2  is  involved in  LPS 
signalling  and  septic  shock  (Takeuchi  et al.,  1999).  Furthermore WT  and  TLR-2 
deficient  macrophages  produced  IL-6,  TNF-a and  NO  (i.e.  nitrite)  in  response  to 
LPS while TLR-4 deficient macrophages were unable to produce these inflammatory 
mediators (Takeuchi et al.,  1999).  Although TLR-4 is the principal receptor for LPS, 
it  has  been  shown  that  LPS  can  be  recognised  and  internalised  independently  of 
CD 14  and  TLR-4.  Studies  using  affinity  chromatography,  peptide  mass 
fingerprinting  and  fluorescence  resonance  energy  transfer  have  shown  the 
involvement of heat shock proteins (hsp) 70 and 90, chemokine receptor 4 (CXCR4) 
and  growth  differentiation  factor  5  (Triantafilou  et  al.,  2001).  Furthermore, 
nucleotide  oligomerisation  domain  (Nod)  1   and  2  have  been  identified  as 
intracellular  recognition  molecules  for  LPS,  which  can  directly  activate  NF-kB 
(Inohara et al., 2002).
In addition to  LBP, CD 14 and TLR-4, the LPS binding complex requires a further 
protein  for  signalling,  myeloid  differentiation  protein-2  (MD-2).  Radioprotective 
105  (RP105) is a lymphocyte specific receptor that has  LRR similar to Drosophila 
Toll  and  TLR-4;  it  was  found  that  a  secretory  molecule  called  MD-1  physically 
associates with  RP105  and is  essential  for B-cell  activation  (Miyake  et al.,  1998). 
The amino acid sequence for MD-1  was used in a computer blast of an  expressed
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sequence tag database and a human cDNA clone with an open reading frame of 160 
aa termed  MD-2  was  identified (Shimazu et al.,  1999).  It was  shown that  MD-2 
associates  with  TLR-4,  as  expression  of MD-2  confers  responsiveness  to  LPS  in 
cells  co-expressing  TLR-4  and  it  co-localises  with  TLR-4  on  the  cell  surface 
(Shimazu et al, 1999).  Furthermore, MD-2 enhances TLR-4 dependent activation of 
NF-kB  by 2 -  3  fold (Shimazu et al.,  1999).  Studies using  MD-2  KO mice have 
shown that MD-2 is indispensable for LPS responses both in vitro and in vivo.  Cells 
isolated  from  MD-2'7 ' mice  are hyporesponsive  to  LPS  and are  unable  to  produce 
inflammatory cytokines.  MD-2 7 ' mice have similar phenotypes to the TLR-4'7 ' mice 
and are hyporesponsive to LPS and survive endotoxic shock (Nagai et al., 2002).  In 
addition it was shown that MD-2 contributes to the correct intracellular distribution 
of TLR-4.  In  MD-2'7 '  cells  TLR-4  predominantly  resides  in  the  golgi  apparatus 
associated  with  the  chaperone  protein  glycoprotein  96  (gp  96)  and  is  unable  to 
translocate to the cell membrane and thus recognise LPS (Nagai et al., 2002).  Cross- 
linking studies have shown that LPS comes into close proximity to TLR-4 only when 
it is bound to CD 14 and its interaction with TLR-4 involves MD-2 (Da Silva Correia 
et al., 2001).
All the components of the LPS recognition and signalling pathway discussed thus far 
are involved extracellularly.  The LPS intracellular signal transduction pathway was 
first  elucidated  by  its  similarities  (once  again)  to  the  Drosophila  Toll  and  IL-1R 
signalling cascades.  In Drosophila an adaptor protein known as  Tube binds to the 
intracellular portion of the  Toll receptor and brings about the activation of Dorsal, 
the NF-kB homologue, via the Pelle pathway (Akira et al., 2001).  In the mammalian 
system the adaptor protein myeloid differentiation factor-88 (MyD88), a homologue 
of  Tube,  binds  intracellularly  to  IL-1R.  MyD88  links  IL-1R  to  IL-1  receptor- 
associated  kinase  (IRAK),  a  serine-threonine  kinase  that  is  a  homologue  of 
Drosophila Pelle  (Muzio et al,  1997; Wesche et al., 1997; Medzhitov et al., 1998). 
The same MyD88 adaptor protein has been found to bind to the intracellular region 
of TLR-4 as all receptors possess a common conserved Toll/ILIR (TIR) domain and 
TLR-4 immunoprecipitates with MyD88 (Medzhitov et al.,  1998).  MyD88-deficient 
mice are resistant to high doses of LPS and increases in serum levels of IL-6, TNF-a 
and  IL-lp  levels  are not  detected  in  these animals.  To  the contrary,  WT  animals 
have  elevated  levels  of inflammatory  cytokines  and  almost  all  these  animals  die
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within  96  h  after  LPS  injection  (Kawai  et  al,  1999).  Similarly,  macrophages 
isolated  from  MyD88  KO  mice  fail  to  produce  any  inflammatory  cytokines  or 
mediators in response to LPS (Kawai et al., 1999).
Upon  ligand  binding  to  TLR-4,  IRAK is phosphorylated and  dissociates  from  the 
receptor complex and interacts with another adaptor protein TNF receptor-activated 
factor 6 (TRAF6)  (Akira et al., 2001; Fujihara et al., 2003).  TRAF6 activates both 
the  MAPK  pathway  resulting  in  AP-1  activation  and  the  inhibitors  of kB  kinase 
(IKK) complex allowing NF-kB activation (Fujihara et al., 2003).  Evidence for the 
involvement of both IRAK and TRAF6 in LPS signalling was provided mainly from 
genetic  manipulation  studies.  In  the human  promonocytic  THP-1  cell  line  it  was 
shown  that  LPS  activates  endogenous  IRAK  as  measured  by  its  in  vitro  kinase 
activity toward myelin basic protein and that LPS triggers the association of IRAK 
with MyD88 (Li et al, 2000).  Furthermore, IRAK-deficient mice are resistant to the 
lethal effects of LPS,  and macrophages isolated  from IRAK deficient mice exhibit 
impaired TNF-a production in response to LPS (Swantek et al., 2000).  In TRAF6- 
deficient macrophages induction of iNOS  is  impaired  in response to high doses of 
LPS  and  NF-kB  activation  is  impaired  in  embryonic  fibroblasts  and  splenocytes 
isolated from the same animals  (Lomaga et al,  1999).  Finally, dominant negative 
TRAF6 mutations significantly impair TLR-4-induced NF-kB activity (Muzio et al., 
1998).
NF-kB  has  been  shown  to  be  activated  by  LPS  through  TGF-p-activated  kinase 
(TAK-1)  and  TRAF6-regulated  IKK  activator  2  (TRIKA-2)  by  activating  IKK 
(Wang et al.,  2001).  However,  IKK phosphorylation and hence NF-kB  activation 
can  also  be brought  about by numerous  MEKs  as  well  as NF-kB  inducing kinase 
(NIK; Guha and Mackman, 2001).
In  addition  to  NF-kB  activation,  LPS  can  induce  IFN-a/p  expression  in  murine 
macrophages  in  an  autocrine/paracrine,  MyD88-independent  fashion.  The 
transcription  factor  signal  transducer  and  activator  of transcription  la  (Statla)  is 
activated by phosphorylation and together with interferon regulatory factor (IRF)  1  
regulate the  expression of iNOS  (Jacobs  and Ignarro,  2001;  Kleinert et al,  2003). 
IFN-a/p expression is also important for the expression of other LPS-inducible genes
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including  IFN-inducible  protein-10  and  monocyte  chemoattractant  protein  5 
(Fujihara  et  al,  2003).  Studies  using  IRF-3-deficient  mice  have  shown  the 
importance of this regulatory factor in the stimulation of IFN-0 as the mice become 
resistant  to  LPS-induced  endotoxic  shock  (Sakaguchi  et al,  2003).  Independent 
studies  have  demonstrated  the  involvement  of  TIR  domain-containing  adaptor 
protein (TIRAP; Homg et al, 2001) and MyD88-adaptor-like (Mai; Fitzgerald et al, 
2001) in the MyD88-independent activation of TLR-4 by LPS and the induction of 
IFN-p  as  well  as NF-kB.  Furthermore,  LPS  activates  a number of other MyD88- 
independent  signalling  molecules  including  PKC  (Paul  et  al,  1997),  Src-type 
tyrosine  kinases,  small  G  proteins,  PI3K  and  the  serine/threonine  protein  kinase 
Akt/protein kinase  B,  all  of which  can  activate NF-kB  as well  as  members  of the 
MAPK pathways (Akira et al, 2001).
1.3.2.  LPS and the MAPK pathway
The activation of MEK/ERK  1/2 by LPS has been shown to be both Ras and c-Raf 
dependent  (Reimann  et al,  1994;  van  der  Bruggen  et al,  1999)  and  independent 
(Buscher et al,  1995).  Dominant negative repressors of Ras and c-Raf inhibit LPS 
induction of the TNF-a promoter in RAW264.7 macrophages (Guha and Mackman, 
2001) and treatment of BAC-1.2F5  macrophages with LPS causes phosphorylation 
and activation of Raf-1  followed by stimulation of MEK-1   and MAPK activity with 
subsequent phosphorylation of the transcription factor, Elk-1  (Reimann et al,  1994). 
Inhibition of MEK by the specific inhibitor U0126 causes failure of macrophages to 
release cytokines such as IL-lp, IL-8 and TNF-a as well as prostaglandin E2 (Scherle 
et  al,  1998).  Treatment  of human  monocytes  with  PD98059  (MEK  inhibitor) 
inhibits LPS induction of TNF-a (van der Bruggen et al, 1999; Guha and Mackman,
2001)  and in murine macrophages,  PD98059 decreases LPS-induced iNOS mRNA 
and expression (Kim et al, 2004).
The  activation  of  p38  has  also  been  implicated  in  LPS  signalling.  Targeted 
disruption of Mkk3, the gene encoding MEK3, upstream of p38,  causes a selective 
defect in the response of fibroblasts to TNF-a, including reduced p38 activation and 
cytokine  expression  (Wysk  et  al,  1999).  Inhibition  of p38  using  the  pathway 
specific  inhibitor 4-(4-Fluoreophenyl)-2-(4-methylsulfmylphenyl)-5-(4-pyridyl)-1H-
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imidazole  (SB203580) results  in  reduced  cytokine  expression  (IL-1(3  and  IL-6)  as 
well as a decrease in LPS-induced iNOS expression (Kim et al, 2004).
The third pathway in the MAPK network, the JNK pathway is also involved in LPS 
signalling  (Hambleton  et al.,  1996).  Treatment of RAW264.7  cells,  murine  bone 
marrow-derived  macrophages  and the human  monocyte  cell  line THP-1  with  LPS 
results in rapid activation of the two iso forms of JNK, p46 and p54 (Hambleton et al., 
1996).  JNK is regulated by the upstream MEK 4 and MEK 7  (Yang et al.,  1997; 
Toumier et al.,  1999) and treatment of THP-1  cells with the monoclonal antibody 
60b, which blocks LPS-LBP binding to CD 14, results in inhibition of JNK activation 
indicating the importance of JNK in downstream gene expression initiated by LPS 
(Hambleton et al., 1996).
The  pathways  involved  in  LPS  signalling,  as  detailed  above,  are  summarised  in 
Figure 3.
1.3.3.  Septic (endotoxic) shock
Septic  shock can  be  defined  as  a  progressive  failure  of the  circulation  to  provide 
blood  to  vital  organs.  Symptoms  of septic  shock include  severe  hypotension  and 
inadequate  tissue  oxygenation,  resulting  in  multiple  organ  failure  (Thiemermann, 
1997; Wolkow, 1998).  The most common cause of septic shock is the contamination 
of blood with gram-negative bacteria  (bacteraemia) and thus the presence of LPS, 
although  gram-positive  bacteria,  viruses  and  parasites  can  also  cause  sepsis 
(Thiemermann,  1997).  Septic  shock  and  multiple  organ  failure  are  an  important 
cause of morbidity and mortality affecting around  1   % of all hospitalised patients 
(Wolkow,  1998) and 30 -  40  % of patients admitted to intensive care units  (ICU; 
Pittet  et al.,  1995).  It  is  known  that  the  development  of multiple  organ  failure 
involves  numerous  pathways  including  inflammatory,  immune,  microvascular, 
hormonal, bioenergetic and metabolic systems (Vincent et al., 2006).
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Figure  3  -   LPS-triggered  signalling  cascades  (Abbreviations:  ERK  -   extracellular  signal- 
regulated  kinases,  IFN  -   interferon,  IKK  -   inhibitors  of kB  kinase,  IRAK  -   IL-1  receptor 
associated  protein  kinase,  IRF3  -   interferon  regulatory  factor 3,  IkB  -   inhibitory  kB  subunit, 
JNK -  C-Jun N-terminal kinases, LBP -  LPS-binding protein, LPS -  lipopolysaccharide, Mai -  
MyD88-adaptor-like, MAPK -  mitogen-activated protein kinase, MD-2 -  myeloid differentiation 
protein 2, MyD88 -  myeloid differentiation factor-88, NF-kB -  nuclear factor-KB, NIK -  NF-kB 
inducing  kinase,  STAT  -   signal  transducers  and  activators  of transcription,  TAK  -   TGF-jl- 
activated  protein  kinase,  TIRAP  -   TIR  domain-containing  adaptor  protein,  TLR-4  -   toll-like 
receptor  4,  TRAF6  -   TNF  receptor-activated  factor  6,  TRIKA2  -   TRAF6-regulated  IKK 
activator 2).
Animal models and human clinical data have shown a definitive role for NO in the 
development  of septic  shock  (Ochoa et al.,  1991;  Nava et al,  1992;  Evans  et al., 
1993;  Liu et al.,  1993).  Treatment of rats  in vivo with  LPS causes  an  increase in 
iNOS  mRNA  levels  in  lung,  liver,  spleen,  skeletal  muscle  and  kidney  and  this  is 
attenuated in the presence of dexamethasone (Liu et al,  1993).  Administration of 
the  NOS  inhibitor  N  -methyl-L-arginine  (L-NMA)  to  animal  models  of  sepsis 
restores blood pressure (Kilboum et al,  1990; Kilboum et al.,  1992; Kilboum et al., 
1994;  Kilboum  et  al.,  1997),  hyporesponsiveness  to  vasoconstrictors  (Julou-
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Schaeffer et al,  1990) and improves renal and hepatic function (Hinder et al,  1996; 
Kilboum et al,  1997).  In clinically septic patients, plasma total nitrite (NO2 ) and 
nitrate (NO3'; NOx) levels are significantly higher than normal control patients (63.1 
±  6.5  pmol/L  septic  vs  28.9  ±  3.6  pmol/L  control)  and  this  is  mirrored  by 
significantly increased endotoxin levels (0.144 ± 0.06 ng/ml vs 0.044 ± 0.02 ng/ml; 
Ochoa  et al,  1991).  Additional  evidence  for  the  involvement  of iNOS  in  septic 
shock  has  been  provided  by iNOS-deficient mice.  These  animals  are  resistant  to 
early  death  by  LPS  and  the  fall  in  central  arterial  blood  pressure  is  markedly 
attenuated  (MacMicking  et  al,  1995).  Macrophages  from  iNOS'7 '  mice  produce 
negligible  NO  (nitrite)  following  stimulation  with  LPS  (Wei  et  al,  1995). 
Furthermore, responses to the thromboxane A2 analogue, U46619 in carotid arteries 
from  iNOS  KO  mice  are  not  impaired  following  LPS  treatment  indicating  the 
importance of iNOS in impaired vascular contractility following LPS treatment and 
hence during septic shock (Gunnett et al, 1998; Chauhan et al, 2003a).
It is now well know that overproduction of NO contributes to the hypotension and 
reduced  circulatory  resistance  in  septic  shock.  Hence,  NO  is  key  to  the 
cardiodepression  and  vascular  hyporeactivity,  all  of which  contribute  to  multiple 
organ  failure  (Landry  and  Oliver,  2001).  NO  can  also  act  deleteriously  by  the 
formation  of  peroxynitrite  resulting  in  DNA  damage  and  impairment  of 
mitochondrial respiration (Hauser et al, 2005; Levy et al, 2005).  On the other hand, 
NO can be protective as it can inhibit leukocyte and platelet aggregation as well as 
scavenge oxygen radicals (Hauser et al, 2005).
Since the high levels of NO produced by iNOS can be so deleterious in septic shock, 
clinical studies were conducted in an attempt to find a suitable drug for the treatment 
or  improvement  of this  systemic  condition.  Results  from  a  phase  II  randomised, 
double-blind,  placebo-controlled  study  using  L-NMA  promoted  the  resolution  of 
shock  (Wei  et  al,  1995),  reduced  the  elevated  plasma  nitrate  concentrations, 
increased vascular tone and reduced both cardiac index and oxygen delivery as well 
as successfully maintaining a target mean arterial blood pressure of > 70 mm Hg and 
reducing  the  requirement  for,  or  withdrawal  of,  conventional  inotropic 
vasoconstrictor agents (Watson et al, 2004).  Despite the promising results from this
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study, a subsequent phase III clinical trial was terminated prematurely as there was 
increased mortality in the treatment group (Lopez et al, 2004).  However, the trials 
met  criticism  in  an  accompanying  editorial  stressing  the  importance  of specific 
versus non-specific NOS inhibitors as complete NO inhibition by inhibiting all NOS 
isoforms could result in blockade of physiological NO functions (Phillip and Parrillo, 
2004).
1.4.  Guanylate cyclase (GC) and cGMP
Cyclic  GMP  is  a  second  messenger  produced  by  the  enzymatic  catalysis  of 
guanosine  5'-triphosphate  (GTP)  by  the  guanylate  cyclase  (GC)  enzymes  and  is 
degraded by hydrolysing phosphodiesterases (PDE).  It was first identified in urine 
in  1963  (Ashman et al,  1963) and was  later designated as  a second messenger in 
1970 (Kuo and Greengard,  1970).  cGMP can bring about its effects by interacting 
with  cyclic  nucleotide-gated  (CNG)  cation  channels,  cGMP-regulated  PDEs  and 
PKG.  There  are  two  forms  of guanylate  cyclase,  soluble  (sGC)  and  particulate 
(pGC).  sGC is principally activated by NO, while pGC is activated by the family of 
natriuretic  peptides  (Feil  et al,  2003;  although  there  are  a  number  of membrane 
bound GCs, which are orphan receptors and whose ligands have yet to be identified; 
Kuhn, 2003).  The soluble isoform exists as a heterodimer composed of an a and P 
subunit and has a covalently bound prosthetic haem group.  Two isoforms of each 
subunit have been identified, ai/<X 2 and Pi/p2 (Russwurm and Koesling, 2002).  The 
particulate  isoform  is  made  up  of  an  extracellular  ligand  binding  domain  (for 
natriuretic peptide binding),  a short transmembrane region and an intracellular GC 
catalytic  domain  and  acts  as  the  natriuretic  peptide  receptor  (Kuhn,  2003).  The 
ability  of NO  and  natriuretic  peptides  to  stimulate  GCs  underlies  their  analogous 
effects in the vasculature.
1.5.  Natriuretic peptides
1.5.1.  Introduction
Natriuretic peptides are a family of highly conserved but widely distributed cardiac 
hormones, which play important roles in cardiovascular homeostasis (Baxter, 2004).
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Three  members  of this  family,  atrial  natriuretic  peptide  (ANP),  brain  natriuretic 
peptide  (BNP)  and  C-type  natriuretic  peptide  (CNP)  have  been  well-characterised 
and  extensively  reviewed  in  the  literature  (Ahluwalia  et al,  2004;  Baxter,  2004; 
Kuhn,  2004;  Potter,  2004;  Vanderheyden  et al.,  2004);  other members  have  been 
documented  but  are  less  well  characterised  and  their  function  and  physiological 
importance have yet to be fully elucidated (Baxter, 2004).  ANP and BNP act in an 
endocrine  manner  to  regulate  fluid  and  electrolyte  balance,  blood  pressure  and 
cardiac  morphology,  while  CNP  is  thought  to  have  a  complementary  role  acting 
locally in the vascular endothelium in a paracrine fashion to control vascular smooth 
muscle tone and proliferation (Ahluwalia et al, 2004).
1.5.2.  History of natriuretic peptides
The presence of endocrine-like secretory granules in the atria was first described by 
Kisch and Jamieson in 1956 (Kisch,  1956).  However, it was not until the late  1970s 
that the role of the heart as an endocrine organ and its connection to the kidney was 
elucidated when de Bold and his co-workers detected a change in atrial granularity in 
accordance  with  changes  in  body  fluid  balance  (de  Bold,  1979).  This  was  later 
attributed  to  an  atrial  hormone  now  know  as  ANP.  In  1981  de  Bold  infused 
anaesthetised rats with an atrial myocardial homogenate (de Bold et al,  1981).  An 
increase in sodium,  potassium and chloride excretion as well as an increased urine 
volume were observed (de Bold et al, 1981), confirming the link between natriuresis, 
ANP and atrial granularity (de Bold,  1982).  Following these observations two more 
members  of  the  natriuretic  peptide  family  with  potent  natriuretic,  diuretic  and 
vasodilating  activity  (Levin  et  al,  1998),  as  well  as  anti-proliferative  and  anti- 
migratory  effects  on  vascular  smooth  muscle  cells  (Casco  et  al,  2002)  were 
identified.  In  1988 Sudoh et al identified a peptide in porcine brain that had similar 
biological and structural properties as ANP and hence was called BNP  (Sudoh et al, 
1988;  Sudoh et al,  1989).  CNP  was  isolated two years  later,  again  from porcine 
brain  by  Sudoh  et  al  (Sudoh  et  al,  1990)  but  it  was  later  revealed  that  the 
endothelium  is  the  main  site  for  CNP  synthesis  (Suga  et al,  1992b).  Additional 
members  of  the  natriuretic  peptide  family  exist  with  structural,  biological  and 
distributional similarities to ANP,  BNP and CNP.  Dendroaspis natriuretic peptide 
(DNP) was isolated from the venom of the green mamba, Dendroaspis angusticeps
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(Schweitz et al.,  1992), urodilatin was isolated from human urine (Schulz-Knappe et 
al.,  1988) while guanylin and uroguanylin are both intestinal peptides produced by 
the gut epithelium (Kuhn, 2004).
1.5.3.  Natriuretic peptide synthesis, processing and 
expression
Each  natriuretic  peptide  is  encoded  by  a  separate  gene  in  humans  and  all  are 
produced  as  unique  prohormones  that  undergo  post-translational  modification  to 
yield the active peptides.  Peptide synthesis is shown in Figure 4 and  synthesis for 
each peptide is described below.
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Figure 4 -  Natriuretic peptide synthesis.
1.5.3.1.  ANP
ANP is primarily produced in the atria of the heart.  It is encoded in humans as a 151 
aa preprohormone by the Nppa gene (Baxter, 2004) on chromosome 1   (Baxter, 2004; 
Vanderheyden et al., 2004) and the mRNA transcript is approximately  1   kb in size 
(Vanderheyden  et al.,  2004;  the  ANP  gene  in  mice  is  located  on  chromosome  4; 
Tamura et al.,  1996).  The Nppa  gene  consists  of 3  exons  separated  by 2  introns 
(Vesely, 2002).  The prcprohormone undergoes cleavage of its 25 aa signal peptide
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in  the  endoplasmic  reticulum  giving  the  126  aa  prohormone  (proANP),  which  is 
stored in atrial myocyte granules  (Vuolteenaho et al.,  1985) and released into  the 
circulation  in  response  to  stretch,  thyroid  hormones,  glucocorticoids, 
mineralocorticoids,  calcium  and  vasoconstrictive  peptides  such  as  endothelin-1, 
norepinephrine  and  angiotensin  II  (Ang  II;  Vesely,  2002).  Cleavage  of  this 
prohormone  by  corin,  a  cardiac  serine  protease  (Yan  et al.,  2000)  produces  an 
amino-terminal fragment of 98 aa and a carboxy-terminal fragment of 28 aa (ANP), 
which  is  the  biologically  active  peptide  (Vesely,  1995).  In  addition,  alternative 
processing  of the  126  aa  prohormone  in  the  kidney  produces  a  32  aa  peptide, 
urodilatin (Schulz-Knappe et al.,  1988).  It is identical to ANP but with an additional 
4 aa on the N-terminus and is  important  in regulating sodium and water excretion 
(Stoupakis and Klapholz, 2003).
Knockout  mice  have  been  generated  with  a  disrupted  pro-ANP  gene  and  these 
animals  have  been  characterised  to  have  salt-sensitive  hypertension  (John  et  al.,
1995).  Transgenic  animal  models  that  overexpress  ANP  show  hypotension  but 
without  inducing  diuresis  or natriuresis  (Steinhelper et al.,  1990).  ANP  also  has 
direct  anti-hypertrophic  effects  on  the  heart  as  mice  lacking  ANP  exhibit 
cardiomyocyte  and  biventricular hypertrophy,  which  is  independent  of changes  in 
blood pressure (Feng et al., 2003), whilst animals overexpressing ANP have smaller 
hearts (Barbee et al., 1994).  Furthermore, mice lacking the proANP convertase corin 
have elevated levels of proANP and suffer from spontaneous hypertension, although 
no  higher  detectable  levels  of circulating  ANP  are  observed  compared  with  WT 
littermates (Chan et al., 2005).
1.5.3.2.  BNP
BNP was  first  identified  in porcine brain  (Sudoh et al.,  1988) but  in humans  it is 
produced predominantly by the cardiac ventricles (Yasue et al.,  1994).  PreproBNP 
is encoded by the gene, Nppb, in tandem with Nppa (approximately 8 kb upstream) 
on the distal  short arm of chromosome  1   in humans  (Tamura et al.,  1996).  Nppb 
consists of 3 exons and 2 introns (Ogawa et al.,  1994a).  Its preprohormone consists 
of  134  aa  that  undergoes  endoprotease  cleavage  to  give  a  108  aa  prohormone 
(proBNP; Baxter, 2004).  In humans the prohormone is processed to create the 32 aa
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carboxy-terminal, biological active BNP (77 -   108), and an amino-terminal peptide 
(1 -  76) whose physiological role has yet to be identified  (Sudoh et al,  1989; Hunt 
et al, 1995).  The 108 aa prohormone as well as the two cleavage products, BNP and 
amino-terminal proBNP (NT-proBNP), circulate in the plasma  (Vanderheyden et al, 
2004).  The porcine and rat BNP prohormone, in addition to the 32 aa BNP, can be 
processed to yield pBNP-26 and rBNP-45 respectively (Koller and Goeddel, 1992).
Targeted  disruption  of the  Nppb  gene  has  shown  the  importance  of BNP  as  an 
antifibrotic factor and its role as a regulator of ventricular remodelling.  These KO 
animals demonstrate cardiac fibrosis but have normal blood pressure and exhibit no 
left  ventricular  hypertrophy  (Tamura  et  al,  2000).  In  earlier  transgenic  mouse 
studies in which BNP was overexpressed, the mice were hypotensive suggesting the 
potential  use  of  BNP  as  a  long-term  therapeutic  agent  (Ogawa  et  al,  1994a). 
However Natrecor® (nesiritide;  synthetic recombinant form of human BNP) can be 
detrimental to the patient’s health (Topol, 2005) as will be discussed in section 1.6.
1.5.3.3.  CNP
In humans CNP is highly prevalent in the central nervous system, anterior pituitary, 
hypothalamus,  midbrain,  kidney  and  especially  in  vascular  tissues  (Levin  et  al, 
1998;  Stoupakis  and  Klapholz,  2003).  CNP  is  encoded  by  the  Nppc  gene  on 
chromosome 2  in humans and chromosome  1   in mice (Ogawa et al,  1992) and is 
thus physically separate  from the ANP and BNP coding regions.  The human gene 
consists  of  2  exons  separated  by  an  intron  and  produces  a  126  aa  residue 
preprohormone (Ogawa et al,  1992) that is processed at the N-terminus by 23 aa to 
give proCNP (23-126;  Stoupakis and Klapholz, 2003).  The carboxy-terminal end is 
then metabolised by the endoprotease furin (Wu et al, 2003) to give the 22 aa active 
form  of CNP  and  53  aa,  N-terminally  elongated  form  of CNP  (Minamino  et al, 
1990), with the 22 aa peptide being more potent than its 53 aa counterpart (Tawaragi 
et al, 1991; Stoupakis and Klapholz, 2003).
Nppc gene  disruption has revealed CNP’s  importance in  endochondral ossification 
and  its  role  as  a  local  positive  regulator of this  process.  Nppc  KO  mice  exhibit 
dwarfism with the length of femurs, tibiae and vertebrae being 50 -  80 % of their
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WT littermates, in addition to striking narrowing of the growth plate (Komatsu et al.,
2002).  Less  than  50  %  of  CNP  KOs  are  able  to  survive  during  postnatal 
development, although targeted expression of CNP in the growth plate chondrocytes 
improves their survival rate (Chusho et al., 2001).
1.5.4.  Natriuretic peptide structure and homology
All  natriuretic  peptides  possess  a  common  17  aa  ring  structure  formed  by  an 
intramolecular disulfide bond between 2 conserved cysteine residues (Silberbach and 
Roberts,  2001).  The  ring  component  of the  natriuretic  peptides  consists  of  11 
invariant and 6 variable amino acids.  ANP and BNP are very similar and both have 
amino and carboxyl-termini attached to the ring structure while CNP is lacking the 
C-terminal tail (Ogawa et al.,  1994b).  This ring structure is imperative for receptor 
recognition  and physiological  functions  (Inagami et al.,  1987).  The  common  ring 
structure and homology of ANP, BNP and CNP are shown in Figure 5.
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Figure 5 -  Amino acid sequence and primary structure of mammalian natriuretic peptides.
Invariable amino acids are shaded darker blue (adapted from Silberbach and Roberts, 2001).
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ANP and CNP are highly conserved among species with CNP being considered the 
ancestral form of all natriuretic peptides.  All three peptides are found in tetrapods 
but CNP  is the only form found in elasmobranches  (Inagami et al.,  1987) and this 
lead to  the speculation that CNP was the original natriuretic peptide giving rise to 
ANP  and  BNP  by  gene  duplication  (Silberbach  and  Roberts,  2001)  through 
evolutionary  development.  Human  and  porcine  ANP  are  identical  while there  is 
only 1   aa substitution between the human and rat forms (Koller and Goeddel, 1992). 
Similarly porcine  and rat  CNP-53  are  identical,  with  human  CNP-53  having  2  aa 
substitutions;  however,  CNP-22  is  conserved  across  all  mammals  (Koller  and 
Goeddel, 1992).  In contrast, BNP is not as well conserved.  At the amino acid level, 
human, rat and pig BNP are only 50 % homologous while the mature peptides vary 
in size from 26 aa in pigs to 32 aa in humans and 45 aa in rats (Koller and Goeddel, 
1992).
1.5.5.  Natriuretic peptide receptors (NPRs)
Following  the  discovery  of natriuretic  peptides,  the  question  arose,  how  do  these 
peptides mediate their responses?  In  1984 it was  observed that in the presence of 
ANP  there  was  an  increase  in  cGMP  and  activation  of the  particulate  form  of 
guanylate  cyclase  (Waldman  et  al.,  1984).  Molecular  cloning  led  to  the 
identification of several membrane-bound guanylate cyclases in mammals (Tremblay 
et al., 2002) with two of these, guanylate cyclase-A (GC-A) and guanylate cyclase-B 
(GC-B),  also  known  as  NPR-A  and  NPR-B,  acting  as  receptors  for  natriuretic 
peptides  (hence,  natriuretic  peptide  receptors;  Chinkers  et al.,  1989;  Schulz et al., 
1989;  Koller et al.,  1991).  NPR-C was  later identified but this  receptor does  not 
possess  a  guanylate  cyclase  (or  kinase)  domain  (Fuller  et al.,  1988);  rather  it  is 
involved  in  natriuretic  peptide  clearance  (Nussenzveig et al.,  1990;  Cohen  et al., 
1996; see section 1.5.6) and has recently been assigned a signalling function (Murthy 
and Makhlouf, 1999; Ahluwalia and Hobbs, 2005; see section 1.5.5.3).
The  three  members  of the  natriuretic  peptide  family  bind  to  these  high  affinity 
receptors  on  target cells  (Stoupakis  and Klapholz,  2003).  NPR-A and NPR-B are 
guanylate  cyclase  linked  receptors  and  consist  of an  extracellular  440  aa  binding 
domain, a single transmembrane spanning region, a 280 aa kinase homology domain
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(KHD; which shows approximately 30 % homology to protein kinases), and a 250 aa 
guanylate cyclase domain (55 % homologous to other mammalian members of the 
receptor  guanylate  cyclase  family).  There  exists  a  44  %  homology  between  the 
extracellular regions,  63  % homology between the intracellular kinase-like domain 
and  88 % homology between the  guanylate cyclase domains (Koller and Goeddel,
1992).  Like NPR-A and NPR-B, NPR-C has  an extracellular domain and a single 
membrane spanning region but it only has a 37 aa intracellular domain that bears no 
homology to the NPR-A and NPR-B intracellular domains.  The intracellular domain 
of NPR-C is devoid of both guanylate cyclase and kinase activities but it selectively 
activates G proteins of the Gj/0 family via a G-protein-activating domain (Murthy and 
Makhlouf,  1999), which links it to adenylyl cyclase (Pagano and Anand-Srivastava, 
2001), phospholipase-Cp (PLC-p; Murthy et al, 2000) and G-protein gated inwardly 
rectifying  K+   channels  (GIRKs;  Chauhan  et  al.,  2003b).  The  structures  of the 
natriuretic peptide receptors are shown in Figure 6.
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Figure  6  -   Natriuretic  peptide  receptors  NPR-A,  NPR-B  and  NPR-C,  showing  homology 
between the three structures.
1.5.5.1.  NPR-A
NPR-A is encoded by a  16 kb gene on human chromosome  1, consists of 22 exons 
giving rise to a  1061  aa,  135 kDa peptide (Kone, 2001) and the crystal structure of 
the glycosylated, unliganded, dimerised extracellular domain of rat NPR-A has been 
solved (van den Akker et al, 2000; Ogawa et al, 2004).  The mature NPR-A peptide
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is  found in abundance in the vasculature, kidneys and adrenal glands (Levin et al., 
1998; Kone, 2001) and stimulation by natriuretic peptides, especially ANP or BNP, 
brings about vasorelaxation, natriuresis, a decrease in aldosterone synthesis (Kone, 
2001) and stimulation of testosterone production  (Pandey et al.,  1999).  NPR-A is 
most  abundant  in  large  blood vessels,  which  is  consistent with  the  vasorelaxation 
effects brought about by receptor activation (Levin et al.,  1998).  Although NPR-A 
binds all three natriuretic peptides,  it does so with different affinities and kinetics; 
ANP>BNP»CNP  (Suga  et al.,  1992a).  More recently,  DNP  has  been  shown  to 
bind to NPR-A with higher affinity than ANP and BNP (Singh et al., 2006a; Singh et 
al, 2006b).
The functions of NPR-A have partly been elucidated using KO animals.  NPR-A KO 
mice  are  hypertensive  (with  an  average  increase  in  blood  pressure  of  16  mmHg), 
have  low  plasma  renin  concentrations  (one  third  normal),  cardiac  hypertrophy, 
ventricular dilatation and  elevated heart-to-body ratio  compared to WT  littermates 
(133 % vs WT females;  185 % vs WT males; Oliver et al,  1997).  Male NPR-A KO 
mice have reduced testosterone levels (80 ± 10 -/- vs 120 ± 14 +/+, ng/ml) indicating 
that NPR-A plays an important role in testosterone biosynthesis and maintenance of 
the circulating hormone via a NPR-A dependent cGMP signalling pathway (Pandey 
et al.,  1999).  In addition, male NPR-A KO animals show increased susceptibility to 
pulmonary  hypertension  under Hypoxic  conditions  (Zhao  et al.,  1999)  and  exhibit 
sudden death before  6 months  of age  (Oliver et al,  1997).  NPR-A KO mice are 
now  often  used  as  a  unique  model  for hypertensive  disease  as  they  show  similar 
clinical  features  to  untreated  human  hypertensive  patients  (Oliver  et  al,  1997). 
Interestingly,  a  single allele mutation was  identified in the promoter region of the 
NPR-A  gene,  which  causes  a  70  %  decrease  in  NPR-A  expression  in  Japanese 
people.  Out of eight people with this  mutation,  seven suffered  from hypertension 
and one had congestive heart failure (Nakayama et al., 2000).
1.5.5.2.  NPR-B
NPR-B is encoded by a  16.5 kb region of human chromosome 9.  Like NPR-A, this 
receptor consists of 22 exons producing a 1047 aa peptide of approximately 120 kDa 
(Kone,  2001)  but  the  crystal  structure  has  yet  to  be  solved.  NPR-B  is  highly
48CHAPTER 1  -  INTRODUCTION
abundant  in  the  brain,  including  the  pituitary  glands  (Levin  et al.,  1998;  Kone, 
2001).  Binding  and guanylate  cyclase activation  studies  have  shown  that CNP  is 
likely to  be  the  only  endogenous  ligand  for NPR-B  as  it  selectively activates  the 
receptor at physiological concentrations  of 100 nM but has the ability to  stimulate 
cGMP signalling at concentrations as low as 0.5 nM.  Human CNP binding is 50 -  
500 fold higher than the other human natriuretic peptides (Koller et al.,  1991) with 
the order of binding affinity being CNP>ANP>BNP (Suga et al,  1992a).  In NPR-B 
KO mice there is dramatic impairment of endochondral ossification and attenuation 
of  longitudinal  vertebra  or  limb-bone  growth  leading  to  reduced  body  size  and 
dwarfism.  Using this model it has also been shown that NPR-B is important in the 
embryonic development of the female reproductive tract as female KO animals are 
infertile while males are fertile (Tamura et al., 2004).
1.5.5.3.  NPR-C
NPR-C is encoded on human chromosome 5  and is a 540 aa peptide (Kone, 2001). 
The  mature peptide  exists as  a homodimer (Kone,  2001),  each monomer having  a 
size  of  approximately  60  kDa  (Cohen  et  al.,  1996),  and  possessing  its  own 
membrane  spanning  domain  (Levin  et  al.,  1998);  monomers  are  linked  by  a 
disulfide bond  (Kone,  2001).  The crystal structure of the unbound and natriuretic 
peptide bound receptor extracellular domain have been solved (He et al., 2001; He et 
al., 2006).  NPR-C is the most abundantly and widely expressed natriuretic peptide 
receptor and is found in major endocrine glands, lungs, kidneys and the vascular wall 
(Kone,  2001).  In  addition  it  is highly  localised in cells and tissues that receive a 
large proportion of cardiac output;  these include vascular endothelial cells,  smooth 
muscle cells and the renal cortex (Cohen et al.,  1996).  All natriuretic peptides bind 
to NPR-C with high affinity but it has highest affinity for ANP  (ANP>CNP>BNP; 
Suga et al.,  1992a).  NPR-C  is known to act as a clearance receptor (Maack et al., 
1987; Matsukawa et al.,  1999; see section 1.5.6) but studies have also suggested that 
it  has  a  signalling  function  through  a  G-protein-activating  domain  (Murthy  and 
Makhlouf,  1999).
NPR-C KO mice have been developed and have assisted in clarifying  the biological 
functions of NPR-C (Matsukawa et al.,  1999).  These animals show prolonged half­
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life  of exogenous  ANP  (2.40 ±  0.08  -/-  vs  1.44  ± 0.05  +/+,  min)  and  are  mildly 
hypotensive  (110 ± 2.3  -/- vs  118.7 ±  1.9 +/+, mmHg),  in accord with a clearance 
function for this NPR subtype.  They also have increased daily urinary output (2.0 ± 
0.1  -/-vs  1.1 ±0.1  +/+, ml/day) and inability to concentrate urine indicating altered 
renal function, decreased intravascular volume, increased number of red blood cells 
(10.4 ± 0.1  -/- vs 9.7 ±0.1  +/+,  106/mm3), haematocrit (53.6 ± 0.9 -/- vs 49.9 ±  1.0 
+/+,  %)  and haemoglobin  (16 ± 0.2  -/- vs  15.6 ± 0.2  +/+,  g/dl)  levels.  However, 
plasma ANP and BNP levels are not higher in these animals (plasma ANP 88.5 ± 9.0 
-/- vs  114.5 ± 5.9 +/+, pg/ml; plasma BNP 22.1  ±  1.9 -/- vs 21.6 ± 3.8 +/+, pg/ml) 
suggesting that there is probably a homeostatic decrease in cardiac secretion of ANP 
and BNP, and any pathological effects seen in the NPR-C KO animals are not due to 
elevated plasma levels of ANP and BNP (Matsukawa et al, 1999).  NPR-C KO mice 
all have increased basal bone turnover and skeletal abnormalities including hunched 
backs,  dome-shaped  skulls,  elongated  tails,  femurs,  tibiae,  metatarsal  and  digital 
bones,  increased  body  length,  decreased  body  weight,  smaller  and  constricted 
thoracic cages as well as delay in development of secondary ossification centres in 
long bones (Matsukawa et al.,  1999) suggesting a role akin to NPR-B in regulating 
bone homeostasis.
1.5.6.  Natriuretic peptide clearance
Plasma  natriuretic  peptide  levels  are  controlled  by  both  the  rate  of synthesis  and 
release  as  well  as  their removal  from  the  circulation.  Natriuretic  peptides  can  be 
removed by two distinct methods, receptor mediated endocytosis involving NPR-C 
and  enzymatic degradation by neutral endopeptidase  (Vanderheyden et al,  2004). 
Neutral  endopeptidase is a non-specific, membrane-bound, zinc containing enzyme 
present on the surface of endothelial  cells,  smooth muscle cells,  cardiac  myocytes 
and fibroblasts as well as on brush border membranes in the proximal tubules of the 
kidneys  (Valli  et al,  1999;  Vanderheyden  et al,  2004).  Natriuretic  peptides  are 
cleaved by this  enzyme  opening  the ring  structure  and thus making them  inactive 
(Valli et al.,  1999).  Alternatively, natriuretic peptide plasma levels are controlled by 
NPR-C.  NPR-C  has  a  single  tyrosine  in  the  cytoplasmic  domain  (Tyr508),  which 
plays  an  important role  in clathrin-coated pit receptor internalisation  although it is 
not  flanked  by the degenerate  sequence  found on other receptors having the same
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method  of internalisation  (Cohen  et  al.,  1996).  Native  NPR-C  undergoes  rapid 
constitutive endocytosis in mammalian cells, the rate is not altered by ligand binding 
and dimerised receptors  are internalised twice as  fast  as  monomers  (Cohen et al., 
1996).  Endocytosed  receptor-ligand  complexes  are  dissociated  intracellularly  in 
endosomes, the ligand (natriuretic peptide) is lysosomally hydrolysed and the native 
receptors are recycled back to the cell surface (Nussenzveig et al., 1990; Cohen et al.,
1996).  Under normal conditions neutral endopeptidase is likely to play a relatively 
minor  role  in  metabolic  clearance  but  in  cardiovascular  disease  where  there  is 
increased levels of natriuretic peptides and a large fraction of NPR-C are occupied, 
neutral  endopeptidase  could  play  a  greater  role  in  natriuretic  peptide  clearance 
(Okolicany  et  al.,  1992;  Maack,  2006),  hence  the  effectiveness  of  neutral 
endopeptidase  inhibitors  in  cardiovascular  disease  (but  do  little  in  healthy 
volunteers).
1.5.7. Natriuretic peptide signalling
Both ANP and BNP exert their biological effect by binding to NPR-A while CNP is 
the  sole  endogenous  ligand  for  NPR-B  (Roller  et  al.,  1991).  Binding  of  all 
natriuretic peptides to their cognate receptors activates the guanylate cyclase moiety, 
which then brings about an increase in intracellular cGMP subsequently initiating the 
cGMP-dependent signalling cascade (Roller et al., 1991; see section 1.4).
NPR-A and NPR-B exist as homodimers and in a highly phosphorylated basal state 
(phosphorylated  on  conserved  serines  and  threonines)  when  ligand  is  not  bound. 
Upon  ligand  binding  the  receptor  is  transformed  from  a  “loose”  to  a  “tight” 
conformation  that  facilitates  activation  (Silberbach  and  Roberts,  2001)  and  is 
concomitantly dephosphorylated and desensitised.  The binding of natriuretic peptide 
to  the  extracellular  domain  brings  about  conformational  changes  in  the  RHD 
allowing adenosine 5'-triphosphate (ATP) binding and ‘disinhibition’ of the catalytic 
guanylate  cyclase  domain  thus  bringing  about  cGMP  production  (Silberbach  and 
Roberts,  2001;  Tremblay  et al.,  2002).  More  recently  it  has  been  suggested  that 
NPR-B can alternatively signal through G-protein coupling, as it possesses G-protein 
coupling domains (Borges et al., 2001; Alfonzo et al., 2006).
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In the case of NPR-C, natriuretic peptide binding to the extracellular domain of the 
dimerised receptor allows Gi activator peptide sequences on the cytoplasmic domain 
to bind and activate Gj regulatory proteins, bringing about Gj-coupled signalling and 
inhibition of adenylyl cyclase activity (Pagano and Anand-Srivastava, 2001).  NPR- 
C Gj-coupling can also result in inositol triphosphate (IP3) and diacylglycerol (DAG) 
formation, which are involved in intracellular Ca2+ mobilisation and PKC activation 
(Anand-Srivastava, 2005).
1.6.  Functions of natriuretic peptides in the 
cardiovascular system
Natriuretic peptides exert a wide range of physiological actions and are thought to be 
critical  ‘cardioprotective  hormones’.  Well  characterised  cardiovascular  actions  of 
ANP and BNP include stimulation of renal natriuresis and diuresis,  suppression of 
the  renin-angiotensin-aldosterone  system,  inhibition  of  vasopressin  and 
catecholamines, vasodilatation and inhibition of growth of vascular smooth muscle 
and  endothelial  cells  (Ahluwalia  et al,  2004;  Woods,  2004).  ANP  and  BNP  are 
secreted from the heart in response to atrial stretch and pressure, but BNP has lower 
circulating  levels  than  ANP,  which  become  equal  in  certain  pathophysiological 
conditions such as myocardial hypertrophy and congestive heart failure (Tremblay et 
al.,  2002).  Plasma concentrations  of natriuretic  peptides  under physiological  and 
pathophysiological conditions are summarised in Table 3.  ANP acts primarily on the 
kidney  by  increasing  glomerular  filtration  rate,  and  salt  and  fluid  excretion,  in 
response to increases in blood pressure and/or volume.  This effect is brought about 
through  NPR-A  and  cGMP  as  it  can  be  blocked  by  the  NPR-A/NPR-B  specific 
antagonist,  HS-142-1  (Zhang  et  al,  1994),  and  NPR-A  KO  mice  develop  salt- 
sensitive hypertension (John et al, 1995).
Administration  of ANP  to  normotensive  rodents  and  humans  brings  about  small 
decreases  in  blood  pressure;  these  changes  are  exacerbated  in  models  of 
hypertension.  ANP alters blood pressure by reducing plasma volume via a shift of 
fluid from the intravascular to the interstitial compartment, decreasing central venous 
pressure and thus reducing cardiac output but maintaining total peripheral resistance 
(Wijeyaratne and Moult, 1993).
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ANP BNP CNP
Plasma half life (min) -2 -2 0 -2.6
Plasma Concentration (nmol/ml)
Normal 6.4 ±0.9 0.9 ± 0.007 1.4 ±0.6
In Congestive heart failure 87 ± 12* 87 ± 11* 1.4 ±0.2
In myocardial infarction 33.4 ±6.1* 60 ± 9.4* N.D.
In pulmonary arterial hypertension 14.0* 15.3* N.D.
In chronic renal failure 43 ± 11* 130 ±37.4* 3.0 ± 0.4*
In subarachnoid haemorrhage 5.9 ± 1.0 15.1 ±3.8* 2.0-2.6
In cirrhosis 27.98 ±3.71* 16.0 ±1.91* 1.36 ± 0.18
Table 3 -  Plasma concentrations of natriuretic peptides under physiological and pathophysiological 
conditions.  Values represent the mean patient values from a representative study (Potter et al, 2006), 
* indicates significant increases.
As will be discussed in greater detail in section  1.8.2.1, ANP acts in a vasoprotective 
manner, especially during the development of atherosclerosis (Kiemer et al, 2005). 
The Framingham Heart Study offspring cohort investigated the relationship between 
plasma  BNP  and  N-terminal  pro  ANP  to  body  mass  index  (BMI)  and  found  that 
obese and overweight individuals have considerably lower plasma natriuretic peptide 
levels than those with a normal BMI, which could contribute to their susceptibility to 
cardiovascular disease (Wang et al., 2004).  ANP and BNP have been shown to have 
potent lipolytic effects in isolated human adipocytes similar to the effects seen with 
(3-adrenergic  receptor agonists  (e.g.  isoproterenol),  but ANP  and  BNP  bring about 
their  effects  through  an  increase  in  cGMP  (not  linked  to  cGMP-inhibitable 
phosphodiesterase-3B  and  changes  in  cAMP  production;  Sengenes  et  al,  2000). 
However, it is worth noting that epidemiological studies have suggested that NPR-C 
could be important in modulating abdominal adiposity, since individuals carrying an 
allele  variant  in  the  promoter  region  of  NPR-C,  resulting  in  reduced  NPR-C 
expression  in  adipocytes,  have  a  significantly  lower  prevalence  of  obesity  and 
abdominal adiposity (Sarzani et al, 2004).  It has been suggested that this could be 
due  to  reduced  clearance  of  natriuretic  peptides,  which  increases  their  local 
concentrations  favouring  fat mobilisation  (Maack,  2006).  In addition,  ANP  levels 
are elevated following prolonged exercise suggesting that ANP could play a role in
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lipid mobilisation  from adipose tissue required by the huge  energy demand during 
exercise  (Moro  et  al.,  2004).  Since  obesity  presents  an  underlying  risk  for 
cardiovascular disease, it is not surprising that exogenous application of ANP in the 
form of carperitide (recombinant human ANP), which is available for the treatment 
of acute and refractory heart failure, has beneficial vasoprotective effects (Kikuchi et 
al., 2001) and increases lipid mobilisation (Lafontan et al., 2005).
Carperitide  has  also  been  shown  to  protect  against  ischaemia-reperfusion  injury. 
Intravenous administration of synthetic ANP limits infarct size in dogs (Takagi et al.,
2 0 0 0)  and preischaemic infusion reduces infarct size after ischaemia-reperfusion in 
isolated  rat  hearts  (Okawa  et  al.,  2003).  This  cardioprotective  effect  of ANP  is 
dependent on the NO-PKC pathway (Okawa et al., 2003).  Sangawa et al have also 
reported that perfusion of ANP at the beginning of reperfusion protects isolated rat 
hearts  from ischaemia-reperfusion injury (Sangawa et al.,  2004).  A clinical  study 
involving  intracoronary  injection  of ANP  following  a  first  attack  of myocardial 
infarction and  subsequent coronary angioplasty,  demonstrated that ANP  attenuates 
myocardial  reperfusion  injury,  preserves  left ventricular function and prevents  late 
remodelling after angioplasty (Kuga et al.,  2003).  Akin to ANP,  BNP is released 
during  ischaemia  and  can  act  in  a  cytoprotective  manner  (D'Souza  and  Baxter,
2003).  In isolated rat hearts,  acute infusion of exogenous  BNP markedly protects 
against  myocardial  ischaemia-reperfusion  injury  in  a  concentration-dependent 
manner  and  involves  elevation  of  cGMP  and  ATP  sensitive  potassium  (K Atp ) 
channel opening (D'Souza et al., 2003b).  Furthermore, there is evidence to suggest 
that the NO/sGC system may play a role in the anti-ischaemic actions of BNP, since 
the infarct-limiting actions of this natriuretic peptide are abrogated by treatment with 
the  NOS  inhibitor  NG -nitro-L-arginine  methyl  ester  (L-NAME)  and  the  sGC 
inhibitor lH-[l,2,4]oxadiazolo[4,3-a]quinoxalin-l-one (ODQ; D'Souza et al, 2003a).
Taken  together,  the  reduced  natriuretic  peptide  levels  observed  in  individuals 
susceptible to cardiovascular disease (Wang et al., 2004) and the elevated levels seen 
during heart failure, myocardial infarction and pulmonary hypertension (Potter et al., 
2006)  suggest  that  a  basal  level  of natriuretic  peptides  is  required  to  prevent  the 
development of cardiovascular disease, but once a cardiovascular insult has occurred 
then  natriuretic  peptide  levels  are  increased  to  help  in  the  resolution  of disease.
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However, it is worth noting that patients with elevated levels of BNP after an acute 
coronary syndrome have a higher likelihood of further adverse cardiovascular events 
(de Lemos et al, 2001).
In accordance with the functions of natriuretic peptides, they have been implicated in 
a number of cardiovascular diseases, thus representing prime targets for therapeutic 
intervention (Tremblay et al.,  2002).  Recently there has  been great interest  in the 
levels of BNP and NT-proBNP as diagnostic tools for cardiovascular risk (Talwar et 
al., 2000; de Lemos et al., 2001; Kragelund et al., 2005).  During heart failure BNP 
levels in the circulation are raised (Yandle et al,  1993; Gehi et al., 2005); patients 
with  BNP  levels  >80  pg/ml  after an  acute  coronary  syndrome  are  at  high  risk  of 
death, a new myocardial infarction and heart failure, while those with normal BNP 
levels appear to have a low long-term risk of death and heart failure (de Lemos et al.,
2001).  NT-proBNP has also been established as a marker of long-term mortality in 
patients with stable coronary disease (Kragelund et al., 2005) and it has been shown 
to  have  a  biphasic  pattern  of  plasma  concentration  following  acute  myocardial 
infarction.  Measurements  of NT-proBNP  prior  to  hospital  discharge,  following 
acute myocardial infarction are more predictive of adverse outcome in comparison to 
measurements taken soon after admission (Talwar et al, 2000).  Therefore BNP and 
NT-proBNP  levels  following  acute  coronary  events  are  useful  tools  in  predicting 
long-term risk of death and future nonfatal cardiac events (de Lemos et al., 2001).
In addition to the raised BNP levels, BNP clearance is upregulated in patients with 
heart failure and this limits the rise in the concentration of circulating BNP (Adams 
et al., 2003).  For this reason two classes of therapeutic agents have been developed, 
recombinant human BNP and neutral endopeptidase inhibitors.  Human recombinant 
BNP  (identical  to  the  endogenously produced  hormone;  Adams  et  al.,  2003)  has 
been marketed as Natrecor®  (nesiritide) and  following extensive clinical  trials was 
approved for human use by the Food and Drug Administration (FDA) in 2001 for the 
treatment of acute decompensated congestive heart failure (Topol, 2005).  Although 
nesiritide has been on the market for a few years now, there has been no long term 
study showing decrease in length of hospitalisation, re-admission rate, or mortality 
and there have been safety problems associated with its administration  (Gehi et al,
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2005; Topol, 2005).  Neutral endopeptidase inhibitors have been developed and are 
currently administered in conjunction with angiotensin-converting enzyme inhibitors 
(vasopeptide  inhibitors  (VPIs),  marketed  as  omapatrilat,  fasidotril,  sampatrilat; 
Campbell,  2003) in patients with congestive heart  failure  (Lapointe and Rouleau, 
2002).
CNP, in contrast to ANP and BNP acts in a paracrine fashion and does not circulate 
in  high  concentrations  (Ahluwalia  et  al,  2004).  It  possesses  weak  natriuretic 
properties but is a potent vasodilator and shows anti-mitogenic properties (Ahluwalia 
et  al.,  2004).  CNP  increases  cGMP  levels  more  than  ANP  in  cultured  vascular 
smooth  muscle  cells  and  relaxes  aortic  rings  (Tremblay  et  al.,  2002),  and  local 
infusion  of CNP  increases  forearm  blood  flow  NO-independently  (Honing  et  al.,
2001).  CNP has also been characterised as an endothelium-derived hyperpolarising 
factor (EDHF) via activation of NPR-C (Chauhan et al., 2003b).  CNP released from 
the  endothelium activates NPR-C  on the  underlying  smooth muscle  cells  bringing 
about relaxation via Gj-coupling to GIRKs on smooth muscle cells and subsequent 
hyperpolarisation (Chauhan et al.,  2003b).  Responses to  CNP and  EDHF are not 
blocked by HS-142-1  and  are  attenuated by Pertussis  toxin  (PTx;  Chauhan et al, 
2003b)  giving  a  definitive  role  for  Gj-coupling  and  signalling  via  NPR-C. 
Furthermore,  CNP  has  been  shown  to  be  protective  against  ischaemia-reperfusion 
injury  through  vasorelaxation  with  the  involvement  of  NPR-C  activation  and 
signalling  (Hobbs  et  al.,  2004).  Finally,  a  single  nucleotide  polymorphism 
(G2628A)  in  the  3'-untranslated  region  of the  CNP  gene has  been  reported  to  be 
associated with hypertension (Ono et al., 2002).
More recently, the newest member of the natriuretic peptide family, DNP, has been 
shown,  by immunoreactivity,  to be present in human plasma and to be elevated in 
congestive heart failure (Schirger et al.,  1999).  Akin to other natriuretic peptides it 
possesses natriuretic and diuretic properties (Lisy et al.,  1999),  is anti-proliferative 
(Woodard et al, 2002), causes vasorelaxation of isolated human arteries via cGMP 
(Best  et  al.,  2002)  and  has  been  proposed  to  protect  against  post-ischaemic 
myocardial dysfunction (Ha et al, 2006).  However, DNP has yet to be purified from 
human  plasma  and  therefore  its  relevance  to  human  physiology  is  uncertain 
(Richards et al, 2002).
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1.7.  Functions of natriuretic peptides in the immune 
system
Natriuretic peptides play a vital role in the immune system.  ANP has been shown to 
prime polymorphonuclear neutrophils (PMNs) to secrete superoxide anion, mobilise 
PMNs  and  increase  oxygen  radical  production  in  the  macrophage  cell  line  J774 
(Vollmar et al.,  1997).  Furthermore, ANP at high concentrations suppresses, while 
at  low  concentrations  stimulates,  IgG  phagocytosis  (Vollmar  et  al.,  1997).  In 
macrophages ANP affects pro-inflammatory protein expression including iNOS and 
COX-2.  For  example,  in  LPS  activated murine  macrophages  ANP  inhibits  iNOS 
expression and NO production via GC coupled NPR-A (Kiemer and Vollmar,  1998) 
while CNP has no effect  (Kiemer and Vollmar,  1997).  In addition to iNOS,  ANP 
affects  COX-2  by  reducing  both  mRNA  and  protein  expression  via  inhibition  of 
LPS-induced  PGE-2  with  the  involvement  of  NPR-C  and  inhibition  of  cAMP 
production (Kiemer et al., 2002b).  Furthermore, ANP inhibits TNF-a production in 
IFN-y-activated  macrophages  via  p38  suppression  (Tsukagoshi  et  al.,  2001)  and 
inhibits  pro-inflammatory  transcription  factors  such  as  NF-kB  and  AP-1  in  LPS- 
activated macrophages  (Kiemer et al.,  2000;  with the possible involvement of p38 
MAPK).  Thus, ANP can affect TNF-a effector functions  (Vollmar, 2005) such as 
endothelial permeability (Tsukagoshi et al, 2001).  ANP has also been shown to be 
released endogenously by macrophages when activated (Vollmar and Schulz,  1994). 
In human umbilical vein endothelial cells (HUVEC), haem oxygenase-1   (HO-1) is 
induced by ANP via cGMP with the involvement of ERK and AP-l/JNK pathways 
(Kiemer et al., 2003).  In messengial cells ANP negatively regulates platelet derived 
growth factor (PDGF) and fibroblast growth factor (FGF) -stimulated ERK activity 
via NPR-A and the involvement of cGMP (Pandey et al., 2000).  In addition to the 
innate  immune  system  ANP  also  affects  adaptive  immunity.  It  regulates 
thymopoesis and T-cell maturation via NPR-A/cGMP signalling in dendritic cells, as 
well as controlling the balance between Th 1  and Th 2 responses (Vollmar, 2005).
CNP  has  also  been  shown  to  play  a  role  in  inflammation.  Akin  to  ANP,  CNP 
suppresses COX-2 but does not affect cyclooxygenase-1  (COX-1) in LPS-activated 
murine macrophages (Kiemer et al., 2002b).  Furthermore, CNP reduces cytokine or 
histamine-induced  leukocyte  rolling  in  the  mouse  mesenteric  system  possibly
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through the activation of NPR-C  (Scotland et al.,  2005b).  In addition it has been 
postulated  that  CNP  could  play  a  role  in  protecting  against  development  of 
atherosclerosis.  CNP and NPR-B/NPR-C mRNA expression is high in low-severity 
disease while levels are reduced in high severity cases, indicating a potential role for 
CNP in protection against atherosclerosis  (Casco et al., 2002) as will be discussed 
further in section 1.8.2.3.  Moreover, circulating BNP and CNP levels are elevated in 
patients with septic  shock (BNP:  500 (239 -   1017) septic vs 319 (132 -  808) non- 
septic ICU patients pg/ml (Cuthbertson et al., 2005); CNP:  13.2 ±  10.1  septic vs  1.4 
± 0.6  healthy volunteers,  pmol/ml;  Hama  et al.,  1994).  Finally  CNP  (and  ANP) 
inhibit  oxidised  low density lipoprotein  (LDL)-stimulated vascular  smooth muscle 
cell migration and proliferation by inhibiting the MAPK signalling pathway (Prins et 
al., 1996) thus affecting vascular remodelling, a major contributor to development of 
vascular inflammatory disease.
1.8.  Role of natriuretic peptides in atherosclerosis
1.8.1.  Introduction
Atherosclerosis,  hardening  of  the  arteries,  is  a  multi-factorial  pathological  and 
inflammatory  process  resulting  in  cardiovascular  disease  including  myocardial 
infarction  and  stroke,  which are the primary causes  of death  in the western  world 
(Shoenfeld et al., 2001; Sherer and Shoenfeld, 2006).
Russell  Ross  originally  proposed  the  “response  to  injury”  hypothesis  in  which  he 
described  the  first  step  in  the  development  of atherosclerosis  to  be  endothelial 
denudation  followed  by  adherence  and  aggregation  of  platelets  together  with 
uncontrolled  smooth  muscle  proliferation  (Ross  and  Glomset,  1976a;  Ross  and 
Glomset,  1976b).  However, this hypothesis has since been revised and Russell Ross 
published  a  historic  paper  in  1999  emphasising  the  importance  of  endothelial 
dysfunction, rather than complete loss,  in the  early development of atherosclerosis 
(Ross,  1999).  Initiation of atherosclerosis is influenced by a number of ‘risk factors’ 
including  smoking,  hypertension,  hyperlipidemia,  hyperhomocysteinemia  and 
diabetes  mellitus,  all  of which  cause  endothelial  dysfunction  (Celermajer  et  al., 
1994).
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It has been demonstrated that both cellular and humoral immunity play a key role in 
atherosclerotic  plaque  development  (Ross,  1999;  Sherer  and  Shoenfeld,  2006; 
Tedgui and Mallat, 2006).  Atherosclerotic plaques are more likely to form in arterial 
sites where there is decreased shear stress, increased turbulence and in the setting of 
an unfavourable  serum lipid profile,  especially in the presence of LDL cholesterol 
(Ross,  1999;  Crowther,  2005).  Under  physiological  conditions  circulating  blood 
constantly induces  shear-stress on the vessel wall and the endothelium.  This shear 
stress  induced  by  laminar  flow  is  mechanotransduced  into  a  biochemical  signal 
resulting  in  gene expression,  which  is  crucial  for normal  vascular  function  and  is 
atheroprotective  by  inhibiting  proliferation,  thrombosis  and  inflammation  of the 
vessel  wall  (Cunningham  and  Gotlieb,  2005).  Normal  laminar  flow  causes  the 
expression  of eNOS  and  the  production  of NO,  which  enhances  vasorelaxation, 
inhibits  platelet  activation  and  aggregation,  apoptosis  and  endothelial-dependent 
monocyte adhesion (Tsao et a l, 1996; Freedman et al., 1999; Dimmeler et a l, 1999). 
Around  curvatures,  branch  ostia  and  bifurcations,  there  is  disruption  to  the  blood 
flow  and  hence  reduced  shear  stress,  which  is  associated  with  reduced  eNOS 
production, reduced vasodilatation and impaired endothelial cell repair.  In addition 
there  is  an  increase  in  reactive  oxygen  species  (ROS),  endothelial  permeability, 
leukocyte  adhesion,  apoptosis,  smooth  muscle  cell  proliferation  and  collagen 
deposition (Cunningham and Gotlieb, 2005).  It is at these sites that atherogenesis is 
favoured  and  most  commonly  observed.  Reduction  in  shear  stress  causes 
upregulation  of leukocyte  adhesion  molecules  including  L-selectin,  integrins  and 
platelet-endothelial-cell adhesion molecule- 1  as well as upregulation of endothelial 
adhesion molecules such as E-selectin, P-selectin, intercellular adhesion molecule-1  
(ICAM-1),  and  vascular-cell  adhesion  molecule-1  (VCAM-1;  Ross,  1999). 
Expression  of these  molecules  on  the  endothelial  surface  causes  recruitment  of 
monocytes and T-cells and the migration of leukocytes into the artery wall.  It is the 
macrophages  in  the  artery  wall  that take  up  oxidised-LDL  to  become  foam  cells. 
The  presence of foam  cells  and  T  lymphocytes  marks  the  beginning of the  fatty- 
streak formation (Ross,  1999).  The immune cells release a milieu of inflammatory 
mediators  including  growth  factors  and  cytokines,  which  cause  migration  and 
proliferation of the underlying smooth muscle cells, which can then release their own 
mediators  including  IL-ip,  TNF-a  and  P,  IL-6,  macrophage  colony-stimulating 
factor  (M-CSF),  monocyte  chemotactic  protein-1  (MCP-1),  IL-18  and  CD-40L
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resulting in a self-perpetuating inflammatory process within the plaque (Ross,  1999; 
Crowther,  2005;  Sherer  and  Shoenfeld,  2006).  The  early  development  of  an 
atherosclerotic plaque  is  shown  in  Figure  7.  As  the  fatty streak  grows  it  forms a 
fibrous  cap  (often  associated  with  calcification)  that  isolates  the  lesion  from  the 
lumen  and  this  can  become  progressively  weaker  resulting  in  plaque  rupture, 
thrombosis and distal occlusion (Ross, 1999).
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Figure 7 -  Early development of an atherosclerotic plaque (Sherer and Shoenfeld, 2006).
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1.8.2.  Role of natriuretic peptides in the pathogenesis of 
atherosclerosis
Natriuretic  peptides  are  known  to  contribute  to  the  regulation  of  inflammatory 
responses,  as  discussed  in  section  1.7,  and  their  role  in  the  development  of 
atherosclerosis might be of utmost clinical relevance (Kiemer et al, 2005).
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1.8.2.1.  ANP
Vascular  permeability,  the  increase  in  endothelial  cell  leakiness  and  formation  of 
intercellular  gaps  in  vascular  endothelium,  is  considered  to  be  one  of the  initial 
stages  in the development of an atheromatous plaque (Kiemer et al.,  2005).  Both 
vascular endothelial growth factor (VEGF) and TNF-a are able to induce increases 
in permeability involving  fibre formation and actin polymerisation.  These VEGF- 
and TNF-a-induced increases in permeability have been shown to be abrogated by 
ANP (Kiemer et al., 2002c; Pedram et al., 2002).  In aortic endothelial cells VEGF- 
induced vascular permeability sequentially involves Src, ERK, JNK, PI3K and Akt, 
resulting in serine/threonine phosphorylation and architectural disruption of protein 
components of the endothelial cell tight junction.  ANP inhibits VEGF-induced Src 
activation (via cGMP) and subsequent downstream signalling resulting in preventing 
vascular permeability (Pedram et al., 2002).  In vivo, transgenic mice overexpressing 
ANP,  show  significantly  less  VEGF-induced  vascular  permeability  compared  to 
non-transgenic  littermates  (Pedram  et  al.,  2002).  In  the  case  of TNF-a-induced 
vascular permeability, ANP (via NPR-A/cGMP) abrogates the effects of TNF-a by 
inducing the  MAPK phosphatase-1   (MKP-1) hence reducing the activation  of p38 
leaving  hsp27  unphosphorylated  and  preventing  it  from  promoting  actin 
polymerisation, which  contributes  to vascular permeability (Kiemer et al.,  2002c). 
In addition to counteracting the permeability-increasing actions of TNF-a and VEGF, 
ANP also reduces the production of these mediators giving a double action to ANP 
in  protecting  the  endothelium  from  excessive  activation  during  inflammatory 
responses  such  as  atherosclerosis  (Kiemer  et  al,  2000;  Tsukagoshi  et  al.,  2001; 
Pedram et al., 2002).  In rat coronary endothelial cells, it has been reported that ANP 
decreases endothelial permeability via NPR-C (Hempel et al., 1998).
However, there are studies indicating that ANP can increase vascular permeability. 
Sarker and Fraser have shown that ANP increases endothelial permeability in rat pial 
venular  capillaries  (Sarker  and  Fraser,  2002),  while  Holschermann  et  al  have 
reported  that  increases  in  cGMP  can  both  increase  and  decrease  endothelial 
permeability in the same endothelial cell preparation depending on whether the cells
^ I
are  in  a  basal  state  where  Ca  is  not  involved  (cGMP  reduces  permeability),  or
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whether they have been stimulated and hence Ca2+ has already been released from 
endogenous stores (cGMP increases permeability; Holschermann et a l, 1997).
ANP  has  also  been  reported  to  prevent  leukocyte  attraction  and  adhesion.  As 
discussed  above  in  section  1.8.1,  MCP-1  is  one  of  the  mediators  involved  in 
leukocyte  recruitment  in  atherosclerosis  (Ross,  1999)  and  is  transcriptionally 
activated by TNF-a (Young et al., 2002).  TNF-a-induced expression of MCP-1  is 
reduced by ANP involving p38 and MKP-1 as discussed above (Young et al, 2002). 
Furthermore, ANP  significantly reduces other TNF-a-induced cell  surface proteins 
involved in leukocyte adhesion, such as E-selectin and ICAM-1  via transcriptional 
activation of IkB (Kiemer et al, 2002d).  Cell adhesion molecules are known to be 
expressed on  endothelial  cells under hypoxic  conditions  (Kokura et al,  2002) and 
this has been shown to be attenuated by ANP (Mtairag et al, 2002).  Mtairag et al 
inhibited neutral endopeptidase, thus increasing the levels of ANP and demonstrated 
that  ANP  inhibits  neutrophil-endothelial  interactions  under  hypoxic  conditions 
(Mtairag et al, 2002).  Furthermore, Kugiyama et al demonstrated that inhibition of 
neutral  endopeptidase in cholesterol-fed rabbits  suppressed atherosclerotic changes 
and atheromatous plaque formation (Kugiyama et al,  1996).  They also showed that 
relaxation  of  isolated  aorta  in  response  to  ACh  is  significantly  impaired  in 
cholesterol and cholesterol plus neutral endopeptidase inhibitor fed rabbits, although 
the impairment was significantly less in the latter group.  Vasorelaxation responses 
to  ANP  were  also  impaired  in  cholesterol  fed  rabbits,  but  were  preserved  in 
cholesterol plus neutral endopeptidase inhibitor fed animals (Kugiyama et al, 1996).
In addition to vascular permeability and leukocyte adhesion, migration of endothelial 
cells  as  well  as  arterial  medial  smooth  muscle  cells,  are  key  processes  in  the 
initiation,  progression  and  intimal  thickening  during  the  development  of  an 
atherosclerotic lesion (Ross,  1999).  Ikeda et al have shown that ANP inhibits both 
rat vascular  endothelial  and smooth muscle cell  migration  in a concentration-  and 
cGMP-dependent  fashion  (Ikeda  et  al,  1995;  Ikeda  et  al,  1997),  once  again 
supporting  its  anti-atherogenic  properties.  Furthermore,  Seal  ANP  gene 
polymorphism,  leading  to  the  extension  of human  ANP  (the  peptide  of 28  aa  is 
extended  to  30  aa  by  2  additional  arginines),  is  significantly  associated  with 
multiple-vessel coronary atherosclerosis (Gruchala et al, 2003).
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Finally,  a  study  employing  immunocytochemistry  and  in  situ  hybridization  has 
revealed the localisation of the three natriuretic peptides and their receptors in human 
coronary  arteries  with  variable  degrees  of  atherosclerosis  (Casco  et  al.,  2002). 
During the formation of early atherosclerotic lesions, ANP is localised in the intima, 
at very low levels in the media and in the adventitia, particularly in the vasa vasora, 
while NPR-A, NPR-B and NPR-C are not detected.  In intermediate plaques ANP is 
localised  in the  intimal  level,  in  the  lipid core  regions  and  in the media.  NPR-A 
mRNA is not present, but NPR-B and NPR-C mRNA is present in the intima of the 
plaques.  In advanced atherosclerotic  lesions however both peptide and mRNA are 
restricted to intimal myofibroblasts and micro  vessels of the intima and vasa vasorum, 
suggesting  that  atherosclerotic  plaque  progression  entails  the  downregulation  of 
locally expressed ANP (Casco et al., 2002).
1.8.2.2.  BNP
Although  BNP  is known to  play  a pivotal  role  in  cardiovascular homeostasis  and 
disease,  a  lot  less  is  known  about  its  involvement  in  the  development  of 
atherosclerosis.  Casco  et  al  have  demonstrated  the  localisation  of  BNP  at  the 
different stages of plaque development.  BNP is not present in early and intermediate 
atherosclerotic  lesions,  but  it  is  detected  in  the  intima  and  adventitia  of advanced 
atherosclerotic lesions together with NPR-B and NPR-C (Casco et al., 2002).
BNP  has  been  shown  to  induce  potent  relaxation  in  normal  aortae  from  rabbits 
preconstricted with phenylephrine,  and relaxations are endothelium-independent as 
removal of the endothelium does not affect relaxation potency (Schirger et al., 2000). 
However,  BNP-induced relaxations  are  impaired  in  aortae  from rabbits  fed a high 
cholesterol diet possessing atherosclerotic lesions.  In rabbits fed a high cholesterol 
diet but concomitantly given the neutral  endopeptidase inhibitor candoxatril,  BNP- 
induced  relaxations  are  preserved  when  compared  to  aortae  from  control  animals 
(Schirger et al., 2000).
Akin to ANP,  BNP  inhibits rat  endothelial and smooth muscle cell  migration  in a 
concentration- and cGMP-dependent manner (Ikeda et al,  1995; Ikeda et al,  1997). 
Furthermore, BNP significantly blunts the extent of thrombin-induced permeability
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and enhances the rate of barrier restoration in pulmonary microvascular endothelial 
cells in a cGMP-independent manner (Klinger et al., 2006).  Although this study was 
conducted in pulmonary endothelial cells and is primarily applicable to lung injury, 
it could be extrapolated to other inflammatory diseases such as atherosclerosis where 
endothelial barrier dysfunction is key to progression of disease.
1.8.2.3.  CNP
CNP,  like  ANP  and  BNP  has  been  shown  to  possess  anti-atherogenic  properties. 
Immunological studies on human coronary atherosclerotic lesions have revealed that 
CNP  is  present  in different  cell  types  according to  progression  of atherosclerosis. 
Under  normal  physiological  conditions,  arterial  segments  show  CNP-positive 
endothelial cells (Naruko et al,  1996) and monocytes/macrophages (Ishizaka et al., 
1992).  As  the  development  of  the  atherosclerotic  plaques  progresses,  the 
hypercellular  atherosclerotic  lesions  have  both  CNP-positive  smooth  muscle  cells 
and macrophages while CNP levels in the endothelial cells are decreased (Naruko et 
al.,  1996).  Advanced  atherosclerotic  lesions  show  CNP  expression  in the  plaque 
microvessels  and  adventitial  vasa  vasora  suggesting  a  role  for  CNP  in  vascular 
remodelling  and  in  progression/regression  of the  plaque  of the  diseased  arteries 
(Casco  et  al.,  2002).  Furthermore,  advanced  atherosclerotic  lesions  have  CNP- 
positive macrophages but the majority of the smooth muscle cells within the fibrous 
cap  and  the  surface  endothelial  cells  are  CNP-negative  (Naruko  et  al.,  1996). 
Therefore,  the  severity  of  atherosclerotic  lesions  inversely  correlates  with  CNP 
expression  (Casco  et al,  2002).  It  is  also  interesting  to  note  that  oxidized  LDL 
suppresses  the  secretion  of CNP  from  endothelial  cells  (Sugiyama  et  al,  1995), 
possibly allowing the growth of smooth muscle cells into the lesion.  However, there 
is conflicting evidence as CNP inhibits oxidized LDL-stimulated smooth muscle cell 
migration and proliferation as discussed in section 1.7.  CNP has also been shown to 
have potent inhibitory effects on foetal calf serum (FCS)-induced or PDGF-induced 
migration of rat vascular smooth muscle cells (Ikeda et al., 1997).
CNP  has  also  been  implicated  in  the  regulation  of  leukocyte  adhesion,  platelet 
activation  and  P-selectin  expression  (Scotland  et al.,  2005a).  In  eNOS  KO  mice 
where basal  leukocyte activation  is  high,  CNP  is  able to  suppress  basal  leukocyte
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rolling and this is mimicked by the NPR-C selective agonist cANF4'23, implying the 
involvement of NPR-C.  CNP also suppresses leukocyte rolling induced by IL-1(3 or 
histamine,  inhibits  platelet-leukocyte  interactions  and  prevents  thrombin-induced 
platelet aggregation.  Furthermore,  CNP  attenuates  the  expression  of P-selectin  in 
HUVEC, platelets and leukocytes  (Scotland et a l,  2005a).  It is also worth noting 
that relaxation to CNP in atherosclerotic aortae from cholesterol rabbits is impaired 
compared  to  aortae  from  normal  dietary  fed  rabbits;  however,  incubation  of the 
atherosclerotic aortae from cholesterol rabbits with a neutral endopeptidase inhibitor 
attenuates the impairment of the vasorelaxation response to CNP (Kugiyama et al.,
1996). Taken together, the above evidence suggests an anti-atherogenic role for CNP 
by regulating smooth muscle migration, cellular adhesion and P-selectin expression.
1.9.  Role of natriuretic peptides in cellular growth
All  natriuretic  peptides  have  been  shown  to  have  anti-proliferative  properties  and 
this is particularly important in smooth muscle, endothelial and cardiomyocyte cells 
as it can be cardioprotective (Furuya et al.,  1991; Furuya et al.,  1993; Silberbach and 
Roberts, 2001).  Since it has been suggested that excessive proliferation of smooth 
muscle  cells  in  particular,  is  central  to  the  development  of  restenosis  and 
atherosclerosis  (Ross,  1999),  the  molecular  mechanisms  underlying  the  anti­
proliferative effects of natriuretic peptides have been investigated.
1.9.1.  ANP
ANP  exhibits anti-proliferative properties  in a variety of cell types including renal 
mesangial cells (Appel,  1988), astrocytes (Levin and Frank,  1991), endothelial cells 
(Itoh et al.,  1992; Morishita et al., 1994), cardiac myocytes and fibroblasts (Cao and 
Gardner,  1995; Calderone et al.,  1998), and vascular smooth muscle cells (Morishita 
et al.,  1994; Hutchinson et al,  1997).  Astrocyte growth inhibition by ANP involves 
inhibition of MAPK via NPR-C  (Prins et al,  1996), while in cardiac myocytes and 
fibroblasts the inhibitory effects  are  exerted through NPR-A and cGMP-dependent 
mechanisms (Cao and Gardner,  1995; Calderone et al,  1998).  Endothelial growth 
inhibition by ANP has been reported as cGMP-mediated (NPR-A; Itoh et a l,  1992) 
and cGMP-independent (NPR-C; Pedram et al,  1997).  In addition, ANP attenuates
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the  expression  of VEGF,  which  is  vital  in the  stimulation  of normal  angiogenesis 
(Pedram  et  a l,  1997).  Interestingly  however,  a  study  by  Hook  et  al  in  human 
endothelial  cells  showed that ANP  increases  growth,  thus  potentiating  endothelial 
regeneration  in  a  cGMP-dependent  manner  involving  cGMP-dependent  protein 
kinase stimulation and subsequent Akt and ERK  1/2 activation (Kook et al., 2003). 
The discrepancies between the different studies could possibly be explained by the 
inconsistent concentrations of ANP used in the individual experimental setups.  High 
ANP concentrations of 10‘7 -   10"6 M result in growth inhibition  (Itoh et a l,  1992; 
Pedram et al,  1997) while low, physiological ANP concentrations of 10' 11  M cause 
proliferation (Kook et al, 2003).  It could therefore be postulated that the actions of 
ANP  differ  between  maintaining  normal  homeostasis  and  regulating 
pathophysiological conditions where ANP levels are elevated (Kiemer et al, 2005). 
Like  endothelial  cell  proliferation,  control  of  smooth  muscle  growth  and 
proliferation by ANP has also been reported, by independent studies, to involve both 
NPR-A-  (cGMP-dependent)  and  NPR-C-  (cGMP-independent)  mediated 
mechanisms.  Sharma et al have shown that growth inhibition by ANP in vascular 
smooth muscle cells  is  mediated via NPR-A,  GC  and PKG,  perhaps involving the 
inhibition of ERK  1/2 phosphorylation (Sharma et al, 2002) while Cahill et al have 
reported the involvement of NPR-C in growth inhibition by ANP in a cGMP- and 
cAMP-independent  manner  (Cahill  and  Hassid,  1994).  However,  ANP  can  also 
phosphorylate  and  activate  the  MAPK  pathway  (Tremblay  et  al,  2002),  which 
suggests it can act in a proliferative fashion under certain circumstances as seen in 
endothelial  cells.  It  has  been  reported  that  ANP  exerts  proliferative  actions  on 
smooth muscle cells by enhancing the mitogenic effects of FGF-2, via a mechanism 
that may involve elevation of immediate early gene expression but not enhancement 
of FGF receptor protein levels (Dhaunsi and Hassid,  1996).  However, in support of 
the anti-proliferative actions of ANP it is worth noting that NPR-A KO mice show 
marked cardiac hypertrophy (Knowles et al,  2001) and increased susceptibility to 
hypoxia-induced pulmonary hypertension (Zhao et al, 1999).
1.9.2.  BNP
Unlike ANP and CNP, few studies have addressed the anti-proliferative properties of 
BNP.  Levin  et  al  have  shown  that  akin  to  ANP,  BNP  inhibits  rat  astroglial
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proliferation probably through NPR-C  and cGMP-independent mechanisms  (Levin 
and Frank,  1991).  BNP also inhibits FCS-stimulated human aortic vascular smooth 
muscle cell proliferation, which is accompanied by an increase in cGMP (Schirger et 
al.,  2000)  suggesting the  involvement  of NPR-A.  Furthermore,  BNP  abrogates 
Ang Il-stimulated increases in markers of hypertrophy in adult rat cardiomyocytes 
through cGMP-dependent protein kinases  (Rosenkranz et al.,  2003).  However,  in 
vivo BNP appears to exert antifibrotic rather than antihypertrophic actions  (Tamura 
et al., 2000).  Despite NPR-A KO mice exhibiting cardiac hypertrophy (Oliver et al., 
1997), BNP null animals suffer from fibrosis but are not hypertrophic (Tamura et al., 
2000).
1.9.3.  CNP
The anti-atherogenic profile of CNP, like ANP and BNP is strengthened by its anti­
proliferative properties.  CNP has been reported to inhibit DNA synthesis in cardiac 
fibroblasts  (Cao  and  Gardner,  1995)  and  inhibit  vascular  smooth  muscle  growth 
(Furuya et al.,  1991; Furuya et al.,  1993; Cahill and Hassid,  1994; Hutchinson et al.,
1997).  However,  controversy  exists  as  to  the  receptor  responsible  for  the  anti- 
mitogenic  activity and the underlying mechanisms involved in  smooth muscle cell 
inhibition by CNP.  Several publications have documented the involvement of NPR- 
B,  and  thus  cGMP-dependent  signal  transduction  pathways,  in  growth  inhibition. 
Furuya et al have  shown that CNP inhibits DNA synthesis and growth  in vascular 
smooth muscle cells via cGMP-dependent mechanisms  (Furuya et al.,  1991).  The 
same  group  also  reported  that  CNP  inhibits  intimal  thickening  following vascular 
injury with  an  elevation  of cGMP  levels,  concluding that NPR-B  is  probably  the 
receptor responsible for these inhibitory effects (Furuya et al., 1993).  These findings 
have been further substantiated by Hutchinson et al who showed increases in cGMP 
levels  correlate  with  growth  inhibition  and  that  CNP  decreases  PDGF-stimulated 
MAPK activity (Hutchinson et al.,  1997).  In contrast, Cahill et al have suggested 
that  CNP  inhibits  growth  in  aortic  smooth  muscle  cells  via NPR-C  and  thus  in  a 
cGMP-independent  manner,  as  cGMP  levels  are  not  altered  (Cahill  and  Hassid,
1994).  It  is  also  worth  noting that  small  cytoplasmic  domain peptides  of NPR-C 
have been shown to inhibit vasoactive peptide (e.g. Ang II,  endothelin-1, arginine-
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vasopressin)-induced phosphorylation of ERK  1/2 and growth inhibition in vascular 
cells (Hashim et al., 2006).
Endothelial/smooth  muscle  cell  co-culturing  experiments  have  revealed  that 
endothelial  expression  of CNP  is  at  least  in  part  regulated  by  TGF-f3,  and  CNP 
released from endothelial cells inhibits growth of the underlying smooth muscle cells 
(Komatsu  et  al.,  1996).  In  addition,  adenovirus-mediated  gene  transfer  of CNP 
causes  G1  growth  inhibition  of vascular  smooth  muscle  cells  (Doi  et  al.,  1997). 
However,  CNP  has  an  opposite  effect  on  endothelial  cells,  in  which  it  stimulates 
growth.  Rabbit jugular  vein  grafts  incubated  ex  vivo  with  adenovirus  containing 
CNP,  inducing  overexpression  of CNP,  undergo  accelerated  re-endothelialisation 
(Ohno  et  al.,  2002),  suggesting  that  CNP  could  play  an  important  local  role  in 
angiogenesis.
To the contrary however, CNP has been shown to  enhance the mitogenic  effect of 
FGF-2  in  aortic  smooth  muscle  cells  (Dhaunsi  and  Hassid,  1996),  intimating  that 
regulation of smooth muscle growth could be highly specific and tightly regulated 
depending on the surrounding environment.
1.10.  Current study
In  summary,  there  is  compelling  evidence  in  the  literature  to  suggest  a  role  for 
natriuretic peptides in regulating an inflammatory response, but data are conflicting. 
Both  up  and  downregulation  of  iNOS  expression  and  other  pro-inflammatory 
proteins, by natriuretic peptides have been reported in isolated cell systems (Marumo 
et al.,  1995;  Vollmar and Schulz,  1995a;  Kiemer  and Vollmar,  1998;  Kiemer and 
Vollmar,  2001)  and  therefore  it  is  important  to  determine  a  definitive  role  for 
natriuretic  peptides  during  an  inflammatory  response.  Many  cardiovascular 
disorders  are  inflammatory  diseases  (i.e.  atherosclerosis,  septic  shock)  and  since 
natriuretic peptides are thought to be cardioprotective (Ahluwalia et al., 2004), it is 
imperative  to  determine  their  mechanisms  of action,  thus  helping  in  establishing 
ways  in  which  progression  of  such  disorders  might  be  prevented/regulated  by 
natriuretic peptides and therapeutics that can modulate natriuretic peptide activity.
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In the current study NPR-A KO mice, the RAW264.7 murine macrophage cell line 
and primary rat aortic smooth muscle cells were used to investigate:
1.  Ex  vivo  pharmacological  characterisation  of the  role  of NPR-A  in  the 
pathogenesis of septic shock.
2.  The effect of natriuretic peptides on pro-inflammatory protein expression 
(iNOS) via the particulate guanylate cyclase isoform.
3.  The  involvement  of  MAPK  pathways  in  regulating  pro-inflammatory 
protein expression.
4.  The role of natriuretic peptides, and specific natriuretic peptide receptors, 
in MAPK signalling and downstream regulation of cell proliferation.
The underlying hypotheses for the current study are:
1.  Natriuretic  peptides  (ANP  and  BNP)  affect  pro-inflammatory  protein 
expression and  vascular  function  in  vivo  under  inflammatory conditions 
(Chapter 3 -  Ex vivo pharmacological characterisation of the role of NPR- 
A in pathogenesis of septic shock).
2.  Natriuretic  peptides  (ANP  and  CNP)  affect  pro-inflammatory  protein 
expression  in  vitro  (Chapter 4 -   Regulation  of pro-inflammatory protein 
expression (iNOS) by natriuretic peptides (ANP and CNP) in vitro)
3.  Natriuretic  peptides  (ANP  and  CNP)  modulate  MAPK  pathways  and 
regulate cell proliferation via activation of GC-linked NPRs (Chapter 5 -  
Role  of  natriuretic  peptides  and  their  receptors  in  regulating  MPAK 
signalling and cell proliferation).
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2. Materials and Methods
2.1.  Reagents
Salmonella  typhimurium  or  Escherichia  coli  (serotype  0111:B4)  LPS  were 
purchased from Sigma (Poole, Dorset, UK) and re-suspended in distilled water to a 
concentration  of  10  mg/ml.  Recombinant  rat  IFN-y,  IL-1 (3  and  TNF-a  were 
purchased  from  PeproTech  EC  (London,  UK).  IFN-y was  reconstituted  in  5  mM 
Tris HC1 pH 8.0 and 100 mM NaCl to a concentration of 1   mg/ml, equivalent to  1  x 
106 units specific activity.  IL-1 p and TNF-a were reconstituted in distilled water to 
a concentration of 100 pg/ml, equivalent to 1  x 105 and 4 x 105 specific activity units, 
respectively.  Rat  ANP  was  obtained  from  Sigma  and  re-suspended  to  a 
concentration  of  1   mM  using  distilled  water.  CNP  (human  and  porcine)  was 
purchased  from Calbiochem (Nottingham,  UK) and re-suspended in distilled water 
to a concentration of 1   mM.  PD98059 and SB203580 were purchased from Alexis 
Biochemicals (Distributed by Axxora (UK) Ltd, Nottingham, UK), reconstituted in 
dimethyl sulphoxide (DMSO) to concentrations of lOmM.  8-Bromoguanosine 3', 5'- 
cyclic  monophosphate  (8-Bromo-cGMP)  was  purchased  from  Sigma  and 
reconstituted to  100  mM  in  distilled  water.  Pertussis  toxin  (Bordetella pertussis) 
was purchased from Calbiochem and was reconstituted to a stock concentration of 
100  pg/ml  in  distilled  water.  Angiotensin  II  was  purchased  from  Sigma  and 
reconstituted in distilled water to a concentration of 1   mM.  U46619 was purchased 
from  Biomol  International  (Exeter,  UK)  and  re-suspended  in  ethanol  to  a 
concentration of 1  mM, ACh was obtained from Sigma and re-suspended in distilled 
water to  a concentration  of 10  mM,  SPER-NO  was bought  from  Calbiochem  and 
was re-suspended  in distilled water to a concentration of 10 mM just prior to use. 
All other reagents above were aliquoted and stored at -20°C until required when they 
were  diluted  to  appropriate  concentrations  in  growth  medium  or  distilled  water. 
M372049, a selective NPR-C antagonist  (Veale et al., 2000;  Figure  8) was a kind 
gift from AstraZeneca Pharmaceuticals (Wilmington, USA) and was reconstituted to 
1   mg/ml  in distilled water just prior to use.  M372049  is  a competitive antagonist 
with  a  Kj  = 21  nM  with respect to  inhibition  of I125-ANP  binding to  recombinant 
CHO  cells  expressing  human  NPR-C  or  membranes  (48000  g  fraction)  prepared 
from  recombinant  baculovirus-Sf21  cells  expressing  NPR-C  (personal
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communication,  Dr  C.A.  Veale,  AstraZeneca  Pharmaceuticals).  It  has  an 
approximate pA2  value of 11.14 against CNP-induced relaxation  of rat mesenteric 
small  arteries  in  vitro  (IC50  =  4  nM;  Villar  et  al.,  2007).  In  rat  isolated  aorta, 
M372049 does not alter relaxant responses to ANP, CNP, ACh and SPER-NO which 
have been shown previously to be mediated via NPR-A and NPR-B (Madhani et al., 
2003),  however,  in  rat  isolated  mesenteric  resistance  arteries  M372049,  at  a 
concentration of 100 nM, completely blocks the CNP-induced relaxation (Villar et 
al, 2007).
Figure 8 -  Chemical structure of M372049.
2.2.  Cell culture
2.2.1.  RAW 264.7 -  Murine macrophage cell line
RAW  264.7  murine  macrophage  cells  (TIB-71  from  American  Type  Culture 
Collection, Manassas, USA) were cultured in suspension in glass stirrer bottles using 
Roswell  Park  Memorial  Institute  (RPMI)  1640  medium  with  25  mM  N-2- 
hydroxyethylpiperazine-N'-2-ethanesulfonic  acid  (HEPES)  supplemented  with  100 
U/ml  penicillin,  100  pg/ml  streptomycin,  2  mM  L-glutamine  (all  purchased  from 
Life Technologies, Paisley, UK) and 10 % heat inactivated New Zealand FCS (TCS 
Biologicals  Ltd,  Buckingham,  UK).  Cells  were  grown  at  37°C  in  a  humidified 
incubator with 5 % CO2 in air.  Routinely cell number and viability were quantified 
using trypan blue exclusion.  Equal volumes of cell suspension and trypan blue (Life 
Technologies) were mixed and a small volume was transferred to a haemocytometer. 
Cells  were  counted  under  an  inverted  microscope  (Axiovert25,  Carl  Zeiss 
Microimaging Inc., Herfordshire, UK) with unstained, luminescent cells counted as
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viable  and  blue  stained  cells  counted  as  dead.  Cells  were  only  used  for 
experimentation if viability was above 95 %.
2.2.2.  Rat aortic smooth muscle cells (RAoSMC)
2.2.2.1.  Isolation
Vascular aortic smooth muscle cells were prepared by enzymatic dissociation from 
rat aortae of male Sprague-Dawley rats (200 - 250 g).  The rats were euthanised by 
cervical dislocation and thoracic aortae excised aseptically into phosphate buffered 
saline  (PBS) supplemented with  100  U/ml penicillin and  100  pg/ml  streptomycin. 
Loose fat and adventitia were removed with fine forceps and the cleaned aortae were 
preincubated  in PBS  containing  1   mg/ml  collagenase Type  I, 0.25  mg/ml  soybean 
trypsin  inhibitor,  1   mg/ml  bovine  albumin,  0.2  mM  CaCL  (all  purchased  from 
Sigma),  100  U/ml  penicillin  and  100  pg/ml  streptomycin  (referred  to  as  ‘enzyme 
solution’)  for  30  min  at  37°C  in  a  humidified  incubator  with  5  %  CO2  in  air. 
Following  incubation  the  aortae  were  opened  longitudinally  and  the  intima  was 
removed by scraping the inner surface of the vessels using the blunt edge of a pair of 
scissors.  The remaining tissue, comprising mostly media, was transferred into fresh 
enzyme solution, minced to approximately 1   mm2 pieces and incubated as described 
above for  1   h vortexing every  10 min.  Following incubation, enzyme solution was 
replenished at 30 min  intervals,  cells pelleted by centrifugation (200 g  for 5 min), 
resuspended in Dulbecco’s modified eagle medium (DMEM) supplemented with 100 
U/ml  penicillin,  100  pg/ml  streptomycin,  2mM  L-glutamine  and  10  %  heat 
inactivated FCS, transferred to a tissue culture flask and incubated for 15 min.  The 
medium containing cells that had not adhered was replenished with  fresh medium 
and transferred to a clean tissue culture flask.  This was incubated for a further  15 
min and then discarded replacing it with fresh medium.  This process of differential 
plating was repeated every 30 min until most of the aortae had been digested.  Cells 
grown  to  confluency  were  detached  using trypsin/ethylenediamine-tetraacetic  acid 
(EDTA; 0.25 % trypsin/1  mM EDTA; Life Technologies) and seeded in secondary 
culture.  Once  a  pure  population  of RAoSMC  was  obtained  cells  were  used  for 
experimentation up to passage 15.
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2.2.2.2.  Characterisation
2.2.2.2.1.  Immunocytochemistry
Immunocytochemistry  was  used  to  ascertain  that  a  homogeneous  population  of 
smooth  muscle  cells  had  been  isolated.  Cells  were  seeded  onto  sterilised  glass 
coverslips  in  6  well  plates  and  grown  in  DMEM  supplemented  with  100  U/ml 
penicillin,  100  pg/ml  streptomycin,  2  mM  L-glutamine  and  10  %  heat  inactivated 
FCS at 37°C in a humidified incubator with 5 % CO2 in air for 24 h.  Coverslips with 
an  attached  monolayer  of  cells  were  washed  several  times  in  PBS,  fixed  and 
permeabilised in 100 % ice cold methanol at <4°C for 5 min, washed several times in 
PBS and blocked with PBS containing 5 % goat serum (Sigma, Poole, Dorset, UK) 
for  30  min.  Cells  were  subsequently  labelled  with  1:1600  dilution  of primary 
antibody, mouse monoclonal anti- smooth muscle a-actin (Sigma, Missouri, USA) in 
PBS by incubating for 2 h at room temperature.  After 3 washes with PBS cells were 
incubated with  secondary antibody,  fluorescein  isothiocyanate  (FITC)  -conjugated 
goat  anti-mouse  IgG  (Chemicon),  1:500  dilution  for 90  min  at  room  temperature. 
Cells  were  washed  3  times  in  PBS  followed  by  several  washes  in distilled  water. 
Slides  were  mounted  with  mounting  medium  containing  4',6-diamidino-2- 
phenylindole (DAPI;  Vectashield,  Vector Laboratories,  Burlingame,  USA) and the 
bound antibody was visualised using a Leica TCS-SP1  confocal microscope (Leica, 
Milton Keynes, Bucks, UK; Figure 28, Figure 29, Figure 30).
2.2.2.2.2.  Hill and valley morphology
Primary  rat  aortic  smooth  muscle  cells  (1°  RAoSMC  )  were  seeded  into  tissue 
culture  vessels  and  allowed  to  grow  in  DMEM  supplemented  with  100  U/ml 
penicillin,  100  pg/ml  streptomycin,  2  mM  L-glutamine  and  10  %  heat  inactivated 
FCS at 37°C in a humidified incubator with 5 % CO2 in air.  Medium was replaced 
every  2 - 3   days  until  overconfluency was  achieved;  at this  time cells  push  each 
other to form areas of focal overgrowth.  This was observed using a Leica DM IRB 
inverted  microscope  (Leica)  and  photographs  were  taken  using  a  JVC  KY-F55B 
Colour  Video  Camera  (JVC  Professional,  London,  UK)  attached  to  the  KS300 
Imaging system release 3.0 (Imaging Associates Limited, Thame, UK; Figure 31).
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2.2.3.  Freezing and thawing cells
2.2.3.1.  Freezing cells
Long term preservation of cells was  achieved by storing in  liquid nitrogen.  Cells 
were trypsinised in the case of adherent cells or simply removed from culture and 
pelleted by centrifugation (RAoSMC: 200 g for 5 min; RAW264.7: 400 g for 5 min). 
Cells were resuspended  in supplemented DMEM or RPMI1640 growth medium as 
described  for  the  respective  cell  types  and  counted  using  trypan  blue  exclusion. 
10  %  DMSO was  added  to  the  cells just prior to  freezing.  Cells  were  frozen  in 
cryogenic  vials  at  a  concentration  of 0.5  -   1.0  x  106  cells/ml.  Cryogenic  vials 
containing cells were transferred to a Cryo  1°C freezing container (Fisher Scientific, 
Leicestershire, UK) and placed at -80°C for at least 24 h after which they were stored 
until required in the vapour phase of liquid nitrogen.  Alternatively cryogenic vials 
were kept on ice in the fridge (4°C) for  10 min, transferred to a polythene box and 
kept  at  -20°C  for  2  h  and  then  moved  to  -80°C  overnight.  Following  overnight 
freezing vials were transferred to liquid nitrogen and stored as described above.
2.2.3.2.  Thawing cells
Growth medium was placed into the culture flasks and equilibrated in a humidified 
incubator with 5 % CO2 in air. Cells were removed from liquid nitrogen and thawed 
by constantly agitating in a 37°C waterbath.  Once half the content had thawed the 
vial was removed from the waterbath, the screwtop was opened slightly to reduce the 
overpressure  and re-screwed tightly.  Thawing was  continued  until  all  the content 
was thawed.  Cells were resuspended by carefully pipetting and the content of the 
vial was transferred to the culture flasks.  Alternatively, cells were resuspended in 50 
ml medium, centrifuged at appropriate speeds as described previously for each cell 
type, the supernatant was discarded, the pellet was resuspended in 5 ml medium and 
transferred  to  culture  flasks.  Medium  was  replaced  after  24  h  and  cells  were 
subcultured once 80 -  90 % confluence was achieved.  For adherent cell lines cells 
were subcultured as described in sections 2.2.2.1.  For suspension cells (RAW264.7), 
cells were dislodged from the culture  flask by scraping and transferred to  a stirrer 
bottle containing RPMI1640 growth medium.
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2.3. Determination of iNOS activity and expression in vitro
RAW264.7 cells were seeded into 6 well plates at a concentration of 1  x 106 cells per 
well.  RAoSMC were seeded into 6 well plates at a concentration of 0.5 x  106 cells 
per well or  10 cm dishes at a concentration of 0.5 x  106 cells per dish.  Cells were 
allowed to grow and adhere at 37°C in a humidified incubator with 5 % CO2 in air 
overnight  or  until  80  -   90  %  confluent.  Growth  medium  was  changed  prior  to 
experimentation.  Activators  (i.e.  LPS,  IFN-y,  IL-lp  or  TNF-a)  were  added  at 
appropriate concentrations and cells were incubated (as above) for appropriate times. 
Alternatively,  cells  were  preincubated  with  ANP  or  CNP  for  5  min  or  MAPK 
inhibitors  (PD98059  or  SB203580;  both  at  30  pM)  for  30  min  at  appropriate 
concentrations prior to activator addition.  Medium was removed at each timepoint 
and an aliquot was stored at -20°C  for nitrite determination by chemiluminescence 
(see section 2.6).  Cells were washed twice with cold PBS.  100 -  200 pi whole cell 
homogenisation  buffer  (10  ml  of  50  mM  Tris(hydroxymethyl)aminomethane 
hydrochloride (Tris-HCl),  150 mM NaCl,  1   % Triton X-100, 2 mM EDTA,  8 mM 
ethylene glycol-bis(P-aminoethylether)-N,N,N',N'-tetraacetic acid (EGTA), protease 
inhibitor cocktail; Roche, East Sussex, UK) was added to each well and incubated on 
ice for 5 min.  The cells were dislodged by scraping and the lysate was centrifuged at 
16060 g for 5 min at 4°C.  The pellet was discarded and the supernatant (whole cell 
extract)  stored  at  -20°C  for  iNOS  protein  determination  by Western  blotting  (see 
section 2.5).
2.4. Determination of MAPK phosphorylation in vitro
RAW264.7  cells  or  RAoSMC  were  seeded  and  allowed  to  reach  confluency  as 
described  in section  2.3.  Growth medium  was  changed prior to  experimentation. 
Cells were treated with a cocktail of LPS (100 pg/ml), IFN-y (200 U/ml), IL-ip (400 
U/ml)  and  TNF-a  (1000  U/ml)  for  0-60  min  in  the  presence  and  absence  of 
natriuretic  peptides  (5  min pre-incubation).  Alternatively,  cells were treated with 
ANP (1  pM), CNP (1  nM -   10 pM) or 8-Bromo-cGMP (300 pM) alone.  In certain 
experiments,  cells  were  pre-incubated  with  PTx  (100  ng/ml;  16  h),  M372049  (10 
pM) or PD98059 (30 pM; both 30 min) prior to the addition of CNP.  At appropriate 
timepoints medium was removed and discarded and cells were washed twice with
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cold  PBS.  150  pl/well  (6  well-plate)  or  200  pl/dish  (10  cm  dishes)  of phospho- 
homogenisation  buffer  (10  mM  Tris-HCl,  50  mM  NaCl,  30  mM  sodium 
pyrophosphate,  2  mM  EDTA,  50  mM  NaF,  1   %  Triton  X-100,  1   mM 
phenylmethylsulfonyl  fluoride,  1   mM  sodium  orthovanadate  and  1   pg/ml 
benzamidine, antipain, leupeptin and aprotinin) was added and cells were dislodged 
into the buffer by scraping.  Lysate was centrifuged at 16060 g for 5 min at 4°C, the 
pellet was discarded and the supernatant (whole cell extract) was stored at 20°C for 
total MAPK or phosphorylated MAPK protein determination by Western blot.
2.5.  Sodium dodecyl sulphate polyacrylamide gel 
electrophoresis (SDS-PAGE) and Western blotting
2.5.1.  Sample preparation for SDS-PAGE
Protein concentrations were determined using the bicinchoninic acid based BCA™
2 j
protein assay kit.  Total protein was quantified by its reaction with Cu  reducing it 
to  Cul+  in  an  alkaline  medium  known  as  the  biuret  reaction.  The  colorimetric 
change  is  brought  about  by the  reaction  of bicinchoninic  acid  with  Cul+  and  the 
protein  concentrations  are determined based on  a  standard curve  produced  from  a 
series of dilutions of known concentrations using the common protein bovine serum 
albumin  in  whole  cell  homogenisation  buffer  or  phospho-homogenisation  buffer 
(standard concentrations: 2, 1.5, 1, 0.75, 0.5, 0.25, 0.125 and 0 mg/ml).  25 pi sample 
or  standard  were  mixed  with  200  pi  working  reagent  (made  by  mixing  50  parts 
Reagent A with  1   part Reagent  B) in  a 96-well  plate and  incubated  for 30 min  at 
37°C.  Absorbance  was  measure  at  570  nm  (Victor2™ *   1420  multilabel  counter, 
PerkinElmer Life Sciences, Boston, USA) and total protein was calculated from the 
standard  curve.  Samples were  diluted  using whole  cell  homogenisation  buffer  or 
phospho-homogenisation  buffer to  ensure  equal  loading  of protein  to  the  gel  and 
allow comparative analysis.  A  1:1  dilution was prepared of homogenised samples 
and  sample  buffer  (20  mM  Tris  HC1,  pH  6.8,  2  mM  EDTA,  2  %  SDS,  10  %  2- 
mercaptoethanol, 20 % glycerol, 0.025 % bromophenol blue in distilled water).  The 
samples  were  heated  at  100°C  in  a  heating  block  (Grant  Instruments,  Cambridge, 
UK) for 5 min, placed on ice for a further 5 min and centrifuged at 16060 g for 2 min 
at 4°C.  Samples were then loaded onto the gel for separation or stored at -20°C for 
future analysis.
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2.5.2. SDS-PAGE
Two  glass  plates  were  assembled  using  a  casting  frame  and  held  in  an  upright 
position  using  a  casting  stand  (Mini-Protean  3  cell  and  system,  Biorad, 
Hertfordshire,  UK).  A  separating  gel  containing  7.5  or  15  %  acrylamide  was 
prepared  by mixing  acrylamide/bis  acrylamide  (30  %  solution,  mix  ration  37.5:1, 
Sigma),  separating gel buffer (0.375  M Tris  Base,  0.1  %  SDS,  distilled water,  pH 
8.8),  0.1  %  ammonium  persulphate  (Sigma),  0.001  %  N,N,N',N'-
tetramethylethylenediamine (TEMED; Sigma) in distilled water, and poured into the 
glass assembly.  The gel was overlaid with isopropanol to remove any bubbles and 
smooth  out  the  surface;  this  was  removed  after  the  separating  gel  had  set  and 
polymerised.  A stacking gel containing 4 % acrylamide was prepared by combining 
acrylamide/bis  acrylamide,  stacking  gel  buffer  (0.125  M  Tris  Base,  0.1  %  SDS, 
distilled water, pH 6.8),  0.1 % ammonium persulphate, 0.001 % TEMED in distilled 
water and poured on top of the separating gel.  Combs were inserted and the gel was 
allowed to set.  Combs were removed and the gels were assembled using the Protean 
III gel tank system, running buffer was added (50 mM Tris Base, 0.384 M glycine, 
0.1  % SDS  in distilled water) and  20  pi of diluted sample to  ensure equal protein 
were loaded into each well.  Samples were run alongside  10 pi rainbow high-range 
molecular weight markers (GE Healthcare, Bucks, UK) and 15 pi positive control at 
100 -  150 V until the dye front reached the bottom of the gel.
2.5.3. Western blotting
2.5.3.1.  Wet transfer
Transfer of proteins from gel to nitrocellulose was carried out using the Mini trans­
blot electrophoresis  transfer cell  (Biorad).  Transfer buffer (25  mM Tris Base,  192 
mM glycine, 20 % methanol; made up to  1   litre with distilled water) was prepared 
just  before  required  and  stored  at  4°C  until  used.  A  sandwich  of  filter  paper, 
nitrocellulose, SDS-PAGE gel and fibre pads was built up on the positive side of the 
gel holder cassette (see Figure 9).
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Figure 9 -  Blotting setup using mini trans-blot electrophoretic transfer cell.
The gel holder cassettes were placed into the electrode module and the tank was 
filled with transfer buffer.  The transfer was carried out at 100 V for 75 min.
2.5.3.2.  Immunoblotting
Following transfer, nitrocellulose was stained with  1   % Ponceau S solution (Sigma) 
to  visualise  transferred  proteins  and  then  washed  three  times  in  distilled  water. 
Membranes  were  incubated  in  5  %  dried  skimmed  milk  (Marvel,  Premier 
International  Foods  Ltd,  Spalding,  Lines,  UK)  in  PBSfTween  20  (20  %  lOx  PBS 
without  calcium  and  magnesium  (Life  Technologies),  0.001  %  polyoxyethylene- 
sorbitan  monolaurate  (Tween  20)  from  Sigma  in  distilled  water)  for  60  min  or 
overnight with constant shaking.  The blot was washed 5 times in PBS/Tween 20 (5 
min each wash with shaking) followed by incubation overnight at 4°C with constant 
agitation with primary antibody diluted in 5 % dried skimmed milk in PBS/Tween 
20  (polyclonal  anti-iNOS  (BD  Transduction  Laboratories,  Cowley,  Oxford,  UK), 
polyclonal  anti-p44/p42  MAP kinase, polyclonal  anti phospho-p44/42  MAP kinase 
(Thr202/Tyr204),  polyclonal  anti-p38  MAP  kinase,  anti-phospho-p38  MAP  kinase 
(Thrl80/Tyrl82;  Cell  Signaling Technology,  distributed by New  England  Biolabs, 
Hertfordshire, UK), monoclonal anti-actin (Chemicon) diluted  1:2000  (anti-iNOS), 
1:500  (anti-p44/42,  anti-phospho-p44/42,  anti-p38  and  anti-phospho-p38),  1:20000 
(anti-actin).  Following  incubation  the  blot  was  washed  with  5  changes  of 
PBS/Tween 20 (5 min each wash) and incubated for 60 min with secondary antibody 
diluted in 5  % dried  skimmed milk  in PBS/Tween  20  (peroxidase-conjugated goat 
anti-rabbit immunoglobulins (anti-iNOS, anti-p44/42, anti-phospho-p44/42, anti-p38 
and  anti-phospho-p38),  peroxidase-conjugated  goat  anti-mouse  immunoglobulins
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(anti-actin;  DAKO,  Cambridgeshire,  UK)  diluted  1:1000-1:2000  and  1:5000 
respectively).  The membranes were then washed in PBS/Tween 20 (5 washes, 5 min 
each)  and  the  proteins  were  visualised  using  enhanced  chemiluminescence  (ECL 
Western blotting detection reagents, GE Healthcare).  Equal volumes of reagents  1  
and 2 were mixed just prior to use and this was used to cover the membranes for 2 
min.  Blots were exposed using hyperfilm ECL in an autoradiography hypercassette 
(GE  Healthcare)  and  developed  using  an  automated  developer  (Compact  X4,  X- 
ograph, Wiltshire,  UK).  The  images were  scanned and analysed quantitatively by 
densitometry (Alphalmager®  Imaging  System,  AlphaEase® FC  software version 4; 
Alphalnnotech, San Leandro, California, USA).
2.6.  Chemiluminescence
NO released by cells in culture or in vivo is immediately converted to its oxidative 
products  nitrate  and  nitrite.  Nitrate/nitrite  accumulation  in  the  samples  was 
measured  using  chemiluminescence,  which  has  been  shown  to  provide  greater 
accuracy  and  precision  than  colourimetric  methods  (Cox,  1980).  The  chemical 
reduction  of nitrate and  nitrite  to NO  is  achieved using the  strong reducing  agent 
vanadium  III  chloride  (0.1  M)  in  1   M  hydrochloric  acid  refluxing  at  90°C  under 
nitrogen, while nitrite only reduction to NO involves the use of 25 % sodium iodide 
(6 % solution) and 75 % glacial acetic acid; NO produced by the reduction reaction 
can be subsequently used for nitrate/nitrite determination via its  chemiluminescent 
reaction  with  ozone.  When  the NO  is  combined with  ozone,  metastable  nitrogen 
dioxide  (NO2*)  is  produced,  which  subsequently  emits  a  photon  as  it  returns  to 
ground state, and the emitted light is detected by a photomultiplier (Figure 10).  The 
integrated  electrical  signal  produced  by  the  photomultiplier  is  proportional  to  the 
content of nitrate/nitrite in the sample.  Analysis was carried out using Sievers Nitric 
Oxide Analyser NOA™ 280 (Sievers Instruments, Inc, Boulder, C080301 USA).
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NO3  + 4H+ + 3C  --------^ NO + 2H20   NITRATE
NO2' + 2H+ + C   -------- NO + H20   NITRITE
NO + O3  -------- n o 2*  + 0 2
N 02*   --------► n o 2  +  Light
Figure 10 -  Reactions underlying chemiluminescence analysis of nitrate/nitrite concentration.
A standard curve was produced using  10 pi of 100, 50, 25,  10,  1   and 0.1  pM sodium 
nitrate/nitrite standards according to the species to be analysed.  10 pi of each sample 
(cell free medium or plasma) was injected into the system and the concentrations of 
nitrate/nitrite were calculated from the standard curve.
2.7.  Assessment of cell  proliferation
RAoSMC  proliferation  was  assessed  by  determining  5-bromo-2'-deoxyuridine 
(BrdU) incorporation using a commercially available assay (Roche Diagnostics, East 
Sussex, UK).  Replication of genomic DNA is a prerequisite for cellular proliferation 
and  therefore  monitoring  of  DNA  synthesis  is  an  indirect  parameter  of  cell 
proliferation.  BrdU,  a  pyrimidine  analogue,  is  incorporated  into  replicating  cell 
DNA in place of thymidine and an anti-BrdU antibody is used coupled to a substrate 
reaction  to  quantify  proliferating  cells  (Gratzner,  1982;  Porstmann  et  al.,  1985). 
The  assay  was  carried  out  according  to  the  manufacturer’s  protocol.  In  brief, 
RAoSMC were plated into 96-well plates at a density of 25000 cells/well in triplicate 
in  DMEM  containing  100  U/ml  penicillin,  100  pg/ml  streptomycin,  2  mM  L- 
glutamine and  10 % heat inactivated  FCS  for 24  h in a humidified  incubator with 
5 % CO2 in air.  Cells were switched to DMEM as above but with 0.1  % FCS for 24 
h.  Cells were then pretreated with  10 pM M372049, 30 pM PD98059 or vehicle for 
30 min and then exposed to  1   pM CNP or  100 nM Ang II for 24 h.  At 20 h cells 
were  labelled  with  BrdU  for 4  h.  Culture  medium  was  then  removed,  cells  were 
fixed and the DNA denatured using the FixDenat solution.  Peroxidase-conjugated 
anti-BrdU  antibody  (anti-BrdU-POD)  was  added  to  detect  the  newly  synthesised 
cellular DNA incorporated BrdU and the bound anti-BrdU immune complexes were
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detected  using  tetramethylbenzidine  substrate  reaction.  The  reaction  product was 
quantified by measuring absorbance at 370 nm (reference wavelength: 492 nm) on a 
SpectraMax Plus 96-well microplate reader (Molecular Devices, Berkshire, UK).
2.8.  RNA isolation and reverse transcriptase polymerase 
chain reaction (RT-PCR)
2.8.1.  RNA isolation
Total ribonucleic  acid  (RNA)  was  extracted  from cells  using the RNeasy mini  kit 
(Qiagen,  West  Sussex,  UK).  Briefly,  4  -   5  x  106  cells  were  disrupted  in  buffer 
containing  guanidine  isothiocyanate  and  homogenised  using  QIAshredder 
homogenizers  (Qiagen).  Ethanol  was  added to the  lysate  enabling  selective  RNA 
binding to the RNeasy silica containing gel membrane.  DNase was added (RNase- 
ffee  DNase  Kit,  Qiagen)  to  eliminate  any  DNA  contamination  and  spin  columns 
were centrifuged to remove waste and impurities.  Total RNA was eluted into RNase 
free water and stored at -80°C.
RNA  concentration  and  purity  were  determined  using  a  NanoDrop  ND-1000 
Spectrophotometer  (NanoDrop  Technologies,  Wilmington,  USA).  Concentration 
was determined by measuring absorbance at 260 nm (A260), while the ratio between 
260 nm and 280  nm,  and 260 nm  and 230 nm gave an indication of RNA purity. 
Values  of A260/A280 ratio  should be  approximately 2.0  (Glasel,  1995;  Manchester,
1995)  and A260/A230 ratio should be in the range of 1.8 -  2.2 for pure RNA according 
to the manufacturer’s instructions.
RNA integrity was checked by running 0.5 pg and 1   pg RNA on a  1   % agarose gel. 
Agarose  multi-purpose  molecular  grade  (Bioline,  London,  UK)  was  dissolved  by 
heating  in  0.04  M  Tris-acetate  and  0.002  M  Na2EDTA  in  distilled  water  (TAE; 
National Diagnostics, Hessle Hull, UK).  0.5  pg/ml ethidium bromide (Sigma) was 
added to the gel before setting.  DNA coloured loading buffer (Bioline) was added to 
RNA samples and gels were run at 50 -  100 V in TAE.  Samples were run alongside 
DNA marker HyperLadder II (Bioline) and bands were visualised and photographed 
using  the  automated  gel  documentation  Alphalmager®  imaging  system  and 
AlphaEase® FC software, version 4 (Alphalnnotech).
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2.8.2.  RT-PCR
RT-PCR was carried out using Qiagen one-step RT-PCR kit (Qiagen).  Briefly,  lx 
Qiagen one-step RT-PCR buffer (containing MgCl2),  deoxynucleotide triphosphate 
(dNTP) mix  (containing 400  pM  final  concentration of each dNTP),  lx  Qiagen Q 
solution,  Qiagen  one-step  RT-PCR  enzyme  mix  (containing  Omniscript  and 
Sensiscript reverse transcriptases  and HotStarTaq  DNA polymerase),  gene specific 
forward  and  reverse  primers  (0.6  pM  each;  Figure  11),  1   pi  template  RNA  and 
RNase free water to make up to 50 pi were mixed and RT-PCR was performed on a 
Primus 96 thermocycler (MWG Biotech, Milton Keynes, UK).  Reverse transcription 
was  carried  out  at  50°C  for  30  min  followed  by  thermal  cycling  conditions  as 
follows: 95°C for  15 min then 40 cycles of denaturation at 94°C, annealing at 55°C 
for 1   min and extension at 72°C for 1   min, followed by a final extension at 72°C for 
10 min.
NPR-A Sense
Antisense
5'-CATCCTGGACAACCTGC-3'
5'-TAGGTCCGAACCTTGCC-3'
NPR-B Sense
Antisense
5'-CATGGCAGGACAATCGAACC-3/
5'-TGCCTGCACCTTTGTGATATCG-3'
NPR-C Sense
Antisense
5'-GGCTCAATGAGGAGGATTACGTG-3'
5'-AATCTTCCCGCAGCTCTCGATG-3'
Figure 11 -  Rat NPR-A, B and C gene specific primers.
PCR products were resolved on a  1   % agarose gel as described in 2.8.1.  5  pi of 5x 
DNA coloured loading buffer (Bioline) were added to 20 pi of each PCR product, 
the entire volume was loaded onto the gel and run at 50 -   100 V in TAE alongside 
HyperLadder  2  marker.  Bands  were  visualised  and  photographed  using  the 
Alphalmager® imaging system as described in 2.8.1.
2.9.  Ex vivo animal studies
All  experiments  were  conducted  according  to  the Animals  (Scientific  Procedures) 
Act  1986,  United  Kingdom  and  conform  to  the  Guide  to  the  care  and  use  of 
laboratory animals (NIH publication no. 85-23, 1996).
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2.9.1. Genotyping NPR-A knockout mice
Tail snips from WT (C57BL6; Harlan UK Limited, Bicester Oxon, UK) and NPR-A 
KO  (Oliver  Smithies,  University  of  North  Carolina,  USA)  mice  were  cut  into 
approximately 4 mm lengths.  Total DNA was extracted using the DNeasy tissue kit 
(Qiagen)  as  described  by  the  manufacturer’s  protocol.  Briefly,  tail  snips  were 
homogenised  and lysed with ATL buffer and proteinase K overnight at  55°C  with 
shaking.  Lysate was then loaded onto a DNeasy mini spin column where the DNA 
is  selectively bound to the silica-gel-membrane in the presence of chaotropic  salts. 
The  column was  washed and  DNA  eluted  into  AE  buffer containing  10  mM  Tris 
HC1 and 0.5 mM EDTA at pH 9.0.
PCR was carried out using Taq DNA polymerase kit (Roche Diagnostics).  Briefly, 
lx PCR buffer supplied with enzyme (10 mM Tris HC1, 50 mM KC1, 1.5 mM MgCh, 
pH  8.3),  dNTP  mix  (200  pM  final  concentration  of each  dNTP),  gene  specific 
primers NPR-A WT forward, 3'-GC AT  GGTT C  AGCTCT  A  AG  AC-5', NPR-A NEO 
(KO)  reverse,  3'-CT  AACCCT  GT  G  A  ACT GT  AAGC-5',  NPR-A  reverse,  3'- 
CCTCAGTTATCTACATCTGC-5', all at 0.8 pM, 1 unit Taq DNA polymerase, 2 pi 
template DNA and RNase free water to make up to 25 pi were mixed and PCR was 
performed on a Primus 96 thermocycler (MWG Biotech).  Initial denaturation was 
carried out at 95°C for 30 sec, followed by thermal cycling conditions as follows: 35 
cycles of denaturation at 94°C for 30 sec, annealing at 60°C for 30 sec and extension 
at 72°C for 1  min, followed by a final extension at 72°C for 10 min.
PCR products were resolved on a 2 % agarose gel as described in 2.8.1.
2.9.2. Determination of iNOS activity and expression in vivo
Salmonella  typhimurium  LPS  (12.5  mg/kg,  i.v.)  or  vehicle  (physiological  saline, 
sodium chloride 0.9  %  w/v,  Ivex  Pharmaceuticals,  Antrim, Northern  Ireland,  UK) 
were administered to 9 -  10 week old male WT (C57BL6; 25 -  30 g) or NPR-A KO 
mice (25 -  30 g) via the tail vein.  After  16 h animals were euthanised by cervical 
dislocation  and  tissues  (heart,  lung  and  aorta)  and  blood  collected.  Tissues  were 
snap  frozen  in  liquid nitrogen  and  stored at  -80°C.  They were then homogenised 
using an ice cold mortar and pestle, transferred to whole cell homogenisation buffer
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(composition as in section 2.3) and incubated on ice with vortexing every 10 min for 
a minimum of 30 min.  Samples were centrifuged at  16060 g for 15 min at 4°C and 
the supernatant was retained and stored at -80°C for iNOS protein determination.
Blood  samples  were  centrifuged  at  16060  g  for  5  min  at  room  temperature  and 
plasma was retained for nitrate/nitrite determination by chemiluminescence.
2.9.3.  Functional reactivity of isolated thoracic aorta
Male  NPR-A  KO  or WT  mice  were  treated  with  LPS  or vehicle  as  described  in 
section 2.9.2.  After 16 h the animals were euthanised by cervical dislocation and the 
thoracic aortae were carefully excised and cleaned of connective tissue.  The aortae 
were cut  into  3  rings approximately 4 mm in  length and  mounted in  10 ml  organ 
baths containing Krebs bicarbonate buffer (NaCl  118.41 mM, NaHC0 3 25 mM, KC1 
4.75  mM,  KH2PO4  1.19  mM,  MgS0 4 .7H2 0  1.19  mM,  D-glucose  11.1  mM  and 
CaCl2-6H20 2.5  mM; pH 7.4) maintained at 37°C and bubbled with 95  % O2/ 5 % 
CO2.  The tension was set at 0.3 g and the rings were equilibrated for approximately 
1   h;  Krebs  solution  was  replenished  every  15-20  min  and  the  tension  was  re­
adjusted to 0.3  g if required.  After equilibration,  the rings were primed with KC1 
(4.8 x  10'2M).  The KC1 was washed out and cumulative concentrations of U46619 
(10'10 -  HT6 M) were added; approximately 80 % maximum (ECgo) U46619-induced 
response  was  used  for  experimentation.  Endothelial  integrity  was  assessed  by 
establishing greater than  50  %  relaxation using ACh  (10'6M;  for non-LPS  treated 
animals).  If the contractions to U46619 were not maintained, or relaxation greater 
than 50 % of the U46619-induced tone to ACh was not observed, the tissues were 
discarded.  Following washing, an EC so concentration of U46619 was added to the 
organ  bath  and  following  attainment  of  a  stable  contraction,  cumulative 
concentration-response  curves  to  ACh  (10'9-   10'5   M),  ANP  (10'n -   10'6  M)  and 
SPER-NO (10'9-   10'4 M) were obtained.  Data were captured using PowerLab and 
Chart version 4 (AD Instruments, Oxfordshire, UK).
2.10.  Data Analysis
All statistical analyses were performed using GraphPad Prism (GraphPad Software, 
San Diego, CA, USA).  Densitometric analyses were performed using AlphaEase® 
FC  software  version  4  (Alphalnnotech).  Exposed  films  were  illuminated  with
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transilluminating  white  light  and  an  image  was  captured  using  a  motorised  lens 
camera (focal length:  8.0 ~ 48 mm, maximum aperture ratio:  1:1.2,  6x zoom) with 
flat  field calibration to  easily correct  for non-uniformities  in  light  gathering.  The 
captured image was then analysed using AlphaEase® FC software version 4 utilising 
256 gray scale values.  The software captures an integrated density value which is 
the sum of the gray levels of all the pixels within the boundaries of each band and 
then subtracts a background value computed as a mean of 16 lowest intensity points 
within the assigned boundaries.  The boundary size is kept constant for all  bands. 
All  data  are  plotted  graphically  as  mean  values,  with  vertical  bars  representing 
standard error of the mean (SEM).  A Student’s t-test was used to assess differences 
between two data groups (iNOS expression, plasma NOx and survival in WT versus 
NPR-A  KO  mice).  One-way  ANOVA  followed  by  Bonferroni’s  multiple 
comparison  test  was  used  to  assess  differences  between  individual  experimental 
conditions  when  multiple comparisons  were  being made  to  a  single  control.  For 
organ  bath  experiments  relaxations  are  expressed  as  percent  reversal  of U46619- 
induced tone.  Curves were fitted to all the data using nonlinear regression and the 
concentration  of each  drug,  giving  a half-maximal  response  (EC50),  were  used  to 
compare potency.  Curves were analysed using two-way ANOVA.  For all statistical 
analyses a probability (P) value, *, of <0.05 was considered significant.
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3. Results 1
3.1.  Introduction
NO  and  natriuretic  peptides  have  both  been  described  to  play  crucial  roles  in 
inflammation (Moncada and Higgs,  1993;  Hobbs et al,  1999; Vollmar,  2005) and 
maintaining  cardiovascular  homeostasis  (Ahluwalia  et  al,  2004;  Woods,  2004; 
Naseem, 2005).  During an inflammatory response, various stimuli, including IFN-y, 
IL-ip and TNF-a, cause an increase in NO  levels, primarily due to  an increase in 
iNOS  expression  and  activity  (Lirk  et  al,  2002).  NO  can  then  act  in  a  cGMP- 
dependent  or  independent  fashion  to  bring  about  cytostatic  and  cytotoxic  effects 
(Guzik  et  al,  2003).  However,  the  high  NO  levels  generated  during  an 
inflammatory response  can  prove  detrimental,  exemplified  by the  development  of 
septic  shock (Titheradge,  1999).  Natriuretic peptides parallel the  effects  of NO  in 
the vasculature (Ahluwalia et al, 2004), but there is conflicting evidence concerning 
the effects of natriuretic peptides in the immune system (Vollmar and Schulz,  1995b; 
Kiemer  and  Vollmar,  1997;  Kiemer  et  al,  2002a;  Vollmar,  2005)  and  further 
investigations are warranted.
Studies described in this chapter investigate the hypothesis that natriuretic peptides 
(ANP and BNP) affect pro-inflammatory protein expression and vascular function in 
vivo under inflammatory conditions.  This was evaluated by examining the effect of 
NPR-A gene deletion on in vivo LPS-induced pro-inflammatory protein expression 
(i.e. iNOS), NO production and vascular function.CHAPTER 3 -  RESULTS 1
3.2.  Effect of NPR-A gene deletion on LPS-induced iNOS 
expression and activity in vivo
Genotyping by RT-PCR was carried out on tail snips from both WT and NPR-A KO 
mice to ensure that NPR-A was absent from the KO animals and that the WT mice 
contained  the  receptor being  investigated.  RT-PCR revealed that  all  NPR-A  KO 
animals  used  did not  possess  NPR-A while  all  the  WT  mice  had NPR-A  present 
(Figure 12).
WT and NPR-A KO mice were treated with saline (volume matched to LPS) or 12.5 
mg/kg Salmonella  typhimurium  LPS  (both  i.v.) for  16 h.  Animals  were killed by 
cervical dislocation and organs/blood removed for analysis.  Inducible NOS protein 
expression was determined by Western blot in heart, lung and aorta and plasma NOx 
was  determined  using  chemiluminescence.  Inducible  NOS  protein  expression  in 
response to LPS was reduced in the lung (Figure 14) and aorta (Figure 15) of NPR-A 
KO animals when compared to WT.  Inducible NOS protein expression in the heart 
in response to LPS exhibited an inhibitory trend in NPR-A KO animals but did not 
reach  statistical  significance  (Figure  13).  NOx  levels  in  plasma  were 
indistinguishable  between  saline  treated  NPR-A  KO  and  WT  animals,  however 
levels were  significantly lower in NPR-A  KO mice in comparison to WT animals 
treated with LPS (Figure  16), indicating that iNOS activity is also reduced in NPR-A 
KO animals following administration of LPS.
The  survival  rates  of  WT  and  NPR-A  KO  mice  treated  with  LPS  were 
indistinguishable (Figure 17).
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Figure 12 -  Genotyping of WT and NPR-A KO mice.  Products of expected size were obtained (550 
bp NPR-A KO, 350 bp WT).
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LPS-INDUCED iNOS EXPRESSION IN THE HEART OF 
WILD TYPE AND NPR-A KNOCKOUT MICE
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Figure  13 -  Expression of iNOS protein in heart tissue from WT and NPR-A KO mice treated with 
LPS (12.5 mg/kg; i.v.) for 16 h.  Protein expression was analysed by Western blot (A) and quantified 
by densitometry (B).  Data are represented as mean ± SEM, n = 5.
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LPS-INDUCED iNOS EXPRESSION IN THE LUNG OF 
WILD TYPE AND NPR-A KNOCKOUT MICE
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Figure  14 -  Expression of iNOS protein in lung tissue from WT and NPR-A KO mice treated with 
LPS (12.5 mg/kg; i.v.) for 16 h.  Protein expression was analysed by Western blot (A) and quantified 
by densitometry (B).  Data are represented as mean ± SEM, n = 5; *, p<0.05 versus control.
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LPS-EVDUCED iNOS EXPRESSION IN THE AORTA OF 
WILD TYPE AND NPR-A KNOCKOUT MICE
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Figure  15 -  Expression of iNOS protein in aortic tissue from WT and NPR-A KO mice treated with 
LPS (12.5 mg/kg; i.v.) for  16 h.  Protein expression was analysed by Western blot (A) and quantified 
by densitometry (B).  Data are represented as mean ± SEM, n = 4; *, p<0.05 versus control.
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LPS-INDUCED PLASMA NOx IN 
WILD TYPE AND NPR-A KNOCKOUT MICE
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Figure  16 -  Plasma NOx  levels from WT and NPR-A  KO mice treated  with  LPS  (12.5  mg/kg) or 
saline (both i.v.) for 16 h, determined by chemiluminescence.  Data are represented as mean ± SEM, n 
= 7; *, p<0.05 versus control.
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SURVIVAL RATES OF WILD TYPE AND NPR-A 
KNOCKOUT MICE FOLLOWING TREATMENT WITH LPS
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Figure  17 -  Survival rates of WT and NPR-A KO mice treated with LPS (12.5 mg/kg; i.v.) for 16 h. 
Data are represented as mean ± SEM, n = 15.
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3.3. Effect  of  NPR-A  gene  deletion  on  vascular  function 
induced by LPS in vivo
Since treatment of NPR-A KO mice with LPS (12.5 mg/kg; i.v. for 16 h) revealed a 
decrease  in  iNOS  expression  and  NOx  plasma  levels  in  comparison  to  WT  mice, 
functional  pharmacological  studies  were  conducted  using  thoracic  aortae  from 
saline-(volume  matched  to  LPS)  or  LPS-(12.5  mg/kg),  both  i.v.  for  16  h,  treated 
NPR-A KO and WT mice.
3.3.1. Responses to U46619
In WT mice, LPS caused a significant rightward shift in the concentration-response 
curve to the thromboxane A2 mimetic U46619, (pECso: 7.69 ±0.12 and 7.94 ± 0.05; 
LPS and saline respectively; Figure 18A and Figure 22A).  In NPR-A KO mice LPS 
treatment  had  no  significant  effect  on  responses  to  U46619  compared  to  saline 
(pECso:  6.41  ±0.16 and 7.12 ± 0.18;  LPS and saline respectively; Figure  18B and 
Figure 22B).
In  order  to  explore  the  effects  of LPS  on  relaxant  responses,  tissues  were  pre­
contracted  with  an  approximate  ECgo  of U46619  that  was  titred  to  account  for 
changes in potency occurring between WT and NPR-A KO animals.
3.3.2. Responses to acetylcholine
Treatment  of WT  animals  with  LPS  caused  a  significant  rightward  shift  in  the 
concentration-response  curve  to  the  endothelium-dependent  relaxant  ACh  (pEC5o: 
6.69 ± 0.21  and  7.00 ± 0.08;  LPS  and saline respectively;  Figure  19A  and Figure 
23A) and a significant decrease in Em ax (EmaX :  25.46 ±2.11  and 66.36 ± 2.22;  LPS 
and saline  respectively;  Figure 23A).  Vessels  from LPS treated NPR-A  KO  mice 
also showed a trend towards reduced responsiveness to ACh (pECso: 6.70 ± 0.24 and 
7.30  ±  0.28;  LPS  and  saline  respectively;  Figure  19B  and  Figure  23B)  but  the 
concentration-response  curves  were  not  significantly different.  Furthermore,  Em ax 
was indistinguishable in LPS and saline treated NPR-A KO mice (Emax: 77.31 ± 6.92 
and 79.58 ± 6.93; LPS and saline respectively; Figure 23B).
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3.3.3. Responses to ANP
Aortae from WT mice treated with LPS exhibited a significant rightward shift in the 
concentration-response curve to ANP (pECso: 7.89 ± 0.20 and 8.13 ± 0.13; LPS and 
saline  respectively;  Figure  20A  and  Figure  23A)  accompanied  by  a  significant 
decrease in Em ax (Em ax: 53.61  ± 4.13 and 76.16 ± 3.58; LPS and saline respectively; 
Figure  23B).  Aortae  from  NPR-A  KO  animals  showed  no  vasorelaxation  in 
response to ANP (Figure 20B).
3.3.4. Responses to spermine NONOate
Treatment  of  WT  mice  with  LPS  caused  a  significant  rightward  shift  in  the 
concentration response curve to the NO donor  SPER-NO  (pECso:  5.08 ± 0.16 and 
5.86 ± 0.07; LPS and saline respectively;  Figure 21A and Figure 23A).  However, 
Em ax  was  unchanged  (Em ax:  101.4  ±  12.13  and  94.40  ±  3.01;  LPS  and  saline 
respectively;  Figure 23A).  This shift was not observed in LPS treated NPR-A KO 
animals  as  the  curves  were  superimposable  (pECso:  5.25  ±  0 . 1 2   and  5.42  ±  0.18; 
Em a*:  95.73 ± 7.09 and 91.64 ±  8.83;  LPS and saline respectively; Figure 21B and 
Figure 23B).  SPER-NO was used as a NO donor in this set of experiments as it has 
been  reported  to  have  reproducible  rates  of dissociation,  producing  NO  in  a  first 
order kinetic  process  at  constant  pH.  It  spontaneously generates  NO  without  the 
need for a redox activation step and has a half-life of 39 min which ensures constant 
release of NO for the duration of the experiment (Morley and Keefer, 1993; Fitzhugh 
et al., 2 0 0 0 ).
97CHAPTER 3 -  RESULTS 1
EFFECT OF LPS IN  VIVO ON RESPONSES TO U46619 
IN WILD TYPE AND NPR-A KNOCKOUT MICE
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Figure 18 -  Concentration-response curves to U46619 in aortic rings from WT (A) and NPR-A KO
(B) mice treated  with  LPS  (12.5  mg/kg) or saline  (both  i.v.) for  16 h.  Contraction  is expressed as
mean ± SEM tension in g; *, p<0.05 versus saline treated animals, n = 7.
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EFFECT OF LPS IN  VIVO ON RESPONSES TO ACETYLCHOLINE 
IN WILD TYPE AND NPR-A KNOCKOUT MICE
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Figure 19 -  Concentration-response curves to ACh in aortic rings from WT (A) and NPR-A KO (B)
mice treated with LPS (12.5 mg/kg) or saline (both i.v.) for 16 h.  Relaxation is expressed as mean ±
SEM percentage reversal of U46619-induced tone; *, p<0.05 versus saline treated animals, n = 5.
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EFFECT OF LPS IN  VIVO ON RESPONSES TO ANP 
IN WILD TYPE AND NPR-A KNOCKOUT MICE
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Figure 20 -  Concentration-response curves to ANP in aortic rings from WT (A) and NPR-A KO (B)
mice treated with LPS (12.5 mg/kg) or saline (both i.v.) for  16 h.  Relaxation is expressed as mean ±
SEM percentage reversal of U46619-induced tone; *, p<0.05 versus saline treated animals, n= 9.
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EFFECT OF LPS IN  VIVO ON RESPONSES TO SPERMINE NONOATE 
IN WILD TYPE AND NPR-A KNOCKOUT MICE
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Figure 21 -  Concentration-response curves to SPER-NO in aortic rings from WT (A) and NPR-A KO
(B) mice treated with LPS (12.5 mg/kg) or saline (both i.v.) for 16 h.  Relaxation is expressed as mean
± SEM percentage reversal of U46619-induced tone; *, p<0.05 versus saline treated animals, n = 3.
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EFFECT OF LPS IN  VIVO ON Em ax AND POTENCY (EC50) TO 
U46619 IN WILD TYPE AND NPR-A KNOCKOUT MICE
(A)
WT WT WT WT FOLD
LPS SALINE LPS SALINE SHIFT IN
pECso 
-log (M|
pECso 
-log IM|
Emax 
(% contraction)
Emax 
(% contraction)
EC  5 0  
(POTENCY)
U46619 7.69 ±0.12 7.94 ± 0.05 458.7 ± 20.39 520.2 ±9.73 1.79
(B)
NPR-A KO NPR-A KO NPR-A KO NPR-A KO FOLD
LPS SALINE LPS SALINE SHIFT IN
pEC5 0 PECjo E ^max E *-'m ax e c 50
-log |M| -log fMl (% contraction) (% contraction) (POTENCY)
U46619  6.41 ±0.16 7.12 ± 0.18 529.7 ± 60.64 363.8 ±28.56 5.09
Figure  22  -   Em ax  and  pEC50 values  determined  from  concentration-response  curves to  U46619  in 
aortic rings from WT (A) and NPR-A KO mice (B) treated with LPS (12.5 mg/kg) or saline (both i.v.) 
for  16 h.  Em ax is expressed as mean ± SEM percentage of basal tone and pEC50 is expressed as -log 
[M], mean ± SEM, n = 7.
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EFFECT OF LPS IN  VIVO ON Em ax AND POTENCY (ECS 0) TO 
ACETYLCHOLINE, ANP AND SPERMINE NONOATE IN 
WILD TYPE AND NPR-A KNOCKOUT MICE
(A)
WT 
LPS 
pECso 
-log [M|
WT 
SALINE 
PEC5 0  
-log [M]
WT
LPS
Ejnax
(%
relaxation)
WT
SALINE
E
(%
relaxation)
FOLD SHIFT
IN ECS„ 
(POTENCY)
ACh 6.69 ±0.21 7.00 ±0.08 25.46 ±2.11 66.36 ± 2.22 2.07
ANP 7.89 ± 0.20 8.13 ± 0.13 53.61 ±4.13 76.16 ±3.58 1.77
SPER-NO 5.08 ±0.16 5.86 ±0.07 101.4 ± 12.13 94.40 ± 3.01 6.05
(B)
NPR-A KO 
LPS 
pECso 
-log [M]
NPR-A KO 
SALINE 
pEC so 
-log [M|
NPR-A KO 
LPS
Emax
(%
relaxation)
NPR-A KO 
SALINE 
Emax 
(% 
relaxation)
FOLD SHIFT
IN ECS 0  
(POTENCY)
ACh 6.70 ± 0.24 7.30 ±0.28 77.31 ±6.92 79.58 ± 6.93 4.04
ANP N/A N/A N/A N/A N/A
SPER-NO 5.25 ±0.12 5.42 ±0.18 95.73 ± 7.09 91.64 ± 8.83 1.46
Figure 23 -  Em ax and pEC5 0 values determined from concentration-response curves to ACh, ANP and 
SPER-NO  in aortic rings from WT (A) and NPR-A KO  mice (B) treated with LPS (12.5  mg/kg) or 
saline (both i.v.) for 16 h.  Em ax is expressed as mean ± SEM percentage reversal of U46619-induced 
tone and pEC5 0 is expressed as -log [M], mean ± SEM; n = 5 ACh, n = 9 ANP, n = 3 SPER-NO.
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3.4.  Summary of key results
Deletion  of NPR-A  in  vivo  results  in  NPR-A  KO  animals  presenting  with  less 
vascular  dysfunction  following  LPS  treatment  when  compared  to  WT  control 
animals.  Responses  to  U46619,  ACh,  ANP  and  SPER-NO  were  suppressed  to  a 
greater extent  in WT  compared to  NPR-A  KO  mice  and this  was  paralleled by a 
decrease in iNOS expression and activity in  lung and aortic tissue,  suggesting that 
ANP or BNP (both signal through NPR-A) can act in a pro-inflammatory fashion.
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Regulation of pro-inflammatory protein expression (iNOS) 
by natriuretic peptides (ANP and CNP) in vitro
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4. Results 2
4.1.  Introduction
The findings presented in chapter 3 contrast with studies that suggest ANP acts in an 
anti-inflammatory fashion.  Vollmar and Kiemer have shown that ANP inhibits NO 
production  in  macrophages  by  inhibiting  iNOS  expression  via  the  pGC-coupled 
NPR-A with  the  involvement of cGMP  (Vollmar and  Schulz,  1995b;  Kiemer and 
Vollmar,  1998;  Kiemer  and  Vollmar,  2001).  CNP  however has  been  reported to 
have  no effect on NO production and iNOS expression in macrophages (Kiemer and 
Vollmar,  1997).  Yet, the role of natriuretic peptides in regulating iNOS expression 
remains unclear since ANP, BNP and CNP all upregulate iNOS induction by raising 
intracellular cGMP levels in vascular smooth muscle cells (Marumo et al, 1995).
Thus,  studies  described  in  this  chapter  investigate  the  hypothesis  that  natriuretic 
peptides (ANP and CNP) affect pro-inflammatory protein expression in vitro.  This 
was achieved by assessing the effects of ANP and CNP on pro-inflammatory protein 
expression and activity (iNOS) in vitro, in murine macrophages and vascular smooth 
muscle cells, in the presence of LPS and pro-inflammatory cytokines.
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4.2.  Optimisation of LPS-induced activation of RAW264.7 
macrophages
In order to determine an effective, submaximal concentration of LPS with which to 
study the effect of natriuretic peptides on iNOS expression in vitro, RAW264.7 cells 
were  activated  with  Salmonella  typhimurium  LPS  (0  -   1000  ng/ml)  and  iNOS 
protein  expression  and  activity  determined.  LPS  produced  a  concentration 
dependent increase in iNOS  expression at 24 and 48 h post activation.  Maximum 
iNOS expression was seen at 24 h post activation using 1000 ng/ml LPS (Figure 24) 
and  a  suboptimal  concentration  of  100  ng/ml  was  selected  for  use  in  future 
experimentation.
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LPS-INDUCED iNOS EXPRESSION AND ACTIVITY 
IN RAW264.7 MACROPHAGES
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Figure  24 -  Expression of iNOS protein in RAW264.7 macrophages activated with  LPS (0 -   1000 
ng/ml)  for  24  or  48  h.  Protein  expression  was  analysed  by  Western  blot  (A)  and  quantified  by 
densitometry (B).  Nitrite accumulation in the culture medium was determined by chemiluminescence 
(C).  Data are represented as mean ± SEM, n = 6.
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4.3.  Effect of ANP or CNP on LPS-induced iNOS in 
RAW264.7 macrophages
To  determine  the  effect  of  ANP  and  CNP  on  LPS-induced  iNOS  expression, 
RAW264.7 cells were activated with  100 ng/ml LPS in the presence or absence of 
ANP (10 nM -   10 pM) or CNP (1  nM -   1   jiM), and iNOS expression and activity 
were  assessed  9  and  24  h  post  activation.  iNOS  expression  was  absent  in 
unstimulated cells  or in the presence of ANP or CNP only (data not  shown).  No 
significant alteration in iNOS activity or expression in the presence of ANP or CNP 
was observed.
Since  ANP  has  been  previously  reported  to  inhibit  pro-inflammatory  protein 
expression in rodent macrophages (Kiemer and Vollmar, 1997; Kiemer and Vollmar, 
1998),  a number of additional  experiments were carried out as  follows, with ANP 
being added:
a.  30 min prior to activation
b.  30 min prior to activation and re-added concomitantly with LPS
c.  concomitantly with LPS
No significant difference could be seen in iNOS activity and expression at 24 h post 
activation  for  any  of  the  treatments  (Figure  27)  and  therefore  for  future 
experimentation ANP was added 5 min before LPS activation.
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EFFECT OF ANP ON LPS-INDUCED iNOS EXPRESSION 
AND ACTIVITY IN RAW264.7 MACROPHAGES
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Figure 25 -  Expression of iNOS protein in RAW264.7 macrophages activated with LPS (100 ng/ml) 
for 9 or 24 h in the presence of increasing concentrations of ANP.  Protein expression was analysed 
by  Western  blot  (A)  and  nitrite  accumulation  in  the  culture  medium  was  determined  by 
chemiluminescence (B).  Data are normalised to LPS (control) and represented as mean ± SEM, n = 3.
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EFFECT OF CNP ON LPS-INDUCED iNOS EXPRESSION 
AND ACTIVITY IN RAW264.7 MACROPHAGES
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Figure 26 -  Expression of iNOS protein in RAW264.7 macrophages activated with LPS (100 ng/ml) 
for 9 or 24 h in the presence of increasing concentrations of CNP.  Protein expression was analysed 
by  Western  blot  (A)  and  nitrite  accumulation  in  the  culture  medium  was  determined  by 
chemiluminescence (B).  Data are normalised to LPS (control) and represented as mean ± SEM, n = 6 .
I llCHAPTER 4 -  RESULTS 2______________________________________________________________
EFFECT OF TIME OF ADMINISTRATION OF ANP ON LPS-INDUCED 
iNOS EXPRESSION AND ACTIVITY IN RAW264.7 MACROPHAGES
LPS 0  _ _ + +   +  +  _ _ +   +  +  +
ANP -30 mins  _ _ _   +  +  _  _ _ _   +  +  _
ANP 0  _  +  _ _   +  +  _ + _ _   +   +
Intervention
Figure 27 -  Expression of iNOS protein in RAW264.7 macrophages activated with LPS (100 ng/ml) 
for 24 h in the presence of 1  or 10 pM ANP.  ANP was added 30 min before activation, 30 min before 
activation  and  re-added  at  the  same  time  as  activation  or  concomitantly  at  the  time  of activation. 
Protein expression was analysed by Western blot (A) and nitrite accumulation in the culture medium 
was determined by chemiluminescence (B).  Data are normalised to LPS (control) and represented as 
mean ± SEM, n = 3.
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4.4.  Characterisation of primary rat aortic smooth muscle 
cells
4.4.1.  Morphology
Since vascular smooth muscle cells also express iNOS during septic shock (Beasley 
et  a l,  1991;  Kusano  et  a l,  1999),  I  chose  to  examine  the  effect  of natriuretic 
peptides  on  LPS-induced  iNOS  expression and  activity in  1°  RAoSMC  that were 
isolated by means of differential plating.
Immunocytochemistry was used to confirm that a homogeneous smooth muscle cell 
population  had  been  obtained  by  differential  plating.  Cells  were  stained  for  the 
smooth muscle specific marker a-actin -  (FITC, Green) and with a nuclear stain -  
(DAPI, Blue).  Figure 29 shows the presence of smooth muscle cells, having both 
green  and  blue  staining,  but  the  population  is  contaminated  with  other  cell  types 
(nuclei stained but negative for a-actin), probably fibroblasts.  Following secondary 
differential plating, a homogeneous population of smooth muscle cells was obtained 
(Figure 30).  a-actin staining was not observed under control conditions in which the 
a-actin antibody was omitted (Figure 28).
The  homogeneous  smooth  muscle  cell  cultures  exhibited  typical  hill  and  valley 
morphology  when  grown  to  over-confluency  (Figure  31).  This  configuration  is 
characterised by intertwined and overlapping cells with numerous multilayered and 
focal overgrowth areas (Chamley-Campbell et al, 1979).
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PRIMARY RAT AORTIC SMOOTH MUSCLE CELLS 
WITH NUCLEAR STAINING
Figure  28 -  Primary rat aortic  smooth muscle cells  stained  with  DAPI.  The a-actin antibody was 
omitted for control purposes.  Image generated using confocal microscopy; representative of several 
images.CHAPTER 4 -  RESULTS 2____________________________________________________
NON-HOMOGENEOUS POPULATION OF 
PRIMARY RAT AORTIC SMOOTH MUSCLE CELLS
Figure 29 -  Primary rat aortic smooth muscle cells stained with both DAPI (blue) and smooth muscle 
specific  a-actin (green).  Cells showing both green and blue  staining are smooth muscle cells; cells 
showing only blue  staining are other cell  types, probably  fibroblasts,  contaminating the  population 
(indicated  by a  red  arrow).  Image  generated  using confocal  microscopy;  representative of several 
images.
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HOMOGENEOUS POPULATION OF 
PRIMARY RAT AORTIC SMOOTH MUSCLE CELLS
Figure 30 -  Primary rat aortic smooth muscle cells stained with both DAPI (blue) and smooth muscle 
specific a-actin (green).  Image depicts a homogeneous smooth muscle cell population with each cell 
positive  for  both  nuclear  and  a-actin  staining.  Image  generated  using  confocal  microscopy; 
representative of several images.
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PRIMARY RAT AORTIC SMOOTH MUSCLE CELLS 
EXHIBITING TYPICAL HILL AND VALLEY MORPHOLOGY
Figure 31  -  Homogeneous primary rat aortic smooth muscle cell culture exhibiting typical hill  and 
valley morphology; representative of several images.CHAPTER 4 -  RESULTS 2
4.4.2.  Optimisation of primary rat aortic smooth muscle cell 
activation
Primary vascular smooth muscle cells do not express significant amounts of iNOS in 
response  to  LPS  alone,  but  rather  require  a  ‘cocktail’  of  LPS  and  cytokines 
(MacNaul  and Hutchinson,  1993;  Matsumura et al.,  2001).  Therefore,  in order to 
determine an effective, submaximal concentration of LPS and cytokines with which 
to  study the  effect  of natriuretic  peptides  on  iNOS  expression,  1° RAoSMC  were 
activated with  100  pg/ml  LPS  (.Escherichia coli  or Salmonella  typhimurium),  100 
U/ml IFN-y, 400 U/ml IL-ip and 1000 U/ml TNF-a in varying combinations (Figure
32).  Inducible NOS expression and activity were determined by Western blot and 
chemiluminescence  (nitrite)  respectively.  Inducible  NOS  expression  and  activity 
were  most  prominent  in  the  presence  of LPS  and  all  three  cytokines.  Although 
cytokines alone, and cytokines plus Escherichia Coli LPS gave cell activation, this 
was not as strong as when Salmonella typhimurium LPS was added in the presence 
of IFN-y, IL-ip and TNF-a (Figure 32).  This combination of activators was used in 
additional studies to further optimise the activator cocktail to be used.
Three concentrations for each mediator/activator were selected and these were used 
to activate cells in different combinations (Figure 33).  Nitrite in the culture medium 
was  determined  24  h  post  activation  as  an  index  of  iNOS  activity.  Maximal 
activation was seen with  100 pg/ml LPS, 200 U/ml IFN-y, 400 U/ml IL-ip and 2000 
U/ml  TNF-a (Figure  33).  This  gave an approximately 50  % increase in nitrite in 
comparison to the  initial combination of 100  pg/ml Salmonella  typhimurium LPS, 
100 U/ml IFN-y, 400 U/ml IL-lp and  1000 U/ml TNF-a.  For subsequent studies a 
suboptimal  activator  regime  was  used  comprising  of  100  pg/ml  Salmonella 
typhimurium LPS, 200 U/ml IFN-y, 400 U/ml IL-lp and  1000 U/ml TNF-a (Figure
33).  This will be referred to as 'activator cocktail'.
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ACTIVATION OF PRIMARY RAT AORTIC SMOOTH MUSCLE CELLS 
WITH DIFFERENT LPS/CYTOKINE COCKTAILS
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(B)
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Figure 32 -  Expression of iNOS protein in  1° RAoSMC treated with no activators (1), activated with 
100 pg/ml Salmonella typhimurium LPS (2), 100 jig/ml Salmonella typhimurium LPS, 100 U/ml IFN- 
y, 400 U/ml IL-lp and  1000 U/ml TNF-a (3),  1000 U/ml TNF-a and 400 U/ml IL-ip (4),  1000 U/ml 
TNF-a, 400  U/ml  IL-lp and  100  U/ml  IFN-y (5),  1000  U/ml  TNF-a and  100  U/ml  IFN-y (6),  100 
pg/ml Escherichia Coli LPS (7),  100 pg/ml Escherichia Coli  LPS,  100 U/ml IFN-y, 400 U/ml IL-lp 
and  1000 U/ml TNF-a (8 ) for 24 h. Protein expression was analysed by Western blot (A) and nitrite 
accumulation in the culture medium was determined by chemiluminescence (B).  Data are represented 
as the mean ± SEM, n = 4.
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Figure 33 -  Nitrite accumulation in the culture medium determined by chemiluminescence following 
activation of 1° RAoSMC with different combinations of Salmonella typhimurium LPS, IFN-y, IL-ip 
and  TNF-a at  increasing concentrations.  Suboptimal  activator  regime,  'activator cocktail',  used  in 
subsequent studies is indicated in red.  Graph is representative of 2 separate experiments.
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4.4.3.  Timecourse of iNOS expression in primary rat aortic 
smooth muscle cells in response to activator cocktail
In order to determine the temporal  expression of iNOS in response to the activator 
cocktail,  1° RAoSMC were stimulated with the activator cocktail and samples taken 
at different timepoints (0 -  96 h post activation) to determine iNOS expression and 
activity.  Inducible NOS protein expression was first detectable at 6 h peaking at 48 
h after which expression declined but was still present at 96 h.  The production of 
nitrite  started  slightly  later  than  protein  expression;  nitrite  was  detectable  in  the 
medium at 9 h, continued to increase up to 48 h and subsequently decreased (Figure
34).  24 and 48 h timepoints were selected for use in future experimentation.  Neither 
iNOS expression nor nitrite were detectable in the absence of the activator cocktail 
(data not shown).
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TIMECOURSE OF iNOS EXPRESSION AND ACTIVITY IN 
PRIMARY RAT AORTIC SMOOTH MUSCLE CELLS IN RESPONSE TO 
ACTIVATOR COCKTAIL
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Figure  34  -   Expression  of  iNOS  protein  in  1°  RAoSMC  activated  with  100  pg/ml  Salmonella 
typhimurium LPS, 200 U/ml IFN-y, 400 U/ml 1L-1|3 and  1000 U/ml TNF-a.  Protein expression was 
analysed  by  Western  blot  (A)  and  accumulation  of nitrite  in  the  culture  medium  determined  by 
chemiluminescence (B).  Data are represented as mean ± SEM, n = 4.
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4.5.  Effect of ANP and CNP on activator cocktail-induced 
iNOS expression in prim ary rat aortic sm ooth m uscle 
cells
To  determine  the  effect  of ANP  and  CNP  on  iNOS  expression  in  response  to 
activator cocktail,  1° RAoSMC were treated with increasing concentrations of ANP 
or CNP  (10  nM -   10  pM),  5  min  prior to  activation.  There  were  no  significant 
changes in iNOS expression and activity in the presence of ANP (Figure 35) or CNP 
(Figure  36) at all  concentrations  examined.  The  addition of ANP  or  CNP  in  the 
absence of activators did not alter iNOS expression and only background nitrite was 
detectable (data not shown).
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EFFECT OF ANP ON ACTIVATOR COCKTAIL-INDUCED 
iNOS EXPRESSION AND ACTIVITY IN PRIMARY RAT 
AORTIC SMOOTH MUSCLE CELLS
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Figure 35 -  Expression of iNOS protein in 10 RAoSMC activated with activator cocktail for 24 or 48 
h in the presence of increasing concentrations of ANP.  Protein expression was analysed by Western 
blot (A) and nitrite accumulation in the culture medium was determined by chemiluminescence (B). 
Data are normalised to activators only (control) and represented as mean ± SEM, n = 4.
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EFFECT OF CNP ON ACTIVATOR COCKTAIL-INDUCED 
iNOS EXPRESSION AND ACTIVITY IN PRIMARY RAT 
AORTIC SMOOTH MUSCLE CELLS
(A)
(B)
120
110
100
90
f   80
70
2   8   60 
S 'S   50 
£   40
30 
20 
10 
0
I
I
124 h post activation 
148 h post activation
Intervention
Figure 36 -  Expression of iNOS protein in 1° RAoSMC activated with activator cocktail for 24 or 48 
h in the presence of increasing concentrations of CNP.  Protein expression was analysed by Western 
blot (A) and nitrite accumulation in the culture medium was determined by chemiluminescence (B). 
Data are normalised to activators only (control) and represented as mean ± SEM, n = 4.
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4.6.  Summary of key results
Primary rat aortic smooth muscle cells were successfully isolated and characterised. 
They were shown to be positive for smooth muscle specific a-actin and exhibited a 
typical  hill  and  valley  morphology.  A  submaximal  activator  cocktail  for  the 
induction  of iNOS  in  1°  RAoSMC  was  identified.  However,  no  effect  on  iNOS 
expression  or  activity  was  seen  in  the  presence  of  ANP  or  CNP  in  either  1° 
RAoSMC or RAW264.7 macrophages.
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Role of natriuretic peptides and their receptors in 
regulating MAPK signalling and cell proliferation
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5. Results 3
5.1.  Introduction
Previous results presented herein indicate that there is a lack of effect of ANP and 
CNP on iNOS expression in vitro in both macrophages and RAoSMC, which does 
not fit with preceding studies reporting ANP-mediated inhibition of iNOS expression 
(Kiemer  and  Vollmar,  1997;  Kiemer  and  Vollmar,  1998).  Moreover,  my 
pharmacological  data  in  NPR-A  KO  animals  shown  in  chapter  3  suggest  that 
ANP/BNP act in a pro-inflammatory fashion in vivo, and although there was a slight 
trend for ANP/CNP to increase iNOS expression in macrophages in vitro, there was 
essentially no effect.
In order to try and reconcile these differences and provide more definitive evidence 
supporting a pro- or anti-inflammatory role for natriuretic peptides, I investigated the 
relationship  between ANP  and  CNP,  MAPK  and  iNOS  expression/activity.  ANP 
and  CNP  have  been  shown  to  alter  MAPK  activity  (Kiemer  and  Vollmar,  1997; 
Kiemer and Vollmar,  1998; Pandey et al., 2000; Sharma et al., 2002; Yasoda et al., 
2004), and this pathway is known to regulate iNOS expression (Da Silva et al., 1997; 
Doi  et  al.,  2000;  Chakravortty  et  al.,  2001;  Bhat  et  al.,  2002)  as  well  as  cell 
proliferation (Pearson et al., 2001).  Furthermore, all natriuretic peptides have been 
shown  to  possess  anti-proliferative  properties,  which  appear  to  be  important  in 
cardiomyocytes  and  vascular  smooth  muscle  (Furuya  et  al.,  1991;  Furuya  et  al., 
1993; Silberbach and Roberts, 2001).
In this chapter I  explored the hypothesis that natriuretic peptides  (ANP  and CNP) 
modulate  MAPK  pathways  and  regulate  cell  proliferation  via  activation  of GC- 
linked  NPRs.  Initially,  I  investigated  which  ‘arms’  of the  MAPK  pathway  are 
involved in iNOS  expression and subsequently established the effects of ANP and 
CNP  on  MAPK  (ERK  1/2  and p38) phosphorylation.  Furthermore,  I investigated 
which  natriuretic  peptide  receptor  is  involved  in  the  regulation  of  MAPK 
phosphorylation.  Finally,  I  explored  whether  MAPK  regulation  by  natriuretic 
peptides might influence cell proliferation.
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5.2.  Effect of MAPK phosphorylation inhibitors on 
activator cocktail-induced iNOS expression and 
activity in primary rat aortic smooth muscle cells
In  an  attempt  to  investigate  which  ‘arms’  of the  MAPK pathway are  involved  in 
activator cocktail-induced iNOS expression,  1° RAoSMC were treated with the ERK 
1/2 inhibitor PD98059 (30 pM), or the p38 inhibitor SB203580 (30 pM), for 30 min 
prior to the addition of activator cocktail (100 pg/ml Salmonella typhimurium LPS, 
200 U/ml IFN-y, 400 U/ml IL-ip and  1000 U/ml TNF-a).  Nitrite accumulation in 
the  culture  medium  and protein  expression  were  determined  24  h post  activation. 
PD98059  did  not  modulate  iNOS  but  SB203580  brought  about  a  significant 
inhibition  of iNOS  expression  and  activity  (Figure  37).  Therefore,  the  various 
components  of the  MAPK  phosphorylation  pathway  were  investigated  further  to 
determine if natriuretic peptides were able to modulate their activity.
129CHAPTER 5 -  RESULTS 3
EFFECT OF MAPK PHOSPHORYLATION INHIBITORS ON ACTIVATOR 
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Figure 37 -  Expression of iNOS protein in 1° RAoSMC activated with activator cocktail for 24 h in 
the presence of ERK  1/2 pathway inhibitor, PD98059 or p38 pathway inhibitor, SB203580 (both 30 
pM).  Protein expression was analysed by Western blot (A)  and nitrite accumulation  in the culture 
medium was determined by chemiluminescence (B).  Data are represented as mean ± SEM, n = 4; *, 
p<0.05 versus activators only.
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5.3.  Activation of MAPK pathway phosphorylation in 
primary rat aortic smooth muscle cells
To investigate further the potential effects of natriuretic peptides, primarily CNP, on 
MAPK  regulation,  I  first  examined  which  arms  of  the  MAPK  system  were 
phosphorylated  in  response  to  the  activator  cocktail.  Primary  rat  aortic  smooth 
muscle cells were treated with activator cocktail (100 pg/ml Salmonella typhimurium 
LPS, 200 U/ml IFN-y, 400 U/ml IL-1|3 and 1000 U/ml TNF-a).  Samples were taken 
at  0,  5,  10,  15,  30  and  60  min  and  ERK  1/2  and  p38  phosphorylation  were 
determined  by  Western  blot.  ERK  1/2  (Figure  38)  and  p38  (Figure  39) 
phosphorylation  increased  in  a  time-dependent  fashion  up  to  15  min  and  then 
returned to baseline by 60 min.  Total ERK 1/2 and p38 expression did not change.
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Figure 38 -   Expression  and phosphorylation of ERK  1/2 (p44/p42) protein  in  1° RAoSMC  treated 
with  activator  cocktail  for  0-60  min.  Protein  expression  and  phosphorylation  determined  by 
Western  blot  (A)  and  quantified  by  densitometry  normalised  to  control  (0  min)  (B).  Data  are 
represented as mean ± SEM, n = 4; *, p<0.05 versus control.
132CHAPTER 5 -  RESULTS 3
EFFECT OF ACTIVATOR COCKTAIL ON p38 PHOSPHORYLATION IN 
PRIMARY RAT AORTIC SMOOTH MUSCLE CELLS
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Figure  39 -   Expression  and  phosphorylation of p38  protein  in  1° RAoSMC  treated  with  activator 
cocktail for 0-60 min.  Protein expression and phosphorylation determined by Western blot (A) and 
quantified by densitometry normalised to control (0 min) (B).  Data are represented as mean ± SEM, n 
= 3; *, p<0.05 versus control.
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5.4.  Effect of CNP on MAPK phosphorylation (ERK 1/2 and 
p38) in primary rat aortic smooth muscle cells
To determine the effect of CNP on ERK  1/2 and p38 phosphorylation,  1° RAoSMC 
were treated with  1  pM CNP  for 5  min prior to the addition of activator cocktail. 
Samples  were  taken  at  0,  5,  10,  15,  30  and  60  min  and  ERK  1/2  and  p38 
phosphorylation were determined by Western blot.  CNP did not modulate ERK 1/2 
(Figure 40) or p38 (Figure 41) phosphorylation.
It was postulated that the activator cocktail could be masking the effect of CNP on 
MAPK phosphorylation.  Therefore, 1° RAoSMC were treated with 1   pM CNP alone 
and samples were taken at 0, 5,  10,  15, 30, 60, 90 and  120 min (ERK 1/2) and 0, 5, 
10,  15,  30  and  60  min  (p38).  ERK  1/2  (Figure  42)  and  p38  (Figure  43) 
phosphorylation were significantly increased in the presence of CNP.  In addition, 1° 
RAoSMC were treated with increasing concentrations of CNP (1 nM -  10 pM) for 5 
min and ERK  1/2 phosphorylation was determined by Western blot to explore the 
concentration-dependency of this effect.  CNP increased ERK 1/2 phosphorylation in 
a  concentration-dependent  fashion  up  to  10  pM  (Figure  44)  and  a  suboptimal 
concentration  of  1   pM  was  used  in  future  experimentation.  Although  this  is  a 
comparatively  high  concentration  in  relation  to  other  vasoactive  peptides,  it  is 
commensurate  with  concentrations  of  CNP  released  acutely  from  vascular 
endothelial  cells  by  endothelium-dependent  dilators  (i.e.  ACh;  Chauhan  et  al., 
2003a; Chauhan et al., 2003b; Hobbs et al., 2004).
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Figure  40 -  Expression  and phosphorylation of ERK  1/2 (p44/p42) protein  in  1° RAoSMC treated 
with activator cocktail in the presence or absence of CNP (1  pM) for 0-60 min.  Protein expression 
and  phosphorylation determined by Western blot (A)  and  quantified by densitometry normalised to 
control (0 min with activator cocktail only) (B).  Data are represented as mean ± SEM, n = 4.
135CHAPTER 5 -  RESULTS 3
EFFECT OF CNP ON p38 PHOSPHORYLATION 
IN THE PRESENCE OF ACTIVATOR COCKTAIL 
IN PRIMARY RAT AORTIC SMOOTH MUSCLE CELLS
(A)
Activator cocktail
Activator cocktail 
+ CNP
Activator cocktail
Activator cocktail 
+ CNP
10  15  30  60  min
P38 38 kDa
p38 38 kDa 
Phospho-p38 38 kDa 
Phospho-p38 38 kDa
(B)
c
o
If
o   c  
-C  o
o   o
00   w ' 
CO 
Q.
1100
1000
900
800
700
600
500
400
300
200
100
0
10  15
Time (min)
30 60
Figure  41  -   Expression  and  phosphorylation of p38  protein  in  1° RAoSMC  treated  with  activator 
cocktail  in  the  presence  or  absence  of  CNP  (1  pM)  for  0-60  min.  Protein  expression  and 
phosphorylation  determined  by  Western  blot  (A)  and  quantified  by  densitometry  normalised  to 
control (0 min with activator cocktail only) (B).  Data are represented as mean ± SEM, n = 3.
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Figure  42 -  Expression  and phosphorylation of ERK  1/2 (p44/p42) protein in  1°  RAoSMC treated 
with CNP (1  pM) for 0-120 min.  Protein expression and phosphorylation determined by Western 
blot (A)  and quantified by densitometry normalised to control (0 min) (B).  Data are represented as 
the mean ± SEM, n =8 ; *, p<0.05 versus control.
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EFFECT OF CNP ON p38 PHOSPHORYLATION 
IN PRIMARY RAT AORTIC SMOOTH MUSCLE CELLS
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Figure 43 -  Expression and phosphorylation of p38 protein in  1° RAoSMC treated with CNP (1  pM) 
for  0-60  min.  Protein  expression  and  phosphorylation  determined  by  Western  blot  (A)  and 
quantified  by densitometry normalised to  control (0 min)  (B).  Data are represented  as the  mean ± 
SEM, n =4; *, p<0.05 versus control.
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Figure  44 -   Expression  and  phosphorylation of ERK  1/2 (p44/p42) protein  in  1° RAoSMC  in  the 
presence  of increasing concentrations of CNP (1  nM -   10  pM)  for 5  min.  Protein expression and 
phosphorylation  determined  by  Western  blot  (A)  and  quantified  by  densitometry  normalised  to 
control (without CNP) (B).  Data are represented as the mean ± SEM, n = 8; *, p<0.05 versus control.
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5.5.  Effect of PD98059 on CNP-induced ERK 1/2
phosphorylation in primary rat aortic smooth muscle 
cells
To  confirm  that  activation  of ERK  1/2  signalling  is  due  to  the  actions  of CNP, 
PD98059, a selective MAPK/ERK kinase  (MEK),  ERK  1/2 pathway inhibitor was 
utilised.  PD98059 has been well characterised to inhibit MEK upstream of ERK 1/2 
and  is  therefore  used  as  an  archetypal  inhibitor  of  ERK  1/2  phosphorylation 
(Pumiglia  and  Decker,  1997).  Primary  rat  aortic  smooth  muscle  cells  were  pre­
incubated  with  30  pM  PD98059  for  30  min  before  the  addition  of  1   pM  CNP. 
Samples were taken 5  min after CNP treatment and ERK  1/2 phosphorylation was 
determined  by  Western  blot.  CNP-induced  ERK  1/2  phosphorylation  was 
significantly reversed by PD98059 while total ERK remained unchanged (Figure 45).
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Figure  45 -   Expression and  phosphorylation  of ERK  1/2  (p44/p42) protein  in  1° RAoSMC  in the 
presence of PD98059 (30 pM; 30 min prior to CNP) and CNP (1  pM) for 5 min.  Protein expression 
and  phosphorylation determined by Western blot (A) and  quantified  by densitometry normalised to 
control (PD98059 only) (B).  Data are represented as the mean ± SEM, n = 6; *, p<0.05 versus control.
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5.6.  NPR-A, NPR-B and NPR-C mRNA is present in 
primary rat aortic smooth muscle cells
In an attempt to determine which receptor is responsible for CNP signalling in the 
regulation of the MAPK pathway, RT-PCR was carried out on 1° RAoSMC.  mRNA 
for all three natriuretic peptide receptors was detected and no amplification occurred 
in the absence of RNA or in the absence of the reverse transcriptase step (Figure 46).
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Figure  46 -  mRNA expression for NPR-A, NPR-B  and NPR-C in  1° RAoSMC determined  by RT- 
PCR.  Products of expected size were obtained for all NPRs (714 bp NPR-A, 720 bp NPR-B and 554 
bp NPR-C).  RNA or the RT steps were omitted for control reactions.
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5.7.  Effect of the NPR-C antagonist, M372049 on CNP- 
induced MAPK phosphorylation (ERK 1/2 and p38) in 
primary rat aortic sm ooth m uscle cells
In an attempt to assign a role to NPR-C in MAPK phosphorylation induced by CNP, 
1° RAoSMC were treated with  1   pM or  10 pM NPR-C antagonist M372049 for 30 
min  before  the  addition of CNP.  Samples  were  taken  10  min after CNP  (1  pM) 
addition and ERK  1/2 and p38 were determined by Western blot.  M372049 alone 
did not alter the background phosphorylation of ERK  1/2 and p38  (Figure 48  and 
Figure  50  respectively).  ERK  1/2  and  p38  phosphorylation  were  significantly 
increased  by  CNP;  however,  only  ERK  1/2  phosphorylation  was  attenuated  by 
M372049 (Figure 47/Figure 48).  The increase in p38 phosphorylation brought about 
by CNP was not altered by M372049 at either concentration (Figure 49/Figure 50). 
Total ERK 1/2 and p38 levels were unaltered in all experimental treatments.
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Figure  47  -   Phosphorylation  of ERK  1/2  (p44/p42)  protein  in  1°  RAoSMC  in  the  presence  of 
M372049 (1  pM or  10 pM) and CNP (1  pM) for  10 min.  Phosphorylation determined by Western 
blot and quantified by densitometry normalised to control (CNP only).  Data are represented as the 
mean ± SEM, n = 5; *, p<0.05 versus control.
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EFFECT OF THE NPR-C ANTAGONIST, M372049 (10 jiM)
ON CNP-INDUCED ERK 1/2 PHOSPHORYLATION IN PRIMARY 
RAT AORTIC SMOOTH MUSCLE CELLS
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Figure  48 -   Expression  and  phosphorylation of ERK  1/2  (p44/p42) protein  in  1°  RAoSMC  in the 
presence of M372049 (10 pM) and CNP (1  pM) for 10 min.  Protein expression and phosphorylation 
determined  by Western blot  (A)  and  quantified  by densitometry  normalised  to  control  (basal)  (B). 
Data are represented as the mean ± SEM, n = 5; *, p<0.05 versus control.
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EFFECT OF THE NPR-C ANTAGONIST, M372049 (1  AND 10 pM) 
ON CNP-INDUCED p38 PHOSPHORYLATION IN PRIMARY 
RAT AORTIC SMOOTH MUSCLE CELLS
Figure 49 -Phosphorylation of p38 protein in 1° RAoSMC in the presence of M372049 (1  pM or 10 
pM) and CNP (1  pM) for  10 min.  Phosphorylation  determined  by Western blot and quantified  by 
densitometry normalised to control (CNP only).  Data are represented as the mean ± SEM, n = 4.
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EFFECT OF THE NPR-C ANTAGONIST, M372049 (10 pM) 
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Figure  50  -   Expression  and  phosphorylation  of p38  protein  in  1°  RAoSMC  in  the  presence  of 
M372049 (10 pM) and CNP (1  pM) for 10 min.  Protein expression and phosphorylation determined 
by  Western  blot  (A)  and  quantified  by  densitometry  normalised  to  control  (basal)  (B).  Data  are 
represented as the mean ± SEM, n = 3; *, p<0.05 versus control.
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5.8.  Effect of Gj-protein inhibitor, Pertussis toxin on CNP- 
induced MAPK phosphorylation (ERK 1/2 and p38) in 
primary rat aortic smooth muscle cells
NPR-C has previously been characterised to  bring about smooth muscle relaxation 
via  Gj-protein  coupled  signalling  (Chauhan  et  al.,  2003b).  Since  the  NPR-C 
antagonist  M372049  attenuated  CNP  induced  ERK  1/2  phosphorylation,  1° 
RAoSMC were treated with  100 ng/ml PTx to confirm a signalling role for NPR-C 
in CNP induced MAPK phosphorylation.
Primary rat aortic  smooth muscle cells were treated with PTx  for  16 h before the 
addition  of CNP.  Samples  were  collected  5,  10  and  15  min  after  CNP  (1  pM) 
addition  and ERK  1/2  and p38  were determined by Western blot.  Pertussis  toxin 
alone did not alter the background phosphorylation of ERK  1/2  or p38  (Figure 51 
and  Figure  52  respectively).  CNP-induced  ERK  1/2  phosphorylation  was 
completely  abolished  by  PTx  (Figure  51).  To  the  contrary,  CNP-induced  p38 
phosphorylation was not altered by PTx (Figure 52).  Total ERK 1/2 and p38 levels 
were unaltered.
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Figure  51  -  Expression  and phosphorylation of ERK  1/2 (p44/p42) protein in  1° RAoSMC  in the 
presence of PTx (100 ng/ml) and CNP (1  pM) for  10 min.  Protein expression and phosphorylation 
determined  by  Western blot  (A)  and  quantified  by densitometry  normalised  to  control  (basal)  (B). 
Data are represented as the mean ± SEM, n = 8; *, p<0.05 versus control.
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EFFECT OF PERTUSSIS TOXIN ON CNP-INDUCED p38 
PHOSPHORYLATION IN PRIMARY RAT 
AORTIC SMOOTH MUSCLE CELLS
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Figure  52  -  Expression and  phosphorylation of p38  protein in  1° RAoSMC  in the presence of PTx 
(100  ng/ml)  and  CNP  (1  pM)  for  10  min.  Protein  expression  and  phosphorylation  determined  by 
Western  blot  (A)  and  quantified  by  densitometry  normalised  to  control  (basal)  (B).  Data  are 
represented as the mean ± SEM, n = 7; *, p<0.05 versus control.
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5.9.  Effect of 8-Bromo-cGMP on MAPK phosphorylation 
(ERK 1/2 and p38) in primary rat aortic smooth muscle 
cells
CNP has been shown to signal through both NPR-B in a cGMP-dependent manner 
(Tremblay et al, 2002) and NPR-C in a cGMP-independent fashion  (Hutchinson et 
al,  1997).  Since  M372049  did  not  entirely  block  CNP-induced  ERK  1/2 
phosphorylation and there are reports that NPR-B could be Gj-coupled (Borges et al, 
2001;  Alfonzo et al., 2006),  1° RAoSMC were treated with  300  pM of the cGMP 
analogue 8-Bromo-cGMP.  Samples were taken at 0, 5,  10,  15, 30 and 60 min after 
treatment and ERK  1/2 and p38  were determined by Western blotting.  8-Bromo- 
cGMP increased ERK 1/2 phosphorylation, albeit to a significantly lesser extent than 
CNP.  However, the time course of this effect was similar to that obtained with CNP 
(Figure 53).  p38 phosphorylation was not altered by 8-Bromo-cGMP  (Figure 54). 
Total ERK 1/2 and p38 remained unchanged.
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Figure  53 —  Expression  and phosphorylation of ERK  1/2 (p44/p42) protein in  1° RAoSMC treated 
with 8-Bromo-cGMP (300 pM) for 0-60 min.  Protein expression and phosphorylation determined 
by  Western  blot  (A)  and  quantified  by  densitometry  normalised  to  control  (0  min)  (B).  Data  are 
represented as the mean ± SEM, n =3; *, p<0.05 versus control.
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EFFECT OF 8-BROMO-cGMP ON p38 PHOSPHORYLATION IN 
PRIMARY RAT AORTIC SMOOTH MUSCLE CELLS
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Figure  54  -  Expression  and  phosphorylation of p38  protein in  1° RAoSMC  treated with 8-Bromo- 
cGMP (300 pM) for 0-60 min.  Protein expression and phosphorylation determined by Western blot 
(A)  and quantified by densitometry normalised to control (0 min) (B).  Data are represented as the 
mean ± SEM, n =3.
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5.10.  Effect of ANP on MAPK phosphorylation (ERK 1/2 
and p38) in primary rat aortic smooth muscle cells
Since I had established that CNP elicited a time-dependent phosphorylation of ERK 
1/2 and p38, and given that ANP also binds NPR-C  (Koller and Goeddel,  1992),  I 
investigated if ANP was able to induce MAPK phosphorylation in a similar fashion. 
Primary rat aortic smooth muscle cells were treated with  1   pM ANP, samples were 
taken  at  0,  5,  10,  15,  30  and  60  min  and  ERK  1/2  and  p38  phosphorylation 
determined by Western blot.  ANP did not alter ERK  1/2 phosphorylation (Figure 
55)  although  p38  phosphorylation  was  increased  by  ANP  at  10  min  (Figure  56). 
Total  ERK  1/2  and  p38  levels  remained  unchanged  (Figure  55  and  Figure  56 
respectively).
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Figure  55 -  Expression  and  phosphorylation of ERK  1/2 (p44/p42) protein in  1° RAoSMC  treated 
with ANP  (1  pM) for 0-60 min.  Protein expression and phosphorylation determined  by Western 
blot (A) and quantified by densitometry normalised to control (0 min) (B).  Data are represented as 
the mean ± SEM, n =3.
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EFFECT OF ANP ON p38 PHOSPHORYLATION IN 
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Figure 56 -  Expression and phosphorylation of p38 protein in  1° RAoSMC treated with ANP (1  pM) 
for  0-60  min.  Protein  expression  and  phosphorylation  determined  by  Western  blot  (A)  and 
quantified  by densitometry normalised  to  control (0 min)  (B).  Data are represented  as the mean ± 
SEM, n =3; *, p<0.05 versus control.
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5.11.  Effect of CNP on cell proliferation in primary rat 
aortic smooth muscle cells
In an attempt to establish a downstream target for the actions of CNP, and since the 
ERK  1/2 pathway is known to regulate cell proliferation (Pearson et al.,  2001),  1° 
RAoSMC  were  treated  with  CNP  (1  p,M)  for  24  h  and  cell  proliferation  was 
measured by BrdU incorporation.  CNP inhibited basal cell proliferation (Figure 57) 
and growth stimulated by Ang II (100 nM; Figure 58)  The inhibitory effects of CNP 
were attenuated in the presence of the NPR-C antagonist, M372049 (10 pM) and by 
the ERK 1/2 phosphorylation inhibitor PD98059 (30 pM; Figure 57 and Figure 58)
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Figure 57 -  BrdU incorporation in 1° RAoSMC under basal conditions in the absence and presence of 
CNP  (10  pM),  with  or without pre-treatment with  PD98059  (30  pM) or M372049  (10  pM).  Data 
represented as the mean ± SEM absorbance, expressed as a percentage of basal cell growth, n > 6; *, 
p<0.05 versus control.
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EFFECT OF CNP ON ANGIOTENSIN II-STIMULATED CELL 
PROLIFERATION IN PRIMARY RAT 
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Figure 58 -  BrdU incorporation in  1° RAoSMC following growth stimulation with Ang II (100 nM) 
in the absence and presence of CNP (10 pM), with or without pre-treatment with PD98059 (30 pM) 
or M372049 (10 pM).  Data represented as the mean ± SEM absorbance, expressed as a percentage of 
basal cell growth, n > 6; *, p<0.05 versus control.
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5.12.  Summary of key results
In  this  chapter  I  have  shown  that  CNP  causes  a  strong  ERK  1/2  and  p38 
phosphorylation;  however,  ANP  was  essentially  unable  to  cause  ERK  1/2  or p38 
phosphorylation.  CNP-induced ERK  1/2 phosphorylation occurs predominantly via 
Gj-coupled NPR-C  since  phosphorylation  was  blocked  by the  Gj-protein  inhibitor 
PTX   and  the  NPR-C  selective  inhibitor  M372049,  and  this  is  linked  to  growth 
inhibition  in  1°  RAoSMC.  CNP-induced p38  phosphorylation  does  not  appear to 
involve NPR-C.
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6. Discussion and Conclusions
6.1.  Background and aim of current study
The  involvement  of both  NO  and  natriuretic  peptides  in  the  control  of vascular 
homeostasis has been described extensively (Moncada and Higgs,  1993; Levin et al, 
1998; Baxter, 2004; Ahluwalia et al, 2004).  The role of NO in the immune system 
has  also  been  well-characterised.  NO  is  produced  in  response  to  inflammatory 
stimuli including cytokines and LPS in numerous cell types and acts in both cGMP- 
dependent and independent manners to exert cytotoxic and cytostatic effects (Nathan 
and  Hibbs,  1991;  Nathan  and  Xie,  1994).  This  ‘high  output’  NO  production  is 
generated predominantly by the inducible isoform of NOS.  Unfortunately, excessive 
NO production during inflammatory episodes results in NO-mediated host damage. 
For  example,  septic  shock  occurs  when  there  is  extensive  release  of NO  in  an 
attempt to  combat  a  systemic  infection.  These  high NO  levels  cause dysfunction 
within the body,  exemplified by a dramatic decrease in blood pressure followed by 
failure of vital organs often resulting in death (Titheradge,  1999).  NO has therefore 
been termed a vital poison, as a balanced amount of NO production is essential for 
combating  infections  but  mis-regulation  leading  to  either  excessive  or  deficient 
levels is deleterious.
Natriuretic peptides parallel the effects of NO in the vasculature via activation of the 
particulate isoform of guanylate cyclase; however, the role(s) of natriuretic peptides 
in the immune system remain unclear.  Studies evaluating the effect of ANP on pro- 
inflammatory  protein  expression  (e.g.  iNOS),  do  not  provide  a  consensus  as  to 
whether  these  peptides  act  in  a  pro-  or  anti-inflammatory  manner  (Vollmar  and 
Schulz,  1995b;  Kiemer and Vollmar,  1997;  Kiemer et al,  2002a;  Vollmar,  2005). 
Thus, I hypothesised that natriuretic peptides (specifically ANP and CNP) affect pro- 
inflammatory protein expression (e.g. iNOS) via activation of the pGC isoform.  The 
investigations described in this thesis were designed to test this hypothesis  and to 
elucidate  the  mechanisms  by  which  natriuretic  peptides  can  regulate  cell 
proliferation, with particular emphasis on the MAPK pathways.
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6.2.  Summary of key results
In NPR-A KO mice, iNOS expression and NO production in response to  systemic 
administration of LPS  are  significantly  reduced  compared to  WT  controls;  this  is 
mirrored in the ex vivo functional reactivity of vessels from these animals in which 
aortae  from  WT  mice  display  greater  vascular  dysfunction.  Such  observations 
intimate  that  ANP  (and/or  BNP  -   since  it  too  signals  via  NPR-A)  act  in  a  pro- 
inflammatory manner, in vivo, contradicting previous findings (Vollmar and Schulz, 
1995b; Kiemer and Vollmar,  1997; Vollmar, 2005).  Since a reduction in iNOS was 
observed in NPR-A KO animals, the effects of ANP and CNP on iNOS expression 
and  activity  in  vitro,  in  cell  based  systems,  were  investigated.  Despite  previous 
reports suggesting that ANP inhibits iNOS expression (Vollmar and Schulz,  1995b), 
neither ANP nor CNP were able to alter iNOS expression in murine macrophages or 
RAoSMC.  However, CNP did increase MAPK phosphorylation (specifically ERK 
1/2  and  p38)  in  RAoSMC,  pathways  that have  previously been  implicated  in  the 
regulation of iNOS (Chen and Wang,  1999; Monier et al., 2002; Kim et al, 2004); 
indeed,  I  demonstrate  that  iNOS  expression  is  dependent  on  p38  activation  in  1° 
RAoSMC.
The MAPK pathway has also been implicated in growth regulation  (Chen and Wang, 
1999; Pearson et al, 2001; Monier et al, 2002), and the anti-proliferative properties 
of CNP have  been well-characterised,  especially in the vasculature  (Furuya  et al, 
1991;  Furuya  et  al,  1993;  Cahill  and  Hassid,  1994;  Hutchinson  et  al,  1997). 
Although the anti-proliferative properties of CNP have been previously investigated, 
the receptor and signalling pathways involved in mediating this effect are not clearly 
defined.  In  an  attempt  to  establish  the  transduction  pathway(s)  and  natriuretic 
peptide receptor responsible  for the anti-mitogenic actions of CNP,  I employed  1° 
RAoSMC and a selective NPR-C antagonist,  M372049.  CNP caused inhibition of 
RAoSMC growth that was blocked by M372049 and the ERK 1/2 pathway inhibitor 
PD98059.  CNP elicited a transient increase in ERK 1/2 phosphorylation, which was 
also  blocked by PD98059,  PTx  and  M372049.  Interestingly however,  ANP  was 
unable  to  reproduce  the  ERK  1/2  phosphorylation  induced  by  CNP,  despite  the 
ability of 8-Bromo-cGMP  to  elicit ERK  1/2  phosphorylation.  These  observations
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imply  that  CNP  is  acting  predominantly  through  NPR-C  in  a  cGMP-independent 
manner  to  bring  about  its  anti-proliferative  actions  via  activation  of  ERK  1/2 
phosphorylation.
6.3.  Effect of ANP on iNOS expression and vascular 
reactivity in vivo
LPS  has  long  been  recognised  as  one  of  the  prime  inducers  of  septic  shock 
(Thiemermann,  1997)  and the  associated iNOS  expression and elevated NO  levels 
(Liu et al,  1993).  This overproduction of NO contributes to the cardinal symptoms 
of septic  shock,  hypotension,  reduced  circulatory  resistance,  cardiodepression  and 
vascular hyporeactivity,  all  of which  result  in multiple  organ  failure  (Landry  and 
Oliver,  2001).  ANP,  a  key  cardiovascular  homeostatic  hormone  has  also  been 
implicated  in  inflammation  and  has  been  shown  to  inhibit  iNOS  expression  in  a 
number of cell types  in vitro,  suggesting an anti-inflammatory role  (Vollmar and 
Schulz,  1995a;  Pandey et al,  2000;  Tsukagoshi et al,  2001;  Kiemer et al,  2003). 
Moreover, there is a considerable body of evidence intimating an important role for 
natriuretic peptides in the pathogenesis of sepsis in vivo, in both animals models and 
humans (Hinder et al,  1997; Witthaut et al, 2003;  Stubbe et al, 2004;  Miyoshi et 
al, 2006;  Shor et al, 2006; Vellaichamy et al, 2007).  For instance, Miyoshi et al 
reported that i.v. administration of LPS in rats causes an increase in IL-lp and fever, 
which  is  enhanced  by  administration  of  the  NPR-A/B  antagonist  HS-142-1, 
suggesting that ANP acting outside the blood-brain barrier, inhibits IL-ip leading to 
an  inhibition  of second  phase  fever  (Miyoshi  et  al,  2006).  Furthermore,  in  an 
experimental model of ovine sepsis, blockade of NPR-A/B by HS-142-1  increases 
cardiac  filling pressures, maintains mean arterial pressure and increases pulmonary 
transvascular  fluid  flux  independently  of  changes  in  permeability  to  protein, 
suggesting that ANP may play a protective role during sepsis (Hinder et al,  1997; 
Stubbe et al, 2004).  A single in vivo study conducted by Vellaichamy et al in NPR- 
A  KO  mice  reported  that  these  mice  have  elevated  basal  levels  of  the  pro- 
inflammatory  cytokines  TNF-a,  IL-6  and  TGF-pi,  and  exhibit  greater  NF-kB 
binding  activity  as  compared  to  WT  animals,  suggesting  that  ablation  of NPR- 
A/cGMP signalling is associated with a pro-inflammatory phenotype (Vellaichamy 
et al, 2007).
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LPS-induced endotoxaemia in rats causes a rise in plasma ANP and a reduction in 
plasma  volume  (Aiura  et  al.,  1995).  The  early  rise  of plasma  ANP  after  LPS 
injection may be  due  to  local  release  of ANP  by  macrophages  of the  spleen  and 
regulated by PAF and not from a cardiac source (Qu et al,  1998).  Furthermore, the 
increase in plasma ANP following LPS  is dampened by iNOS-derived NO.  In the 
presence of the iNOS inhibitor, aminoguanidine, ANP plasma levels are significantly 
higher following LPS administration, suggesting that the NO pathway may activate 
an inhibitory control mechanism that attenuates ANP secretion during sepsis (Stabile 
et al., 2007).  An increase in cGMP levels in human sepsis has been reported, which 
is  associated  with  a  decline  in  peripheral  resistance.  The  raised  cGMP  levels 
however  cannot  be  attributed  to  sGC  or  pGC  exclusively,  suggesting  that  both 
natriuretic peptides and NO play a role (Schneider et al., 1993).
Elevated  plasma  natriuretic  peptide  levels  have  also  been  demonstrated  in  the 
clinical  arena.  Plasma  ANP  and  BNP  levels  in  patients  with  septic  shock  are 
significantly higher than in control subjects (ANP: 82.7 ± 9.9 pg/ml septic vs  14.9 ± 
1.2 pg/ml control; BNP:  12.4 ± 3.6 pg/ml septic vs 5.5 ± 0.7 pg/ml control; Witthaut 
et al., 2003).  The increased ANP levels are tightly correlated to increases in IL-6 
suggesting that excessively increased pro-inflammatory cytokines contribute to  the 
modulation  of ANP  levels  in  septic  patients  (Witthaut  et  al.,  2003).  Natriuretic 
peptides, particularly ANP and BNP, are also known to be elevated in cardiovascular 
diseases such as heart failure, which is a common complication in sepsis (Potter et 
al.,  2006).  Furthermore,  it has been suggested that ANP,  endothelin-1  and cGMP 
could be markers of severe and fatal myocardial depression early in the course  of 
human septic shock (Hartemink et al., 2001).  Moreover, pro-ANP and N-terminal 
proANP have been described as useful markers of cardiac depression (Mazul-Sunko 
et al., 2001) and myocardial dysfunction (Hoffmann et al., 2005) caused by sepsis 
respectively.  It is worth noting however, that it is hard to distinguish in these studies 
whether  the  elevated  ANP  levels  are  due  to  the  sepsis  or  due  to  the  associated 
cardiac condition.
Akin to ANP, BNP is elevated in sepsis  (Witthaut et al, 2003) and several studies 
have  addressed the question whether BNP  and proBNP are of prognostic  value  in 
patients with sepsis  especially in  terms  of adverse cardiac  events  (Witthaut et al.,
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2003;  Brueckmann et al.,  2005;  Ueda  et  al,  2006).  Some  studies  have  shown  a 
correlation between BNP  or NT-proBNP  and cardiac  functional measures  such as 
cardiac  index  (Witthaut et al.,  2003;  Charpentier et al.,  2004;  Brueckmann  et al.,
2005),  while  others  observed  no  correlation  (Tung  et al.,  2004;  Bal  et  al.,  2006; 
Rudiger  et  al.,  2006).  BNP  has  also  been  suggested  as  a  potential  marker  for 
mortality in septic shock (Castillo et al., 2004).  Recently, a study by Maeder et al 
has  demonstrated  elevated  BNP  levels  in  patients  with  sepsis  and  normal  left 
ventricular function (Maeder et al.,  2005).  This  is further supported by Shor et al 
who showed elevated BNP levels in septic patients who were not in a clinical state of 
congestive  heart  failure  and  had  no  echocardiographic  evidence  of  systolic 
dysfunction (Shor et al., 2006), suggesting that BNP is elevated in sepsis, without 
any indirect effects on the heart.  Thus, there is good evidence that both ANP and 
BNP are elevated as a consequence of sepsis and may contribute to or help prevent 
pathogenesis of the disease.
Sepsis is characterised by vascular smooth muscle dysfunction resulting in impaired 
contractile  function,  hypotension,  inadequate  tissue  perfusion  and  organ  failure. 
This vascular dysfunction has been attributed to raised iNOS expression and activity, 
and the resulting increase  in NO-mediated dilatation (Julou-Schaeffer et al.,  1990; 
Fleming et al., 1991).  Inhibition of iNOS activity in animal models of sepsis as well 
as humans reverses hypotension (Petros et al.,  1994).  Endothelial dysfunction has 
also  been  shown to occur in sepsis and other inflammatory cardiovascular disease 
(Mombouli and Vanhoutte,  1999;  Hingorani et al, 2000).  Utilisation of iNOS KO 
mice  treated  with  LPS  to  induce  sepsis  demonstrated  that  the  absence  of iNOS 
protects  against  LPS-induced  contractile  hyporeactivity  (Boyle,  III  et  al,  2000; 
Hollenberg et al., 2000) as well as endothelial dysfunction (Chauhan et al., 2003a). 
In  a rat  model  of septic  shock  antisense  oligonucleotides  to  iNOS  mRNA  inhibit 
iNOS activity and expression and prevent vascular hyporeactivity to norepinephrine 
(Hoque et al.,  1998).  These studies indicate that iNOS induction plays an integral 
role in mediating endothelial dysfunction associated with sepsis.
Nitric  oxide  is  known  to  control  smooth  muscle  relaxation  via  NO-sensitive 
guanylate  cyclase  signalling  and  it  has  been  suggested  that  the  vascular 
hyporeactivity observed in sepsis could be due to guanylate cyclase desensitisation
167CHAPTER 6 -  DISCUSSION AND CONCLUSIONS
(Hussain et al., 2001; Madhani et al., 2003; Friebe and Koesling, 2003; Madhani et 
a l, 2006; Mullershausen et al., 2006).  Short term exposure of rat thoracic aortae to 
NO  causes  desensitisation  of  NO-induced  relaxation  as  well  as  heterologous 
desensitisation  of  ANP-induced  relaxation  suggesting  a  common  underlying 
mechanism  of negative  feedback  for regulation  of NO/cGMP  signal  transduction, 
perhaps  involving  PDE-5  (Mullershausen  et  al.,  2006).  Madhani  et  al  have 
demonstrated  that  NPR-A/NPR-B-linked  pGC  pathways  are  modulated  by 
NO/sGC/cGMP  in  mouse  aorta  and  there  is  cross-desensitisation  between  NPR 
subtypes (Madhani et al., 2003).  This has also been shown in human vessels where 
the  relaxant  potency  of SPER-NO  and  ANP  is  increased  following  inhibition  of 
endogenously produced NO and decreased with prior exposure to GTN (Hussain et 
al.,  2001).  Inhibition  of endogenous  generation  of NO  by  L-NMA  in  healthy 
volunteers  significantly  enhances  further  the  ANP-dependent  forearm  blood  flow 
(Madhani et al., 2006).  Furthermore, aortae from eNOS KO mice are more sensitive 
to ANP compared to WT animals and responses to ANP in WT mice are increased in 
the presence of NOS or sGC inhibitors (Hussain et al., 2001).  In vivo administration 
of sodium  nitroprusside  and  ANP  to  eNOS  KO  and  NPR-A  KO  mice  causes  a 
significant enhancement in mean arterial blood pressure reduction (Madhani et al.,
2006), suggesting that loss of endothelium-derived NO results in upregulation of the 
sensitivity of both sGC and pGC in vivo, strengthening the evidence for NO/sGC and 
ANP/pGC  cooperative  interactions  and  intimating  that  at  least  in  part,  ANP- 
mediated relaxations  are  dependent  on  endothelial NO release.  Conversely,  mice 
with  selective vascular smooth muscle NPR-A deletion have normal arterial blood 
pressure  and  increased  vasorelaxing  sensitivity  to  sodium  nitroprusside  and  ACh 
compared to control animals showing that endothelial NO contributes to compensate 
for the missing vasodilating effect of ANP (Sabrane et al, 2003).  Taken together, 
these  studies  hint  that  NO/sGC  and  ANP/pGC  crosstalk  may  be  an  important 
physiological homeostatic mechanism, which links the paracrine activity of NO and 
CNP with the endocrine functions of ANP and BNP in regulating vascular tone and 
blood pressure.
In the present study, I used a genetic approach (i.e. NPR-A KO mice) to explore the 
role  of ANP/BNP  in  sepsis  and  to  test  the  hypothesis  that  ANP  acts  in  an  anti­
inflammatory  manner  by  inhibiting  iNOS  expression  and  activity  in  vivo,  as
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previously reported in vitro (Vollmar and Schulz, 1995b; Vollmar, 2005).  The study 
herein has demonstrated that treatment of NPR-A KO mice with LPS for 16 h results 
in inhibition of iNOS expression in lung and aortic tissue, reduced plasma NOx and 
vascular  dysfunction  (in  terms  of  both  constrictor  and  dilator  pathways),  in 
comparison  to  WT  animals.  Relaxation  responses  to  ACh  and  SPER-NO  were 
impaired  in  aortae  from  WT  mice  consistent  with  high  output NO  production by 
iNOS and subsequent endothelial and smooth muscle hyporeactivity. However, this 
dysfunction was abrogated in NPR-A KO animals.  It is worth noting that there is a 
difference in basal WT and NPR-A KO contractile and relaxant responses and hence 
differences in basal endothelial function.  Therefore, it is important to compare fold 
shift  in  potency  since  the  starting  contraction/relaxation  curves  are  not 
superimposable.  NPR-A  KO  animals  are  less  responsive  to  the  vasoconstrictor 
U46619 and show more potent vasorelaxant responses.  This could be explained by 
the crosstalk between pGC and sGC as discussed above; elimination of NPR-A and 
hence  pGC-generated  cGMP  could  result  in  a  compensatory  upregulation  of 
(endothelial (eNOS) derived) NO/sGC  signalling,  hence dampening the contractile 
responses while enhancing NO-dependent vasorelaxation (ACh).  In the presence of 
the NO donor SPER-NO however, NPR-A KO aortae do not respond more potently 
in  comparison  to  WT  and  this  could  be  due  to  the  upregulation  of basal  EDRF 
release in NPR-A KO, which might offset any shift in the SPER-NO curve.  In the 
presence of LPS however, there is less “high output” NO from iNOS in NPR-A KO 
animals resulting in reduced endothelial dysfunction and hence normalised responses 
to both contractile and relaxing agents when compared to saline treated NPR-A KO 
littermates.  Taken together, this study suggests for the first time a pro-inflammatory 
role for ANP/BNP through NPR-A/pGC signalling in sepsis.  It might be expected 
that  CNP,  acting  through  NPR-B  could  have  a  similar  pro-inflammatory  role; 
however,  it  is  worth  remembering  that  this  natriuretic  peptide  is  expressed  and 
released  locally  (i.e.  in  a  paracrine  fashion)  and  is  known  to  signal  through  both 
NPR-B (cGMP-dependent) and NPR-C (cGMP-independent).  Furthermore, it could 
be  speculated  that NPR-A  KO  mice,  akin  to  iNOS  KO  animals  (MacLean  et a l, 
1998; Mclnnes et al.,  1998), might be more susceptible to infection since ANP/BNP 
appear to act in a pro-inflammatory manner to increase iNOS  expression and help 
expedite host defence.
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A  pro-inflammatory  role  for  ANP/BNP  would  fit  with  previous  studies 
demonstrating a key pro-inflammatory role  for  eNOS-derived NO,  that  is  cGMP- 
dependent (at least in part).  Thus, since ANP/BNP act via NPR-A to increase cGMP, 
a  similar  effect  in  sepsis  would  be  expected.  Endothelial  NOS  expression  and 
activity  has  been  shown  to  modulate  iNOS  expression  (Connelly  et  a l,  2003; 
Connelly et al.,  2005)  and  a decrease  in  eNOS  has been  suggested to  reduce the 
vascular dysfunction associated with sepsis (Vo et al, 2005).  It has been shown that 
NO  has  a  biphasic  effect  on  NF-kB  activity  and  can  hence  both  upregulate  and 
downregulate pro-inflammatory proteins (e.g. iNOS).  Nanomolar concentrations of 
NO as might be produced by constitutive NOS were shown to augment macrophage 
activation  and  expression  of iNOS  while  low  micromolar  concentration  of NO, 
similar to those generated by iNOS inhibit gene expression (Connelly et al, 2001). 
This suggests that eNOS could provide the source of “low output” NO to potentiate 
iNOS expression and facilitate the initial cellular response to inflammatory stimuli as 
appears to be mimicked by NPR-A activation.
Vo  et  al  and  Connelly  et  al  have  shown  that  treatment  of WT  mice  with  LPS 
enhanced plasma NOx levels and these were reduced by 50 % in eNOS KO animals. 
This was accompanied by reduced iNOS expression and enhanced vascular reactivity 
to SPER-NO (Connelly et al, 2005; Vo et al, 2005), as has been demonstrated for 
NPR-A  KO  mice  in  the  current  study.  Furthermore,  eNOS  KO  animals  exhibit 
reduced hypotension in response to LPS (Connelly et al, 2005) and this is something 
that merits further investigation in NPR-A KO animals following sepsis.  Perhaps it 
is  not  unreasonable  to  speculate  that  the  NPR-A  KO  animals  should  have  an 
improved haemodynamic profile and hence have reduced hypotension in response to 
LPS  in  comparison  to  WT  animals  as they have reduced  iNOS  and  reduced  high 
output NO, similar to that observed in eNOS KO mice.  In further support of a pro- 
inflammatory role  for  eNOS,  bone  marrow-derived  macrophages  from  eNOS  KO 
mice exhibit reduced NF-kB activity, iNOS expression and NO production following 
exposure  to  LPS  when  compared  to  WT  mice,  suggesting  constitutive  eNOS  is 
necessary to obtain maximal  iNOS expression and activity (Connelly et al, 2003). 
Furthermore,  in  HUVEC,  LPS  activates  eNOS  (and  its  phosphorylation)  through 
PI3K and Akt/protein kinase B-dependent enzyme phosphorylation (Connelly et al, 
2005).  Therefore, a sGC and pGC-mediated increase in cGMP in response to eNOS-
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derived  NO  and  ANP/BNP,  appear  to  have  a  similar  role  in  facilitating  iNOS 
expression, at least during sepsis.  The crosstalk between sGC and pGC could also 
act in a compensatory fashion under pathological conditions (Madhani et al., 2003). 
For instance, in cardiovascular disease (e.g. hypertension and atherosclerosis) there 
is marked endothelial dysfunction associated with reduced NO levels, and this could 
be  compensated  by ANP/CNP-cGMP  pathways.  Conversely,  during  heart  failure 
where  there  are  elevated  natriuretic  peptide  levels  (Potter  et  al.,  2006),  the 
downregulation  of  NO/sGC/cGMP  signalling  could  help  offset  the  systemic 
hypotension seen in such conditions (Madhani et al., 2003).
The  regulation  of  gene  expression,  particularly  iNOS,  by  cGMP-dependent 
mechanisms has been previously documented.  In human glomerular mesangial cells 
cGMP analogues amplify IL-1  p/TNF-a-elicited iNOS induction and this is abrogated 
in the presence of the sGC inhibitor ODQ (Perez-Sala et al., 2001).  Furthermore, in 
rat glial cell cultures, cGMP analogues and zaprinast, an inhibitor of cGMP-selective 
phosphodiesterases, enhance LPS-stimulated iNOS expression and NO accumulation 
while KT5823, an inhibitor of PKG, has an inhibitory effect (Choi et al.,  1999; Choi 
et al., 2002).  The regulation of iNOS by sGC and cGMP has also been demonstrated 
in  macrophages.  In  the  presence  of ODQ  a  reduction  in  iNOS  expression  in 
response to LPS is observed, while the sGC activator BAY 41-2272 increases iNOS 
expression (Connelly et al., 2003).  Adenoviral transfer of iNOS to the endothelium 
and adventitia of intact vessels  impairs contractile responses to phenylephrine and 
this is reversed in the presence of ODQ, suggesting that sGC and cGMP are involved 
in regulating iNOS (Gunnett et al, 2005).  However, the mechanisms underlying the 
NO/sGC/cGMP regulation of iNOS are unclear.  The NO donor S-nitroso-N-acetyl- 
D,L-pencillamine has been shown to activate NF-kB and induce TNF-a mRNA and 
protein expression in  feline cardiac myocytes, and this is blocked by pre-treatment 
with  ODQ  or  a  PKG  antagonist  (Rp-8-Br-cGMPS;  Kalra  et  al.,  2000).  As 
mentioned above, LPS-induced iNOS expression in rat glial cell cultures is inhibited 
by a PKG inhibitor (Choi et al., 1999; Choi et al., 2002), suggesting the involvement 
of cGMP/PKG.  Interestingly, PKG phosphorylates IkB at the critical Ser32 residue, 
which leads to its proteasomal degradation and activation of NF-kB (Traenckner et 
al., 1995; Kalra et al., 2000).  Hence, cGMP generation by sGC and the involvement 
of PKG could be crucial in controlling iNOS expression.  This can be extrapolated to
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the current study, such that ANP/BNP activate NPR-A to increase cGMP production 
and  iNOS  expression  via  PKG  and  IkB  degradation.  Therefore,  it  would  be 
interesting  to  investigate  the  cGMP  levels  present  in  NPR-A  KO  and  WT  mice 
following LPS as well as the phosphorylation status of IkB.
In  the  current  study,  only the  cGMP-dependent pathways  were  investigated  since 
cAMP-dependent  systems  are  not  affected  by  desensitisation;  vascular 
responsiveness to the cAMP-dependent vasodilator epoprestenol and to the adenylyl 
cyclase activator,  forskolin, are similar in WT and eNOS KO mice (Hussain et al., 
1999; Madhani et al., 2006).  However, confirmation of this in a septic model will be 
required in the future by looking at the relaxant responses to forskolin in NPR-A KO 
and  WT  mice  following  LPS  treatment.  Isolation  of  bone  marrow-derived 
macrophages  from  NPR-A  KO  mice  will  help  determine  if PI3K/Akt,  PKG  and 
phosphorylated  IkB  are  involved  in  the  control  of iNOS  by  ANP.  Moreover, 
measurement of eNOS expression in heart, lung and aortic tissue from NPR-A KO 
and WT mice following treatment with LPS might help to determine if cooperative 
cGMP-dependent  regulation  of  pro-inflammatory  protein  expression  occurs  in 
response to LPS.  Furthermore, the plasma levels of ANP, BNP and CNP as well as 
cGMP and various pro-inflammatory cytokines e.g. IL-1, IL-6 and TNF-a should be 
determined  in  NPR-A  KO  and  WT  mice  treated  with  LPS  or  saline,  to  further 
support the proposed pro-inflammatory role for ANP/BNP.
6.4.  Effect of ANP and CNP on iNOS expression in vitro
Previous  studies  evaluating the  effects of natriuretic peptides on pro-inflammatory 
protein expression have suggested an anti-inflammatory role for natriuretic peptides, 
and particularly ANP (as mentioned above).  However, these results conflict with the 
in  vivo  studies  described  herein  in  NPR-A  KO  mice.  Vollmar  and  Kiemer  have 
shown  that  ANP  inhibits  NO  production  in  macrophages  by  inhibiting  iNOS 
expression via pGC-coupled NPR-A with the involvement of cGMP  (Vollmar and 
Schulz,  1995b;  Kiemer  and  Vollmar,  1998;  Kiemer  and  Vollmar,  2001).  This 
inhibition is seen in the macrophage cell lines RAW264.7 and J774, in addition to 
primary bone  marrow-derived  and  peritoneal  macrophages  (Kiemer  and  Vollmar,
1997).  In  contrast,  changes  in  iNOS  expression  and  NO  production  were  not
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observed  in  Kupffer  cells,  although  an  increase  in  cGMP  levels  was  apparent 
(Kiemer et a l, 2002a).  CNP has been reported to have  no effect on NO production 
and iNOS expression in macrophages (Kiemer and Vollmar,  1997).  Yet, the role of 
natriuretic peptides in regulating iNOS expression remains unclear since Maruno et 
al have shown that ANP,  BNP and CNP all upregulate iNOS induction by raising 
intracellular cGMP levels in vascular smooth muscle cells (Marumo et a l, 1995).
Since a pro-inflammatory role for ANP/BNP in the immune system was suggested 
from  the  in  vivo  NPR-A  KO  studies,  the  effect  of natriuretic  peptides  on  iNOS 
expression in RAW264.7 murine macrophages was investigated.  Macrophages were 
treated with LPS to induce iNOS and the effects of ANP and CNP were investigated. 
No significant changes in iNOS expression were observed in the presence of ANP or 
CNP in contrast to previous findings.  The discrepancy between the in vitro and in 
vivo  systems  could  be  explained  by  additional  factors  present  in  vivo  not  being 
available  in  a  cell-based  approach  (e.g.  release  of  additional  pro-inflammatory 
cytokines/mediators by natriuretic peptides).
Since no effect of natriuretic peptides on pro-inflammatory protein expression was 
observed in murine macrophages,  similar  studies were conducted  in  1°  RAoSMC. 
Induction of iNOS was brought about by treating 1° RAoSMC with a combination of 
LPS, IFN-y, IL-ip and TNF-a.  There have been numerous reports documenting the 
activation  of smooth  muscle  cells  with  single  or  dual-combinations  of cytokines 
(Beasley et a l,  1991; Marumo et al,  1995; Kusano et al,  1999; Zhang et al, 2001; 
Hsiao et al,  2003) and induction of iNOS  expression in cells  in  vitro, particularly 
human,  has been notoriously difficult (MacNaul and Hutchinson,  1993).  Inducible 
NOS activation (and nitrite accumulation in the culture medium as an index of NO 
production)  in  1°  RAoSMC  used  in  the  present  study was  best  achieved  using  a 
combination of all four activators, LPS, IFN-y, IL-lp and TNF-a.  Treatment of cells 
with LPS alone, a combination of TNF-a and IL-ip or a combination of TNF-a and 
IFN-y  did  not  bring  about  significant  increases  in  iNOS  expression  and  no 
corresponding increase in nitrite was seen.  The levels of nitrite production observed 
in  1°  RAoSMC  were  approximately  2-fold  lower  in  comparison  to  RAW264.7 
macrophages.  It  has  been  suggested  previously  that  NO  formation  in  vascular 
smooth muscle cells in contrast to monocytes/macrophages, could be limited to some
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extent by the availability of both the NOS substrate L-arginine and certain co-factors 
such as BH4 (Hecker et al., 1999), giving a possible explanation for the lower nitrite 
levels observed in 1° RAoSMC.
Previous studies in smooth muscle cells have investigated the effects of NO, cGMP 
and  natriuretic  peptides  on  iNOS  expression.  NO  has  been  shown  to  inhibit 
cytokine-induced iNOS  expression and NF-kB activity in RAoSMC  (Katsuyama et 
al.,  1998; Hattori et al., 2004).  Yet, it has also been reported that NO has little or no 
effect  on  iNOS  and  NF-  kB  activity  (Zhang  et  al.,  2001).  Further  studies  have 
documented  that  cGMP-dependent  vasodilators  such  as  sodium  nitroprusside 
significantly increase the IL-l|3-stimulated expression of iNOS protein and activity 
(Boese et al.,  1996).  Importantly however, iNOS was not induced using the same 
cytokine combinations in these studies, suggesting that there are multiple pathways 
controlling iNOS  expression, which are  all tightly and differentially regulated.  A 
promoter study using A7r5 cells (rat aortic smooth muscle cells), has shown that the 
iNOS  promoter  is  regulated  differentially  compared  to  macrophages  and  that 
different kB binding sites are involved in the two cell types (Spink et al., 1995).  The 
production of NO in vascular smooth muscle cells causes profound vasodilatation, 
which could be beneficial at the local area of inflammation to facilitate delivery of 
inflammatory  cells  and  mediators  to  combat  the  infection.  Flowever,  iNOS 
expression and NO production must be tightly controlled as inappropriate high levels 
of NO causes widespread vasodilatation resulting in hypotension and multiple organ 
failure  as  exemplified  in  sepsis.  Therefore,  the  need  for  multiple  cytokines  to 
achieve  iNOS  induction  in  smooth  muscle  cells  fits  with  a  systemic  protective 
mechanism.  Two independent groups have shown that akin to NO, ANP, BNP and 
CNP augment the induction of iNOS via cGMP in vascular smooth muscle, however, 
these effects are independent of cGMP-dependent protein kinases and may involve 
cAMP-dependent kinases  (Marumo  et al.,  1995;  Boese  et al.,  1996;  Iimura et al., 
1998).
In the current study,  1° RAoSMC were exposed to ANP or CNP prior to activation 
and  the  effect  on  iNOS  expression  and  activity  was  determined.  Once  again,  in 
contrast to previous findings (Marumo et al.,  1995; Boese et al.,  1996; Iimura et al.,
1998),  no changes  in iNOS  were observed,  despite the presence of mRNA  for all
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natriuretic peptide receptors, suggesting that each isoform is expressed in these cells. 
At  present  it  is  unclear  why  the  natriuretic  peptides  were  unable  to  alter  iNOS 
expression/activity, although this may be due to the phenotype of the smooth muscle 
cells.  Vascular smooth muscle cells switch from a contractile to a synthetic state in 
vivo in response to vascular injury, and NO, cGMP and PKG have been postulated to 
be  involved  in  the  switch  (Komalavilas  et  al.,  1999).  Therefore,  whether  the 
RAoSMC  used in this study were  contractile  or synthetic could play a role  in the 
activation  of  iNOS  and  thus  the  modulation  of  pro-inflammatory  proteins  by 
natriuretic  peptides.  Furthermore,  in  vivo  there  are  other  mediators  produced  by 
surrounding  cells,  especially  endothelial  cells,  which  could have  an  effect  on  the 
responsiveness of the underlying smooth muscle.  In addition, the MAPK pathway 
has been shown to be important in the regulation of iNOS in vascular smooth muscle 
cells  (Baydoun  et  al,  1999;  Doi  et  al,  2000;  Jiang  et  al,  2004)  and  natriuretic 
peptides  might  modulate  these  pathways  to  alter  iNOS  expression.  However, 
multiple  pathways  are  involved  in  controlling  iNOS  expression  and  therefore  a 
subtle  effect  on  one  pathway  by  natriuretic  peptides  could  be  ‘masked’  or 
‘compensated’ for by an alternative modulatory mechanism.
6.5.  iNOS expression and the MAPK pathway
The involvement of the MAPK pathway in the regulation of iNOS has been inferred 
previously  using  well  characterised,  highly  specific  MAPK  inhibitors.  PD98059 
inhibits ERK 1/2 MAPK pathway by blocking the upstream activators (MEK 1/2) of 
ERK  i/2  (Dudley  et  al,  1995)  while  SB203580  inhibits  p38  MAPK  pathway 
(Kumar  et  al,  1997).  In  murine  macrophages  (RAW264.7),  SB203580  but  not 
PD98059 inhibits the LPS-induced stimulation of iNOS by inhibiting NF-kB DNA 
binding  indicating  that  p38,  but  not  ERK  1/2,  is  involved  in  LPS  induced  iNOS 
expression  (Chen  and  Wang,  1999).  Similar  observations  have  been  reported  by 
Monier et al (Monier et al, 2002).  In contrast, Sharma et al have reported that both 
ERK 1/2 and p38 MAPK cascades are involved in endotoxin-induced NO production 
and iNOS  expression,  although  PD98059  seems to inhibit iNOS to  a lesser extent 
than  SB203580  (Kim et al,  2004),  suggesting a predominant role  for p38.  In rat 
vascular  smooth  muscle  cells  transiently  transfected  with  an  iNOS-luciferase 
promoter construct,  PD98059  inhibits  luciferase  activity  in  response to  IL-lp  and
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TNF-a suggesting the involvement of the ERK pathway in iNOS regulation (Doi et 
a l, 2000).  In addition, Baydoun et al observed that  SB203580,  but not PD98059, 
inhibits  iNOS  expression  and  activity,  and  L-arginine  transport,  in  RAoSMC 
(Baydoun et al.,  1999).  In contrast, p38 MAPK has been shown to be involved in 
Ang II regulated IL-ip induced iNOS in rat vascular smooth muscle cells (Jiang et 
a l, 2004).
Thus, although it is likely that ERK  1/2 and p38  MAPK both play a role in iNOS 
expression, the relative contribution of each pathway appears to be tissue specific.  It 
is evident that the protein kinases that are involved in iNOS gene transcription and 
regulation vary from cell to cell (Baydoun et a l,  1999).  Different cell types could 
express  different  combinations  of the  p38  isoforms.  p38a and p380  isoforms  are 
known to be sensitive to SB203580 and other pyridinyl imidazoles while p38y and 5 
are thought to be insensitive to these inhibitors (Kumar et a l,  1997).  Therefore, it is 
possible  that  p38a  and  p  are  the  active  isoforms  in  the  RAoSMC  system  being 
studied and thus p38a and p could still be involved in iNOS regulation.  It is also 
possible  that  there  are variations  in  the  iNOS  promoter between  different  species 
(Geller and Billiar,  1998;  Baydoun et a l,  1999) thus giving an explanation for the 
disparity in the results of the studies described above.
In the current study,  1° RAoSMC were exposed to PD98059 or SB203580 prior to 
stimulation  with  the  activation  cocktail.  iNOS  expression  was  inhibited  by 
SB203580,  but  not  by  PD98059,  implicating  the  involvement  of the  p38  MAPK 
signalling pathway in the regulation of iNOS expression in this cell type, but ruling 
out a contribution from the ERK  1/2 pathway.  Thus, mediators inhibiting p38 but 
not ERK 1/2 should have a negative effect on iNOS.  Conversely, p38 but not ERK 
1/2  activators  should  facilitate iNOS  expression.  Therefore,  I  explored if ANP or 
CNP altered ERK 1/2 or p38 phosphorylation.
The  pattern  of MAPK  phosphorylation  following  activation  of 1°  RAoSMC  with 
LPS  and cytokines was  investigated  in the current study.  Both ERK  1/2  and p38 
were phosphorylated in 1° RAoSMC in a transient fashion over a duration of 60 min 
following exposure to  activator cocktail.  Phosphorylation increased up to  15  min 
post activation and returned to baseline by 60 min.  This indicates that both ERK 1/2
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and p38 can be phosphorylated by the activator cocktail and are likely to be involved 
in pro-infiammatory protein regulation in this cell type, although it is clear that only 
p38  is key for the control  of iNOS.  The involvement of the ERK  1/2 pathway in 
pro-inflammatory protein expression has been described previously.  Uric acid has a 
direct  pro-inflammatory  effect  on  vascular  smooth  muscle  cells  by  stimulating 
MCP-1 production via activation of NFkB, ERK  1/2 and p38 (Kanellis et al, 2003). 
In  human  airway  smooth  muscle  cells,  the  release  of  granulocyte-macrophage 
colony-stimulating factor (GM-CSF), which is known to prime monocytes for a pro- 
inflammatory cytokine response (i.e.  elevation in TNF-a,  IL-lp  and IL-6) is ERK 
1/2  dependent  (Hallsworth  et  al.,  2001).  In  macrophages,  MEKK3,  which  lies 
upstream of all three MAPK pathways, is a crucial regulator of LPS-induced GM- 
CSF  and  IL-6  production  (Kim  et  al,  2007).  The  phosphorylation  of  MAPK 
cascades by LPS and inflammatory cytokines has also been described previously.  In 
macrophages LPS can phosphorylate both ERK 1/2 and p38 (Kim et al, 2004) while 
in RAoSMC ERK 1/2, p38 and JNK/SAPK are phosphorylated by LPS (Yamakawa 
et al,  1999; MacKenzie et al, 2003).  Yamakawa et al reported ERK  1/2 and p38 
phosphorylation increases time dependently in the presence of 100 pg/ml LPS with 
maximal  phosphorylation  occurring  at  30  min  post  activation  (Yamakawa  et  al,
1999), observations that are similar to the ERK 1/2 and p38 phosphorylation patterns 
described in the present study.
6.6.  Effects of ANP and CNP on  MAPK pathways
Since phosphorylation of MAPK cascades by LPS and pro-inflammatory cytokines 
was  observed  in  1°  RAoSMC,  it  was  postulated  that  natriuretic  peptides  could 
modulate  these protein kinases  either through  guanylate  cyclase  coupled NPRs  or 
through  G-protein  coupled NPR-C.  To  test this  thesis,  1°  RAoSMC  were treated 
with ANP and CNP prior to activator cocktail and ERK 1/2 and p38 phosphorylation 
monitored.  CNP did not modulate ERK 1/2 or p38 phosphorylation to a great extent 
although  there  was  a  slight  upward  trend,  especially  in  the  case  of  p38 
phosphorylation.  However,  in the absence of activator cocktail,  CNP  significantly 
enhanced  ERK  1/2  and  p38  phosphorylation.  Conversely,  ANP  was  essentially 
unable  to  alter  ERK  1/2  or  p38  phosphorylation.  Therefore,  the  current  study 
provides  the  first  evidence  that  CNP  can  bring  about  MAPK  phosphorylation
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directly  and  independently  of  LPS  and  pro-inflammatory  cytokines  in  vascular 
smooth muscle cells.  An independent study by Ho et al using rat pinealocytes has 
shown that CNP and ANP are able to elevate the levels of phosphorylated MAPK, 
which  is  accompanied  by  an  increase  in  cGMP  accumulation  with  the  possible 
involvement of PKG (Ho et al.,  1999).  ANP has also been shown to inhibit Akt as 
well as ERK  1/2 phosphorylation in response to lysophosphatydic acid, a bioactive 
lipid mainly released from activated platelets, which participates in the development 
of atherosclerotic plaques by stimulating vascular smooth muscle cell proliferation 
and  ROS  production  (Baldini  et  al,  2005).  Furthermore,  NPR-A  cardiomyocyte 
specific KO mice in an eNOS KO background show cardiac hypertrophy, which is 
accompanied by an increase in ERK 1/2 phosphorylation, suggesting that local ANP 
signalling prevents hypertensive cardiac hypertrophy (Bubikat et al,  2005).  More 
recently,  a  microarray  study  has  confirmed  the  involvement  of  PKC-MAPK 
pathways in the prevention of cardiac hypertrophy (Ellmers et al, 2007).  CNP has 
also  been  shown  to  modulate  the  MAPK  pathways.  Overexpression  of CNP  in 
chondrocytes of a mouse model for achondroplasia rescues the disease phenotype by 
correcting the decreased extracellular matrix synthesis through inhibition of the ERK 
1/2  pathway (Yasoda et al,  2004).  This was  further substantiated by Krejci  et al 
who  demonstrated  that  CNP  antagonises  FGF-2-induced  growth  arrest  of  rat 
chondrosarcoma  chondrocytes  by  the  inhibition  ERK  1/2  phosphorylation  in  a 
cGMP-dependent manner involving PKG (Krejci et al, 2005).
6.7.  MAPK, CNP and proliferation
The  MAPK  pathways  are  known  to  be  involved  in  controlling  numerous 
physiological  and pathophysiological  processes  including  proliferation  (Pearson  et 
al,  2001).  The anti-proliferative properties of CNP have been well-characterised, 
especially in the vasculature, but the receptor and the signalling pathways involved 
in mediating this effect are not clearly defined.  CNP, which acts as a local mediator 
in  the  vasculature  has  been  shown  to  act  through NPR-B/cGMP  (Marumo  et al, 
1995) as well as in a cGMP independent manner (e.g. through NPR-C/Gj-coupling) 
as shown in the resistance arteries  (Chauhan et al, 2003b).  Since CNP was able to 
elicit  a  transient  increase  in  ERK  1/2  and  p38  phosphorylation,  and  all  three 
natriuretic peptide receptors have been  found to  be expressed in  1° RAoSMC,  the
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involvement of the MAPK pathways in the anti-proliferative actions of CNP, and the 
receptor responsible, were investigated.
There  is  compelling  evidence  for  the  involvement  of GPCRs  in  cell  growth  in 
association with the  MAPK  signalling pathway  (Gutkind,  1998a;  Gutkind,  1998b; 
Gutkind, 2000; Waters et al., 2004).  Ligands as diverse as bombesin, endothelin-1, 
somatostatin,  thromboxane  A2,  prostaglandin  F2a,  interleukin-8,  vasopressin, 
bradykinin,  angiotensin,  insulin,  PDGF,  epidermal  growth  factor (EGF) and many 
more have been shown to have mitogenic properties involving activation of GPCRs 
and the MAPK signalling pathway (Rozengurt,  1986; Gutkind, 2000).  It is perhaps 
surprising that a number of these mitogens signal through the non-classical GPCR, 
involving  activation  of single  transmembrane  receptors  coupled  to  either tyrosine 
kinases and the small G-protein Ras or heterotrimeric G-proteins (Patel,  2004).  In 
the case of receptor tyrosine kinases (RTKs), upon ligand binding to an extracellular 
binding  domain  the  receptor  dimerises  and  catalytic  activity  increases  enabling 
phosphorylation  of  tyrosine  residues  on  the  intracellular  catalytic  domain,  by 
transferring  phosphates  from  ATP,  a  process  known  as  autophosphorylation 
(Mohammadi  et  al.,  1996).  Once  the  receptor  has  been  phosphorylated  the 
phosphorylation  sites  act  as  docking  sites  for  multiprotein  complexes  including 
proteins  containing  Src-homology  2  (SH2)  or  phosphotyrosine-binding  (PTB) 
domains (Mohammadi et al,  1996).  These protein complexes can then bring about 
the  activation  of Ras,  a  monomeric  GTP-binding  switch  G-protein  that  can  itself 
activate Raf isoforms bringing about MAPK signalling.  In the case of heterotrimeric 
G-proteins  both  free  Ga  and  Gpy  subunits  initiate  downstream  MAPK  activation 
(Hawes et al,  1995).  Recently, natriuretic peptide receptors have been characterised 
to possess G-protein binding domains (Murthy and Makhlouf,  1999; Murthy et al, 
2000; Borges et al, 2001; Alfonzo et al, 2006),  and although they do not possess a 
seven  transmembrane  structure  of  classical  GPCRs,  they  mimic  single 
transmembrane GPCR signalling.  NPR-C is  linked to Goi, which can bring about 
inhibition of adenylyl  cyclase upon  ligand binding (Anand-Srivastava et al,  1996; 
Pagano and Anand-Srivastava, 2001) as well as production of IP3 and DAG resulting 
in PKC activation (Anand-Srivastava, 2005).  It has also been reported that NPR-C is 
implicated in cell  proliferation  through  Garprotein  dependency  (Levin  and  Frank, 
1991;  Cahill  and  Hassid,  1994),  but  whether  this  involves  MAPK  is  not  known.
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NPR-B has also been shown to possess  G-protein binding domains  but little work 
has been carried out in terms of signalling with the involvement of G-proteins from 
this receptor (Borges et al., 2001; Alfonzo et al., 2006).
The  results  presented  herein  demonstrate  that  CNP  causes  an  inhibition  of  1° 
RAoSMC growth (both basal and Ang II-stimulated), that is blocked by the selective 
NPR-C  antagonist  M372049  and  the  ERK  1/2  pathway  inhibitor  PD98059.  The 
transient increase  in ERK  1/2 phosphorylation elicited by CNP is also blocked by 
PD98059,  the  Gj-protein  inhibitor  PTx  and  M372049.  Conversely,  CNP-induced 
p38 phosphorylation was unaltered by M372049 and PTx.  These observations imply 
that CNP is acting through NPR-C and Gj-protein coupling in a cGMP-independent 
manner  to  bring  about  its  anti-proliferative  actions  via  activation  of  ERK  1/2 
phosphorylation.
Although  previous  studies  have  acknowledged  the  inhibitory  effect  of  CNP  on 
vascular smooth muscle growth,  controversy has  arisen when trying to  establish a 
role for a NPR-B (cGMP-mediated) or NPR-C (cGMP-independent) effect.  Furuya 
et al have  reported that  CNP  inhibits  intimal thickening following vascular injury 
accompanied by an increase in cGMP levels (Furuya et al.,  1993) and inhibits DNA 
synthesis and growth in vascular smooth muscle via cGMP-dependent mechanisms 
(Furuya et al., 1991).  This led to the conclusion that NPR-B is probably the receptor 
involved in these  inhibitory effects  (Furuya et al.,  1991;  Furuya et al.,  1993).  In 
accord,  Hutchinson et al have shown that increases in cGMP levels correlate with 
growth inhibition and have further demonstrated that CNP inhibits PDGF-stimulated 
MAPK  activity  (Hutchinson  et  al,  1997).  MAPK  inhibition  by  CNP  has  been 
reported by other groups  in non-vascular cells via NPR-C  (Prins  et al.,  1996) and 
small  cytoplasmic  domain  peptides  of NPR-C  are  able to  inhibit  the  proliferative 
responses  of  vasoactive  peptides  through  Gj-protein  and  ERK  l/2/PI3K/Akt 
pathways in vascular smooth muscle cells (Hashim et al, 2006).  The involvement 
of NPR-C  in  growth  inhibition  is  further  substantiated  by Cahill  et  al who  have 
suggested that CNP inhibits growth in aortic  smooth muscle cells via NPR-C  in a 
cGMP-independent  manner  (Cahill  and  Hassid,  1994).  Furthermore,  growth 
inhibition via NPR-C and decreased adenylyl cyclase activity has been reported in 
gastric epithelial cells (Gower et al., 2006).
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Evidence  from  this  study  confirms  the  anti-proliferative  properties  of  CNP  in 
vascular smooth muscle cells but goes one step further in apportioning a definitive 
role for NPR-C-mediated ERK  1/2 phosphorylation in this phenomenon.  The data 
reveal that the NPR-C antagonist M372049 is able to reverse the growth inhibition 
elicited by CNP; however, this reversal is not complete giving rise to the possibility 
that both NPR-B and NPR-C may coordinate the anti-mitogenic actions of CNP (see 
below).  The results also provide insight into the intracellular pathways that mediate 
the  anti-proliferative  effects  of  CNP/NPR-C  signalling.  Exposure  of  vascular 
smooth muscle cells to CNP causes a rapid, transient increase in the phosphorylation 
of ERK 1/2, a key arm of the MAPK cascade that is well-established to regulate cell 
growth (Pearson et al.9  2001).  The concentrations of CNP (1  pM and  10 pM) that 
elicit significant increases in ERK  1/2 phosphorylation (and inhibit smooth muscle 
proliferation)  are  commensurate  with  those  released  acutely  from  vascular 
endothelial cells by ACh (Chauhan et a l, 2003a; Chauhan et a l, 2003b; Hobbs et al, 
2004).  Moreover,  both  NPR-C  antagonism  and  the  Gj-protein  inhibitor  PTx 
attenuated CNP induced enhancement in ERK  1/2 phosphorylation, suggesting that 
this CNP-triggered activation of the pathway is also NPR-C-dependent.  The ERK 
1/2  pathway  inhibitor,  PD98059  was  employed  to  link  these  two  facets  of CNP 
bioactivity.  In accord with the proposed thesis, PD98059 blocked both the ERK 1/2 
phosphorylation and inhibition of vascular smooth muscle growth induced by CNP. 
Although  a  decrease  in  ERK  1/2  phosphorylation  has  been  reported  to  result  in 
growth inhibition (Prins et al,  1996; Hutchinson et al,  1997), it is also established 
that activation of ERK  1/2 can lead to p2iwafl/c,pl  stimulation and cessation of the 
cell-cycle (Pumiglia and Decker,  1997; Olson et al,  1998; Ray et al,  1999; Figure 
59).  This is exemplified by the study of Bauer et al who reported that NO, a key 
regulator  of  vascular  responsiveness  and  inflammation,  can  increase  ERK  1/2 
phosphorylation and bring about inhibition of cell proliferation in vascular smooth 
muscle cells  (Bauer et al,  2001).  Since NO  and CNP  are both key endothelium- 
derived vasoactive mediators that possess complementary anti-atherogenic functions 
(Ahluwalia and Hobbs, 2005), it is perhaps not surprising that they evoke the same 
intracellular signalling systems to  exert their anti-proliferative effects.  It could be 
speculated that CNP might  increase p2iwafl/c,pl  in  RAoSMC,  akin to NO, and this 
might form part of future studies, which will endeavour to link p2lwaf,/cipl to CNP- 
induced growth inhibition via NPR-C.  Moreover, the anti-mitogenic effects of NO
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and CNP appear to be mediated in a cGMP-independent fashion, despite the ability 
of both  mediators  to  activate  guanylate  cyclase  enzymes  that  synthesise  cGMP 
(Hobbs  and  Ignarro,  1996;  Ahluwalia  et  al.,  2004),  which  is  well-established  to 
inhibit  cell  growth.  It  is  likely,  however,  that  these  discrete  pathways  are  cell 
specific  and  that  in  vascular  smooth  muscle  cells,  the  cGMP-independent  anti- 
mitogenic effects of NO  and CNP predominate.  Moreover,  activation of the ERK 
1/2 pathway by Gj-coupled NPR-C adds a new dimension to the signalling capacity 
of this  receptor and suggests  it  can  fulfil  a role akin to  other well-recognised  G j- 
coupled receptors that activate the MAPK cascade, such as sphingosine-1-phosphate 
and insulin-like growth factor (Zondag et al, 1998; Hallak et al., 2000; Figure 59).
Although NPR-C  is  probably the  primary receptor  responsible  for the  increase  in 
ERK  1/2 phosphorylation and growth inhibition by CNP, NPR-B and cGMP could 
also be involved, as 8-Bromo-cGMP enhances ERK 1/2 phosphorylation in a similar 
fashion to CNP, albeit with a significantly reduced magnitude.  This would fit with 
previous  reports  linking  NPR-B  activation,  cGMP  formation  and  inhibition  of 
mitogenesis (Furuya et al.,  1991; Furuya et al.,  1993; Hutchinson et al.,  1997).  The 
fact that PTx was able to completely abolish CNP-induced ERK 1/2 phosphorylation, 
while  NPR-C  blockade  only  achieved  approximately  70  %  inhibition,  could  be 
explained  by  the  recent  finding  that  NPR-B  also  possesses  G-protein  coupling 
domains  (Alfonzo  et  al.,  2006).  Treatment  with  PTx  could  potentially  eliminate 
signalling  from  both NPR-B  and NPR-C  whereas  M372049  would  solely remove 
NPR-C-mediated effects.  It is also worth noting, that in non-vascular cell types (e.g. 
adipocytes), it has been proposed that non-primate species (e.g. rodents, rabbits and 
dogs) express NPR-C as the predominant receptor with very low expression of NPR- 
A (Sengenes et al., 2002).  Moreover, vascular smooth muscle cells have previously 
been shown to express predominantly NPR-C, although NPR-A and NPR-B are also 
present  (Hutchinson  et  al.,  1997).  This  could  account  for  the  proposed NPR-C- 
mediated effects on ERK 1/2 phosphorylation and growth presented in this study.
CNP  is  a  potent  vasorelaxant  mediator  in  both  conduit  and  resistance  arteries 
(Madhani et al., 2003; Ahluwalia et al., 2004); ANP to the contrary, is a very poor 
relaxant  in  the  mesenteric  resistance  vasculature  (Villar  et  al,  2007),  unlike  its 
strong  relaxant  effects  in  conduit  vessels  (Madhani  et  al.,  2003).  The  lack  of
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responsiveness  to ANP  in mesenteric  resistance  arteries  is  mirrored in the current 
study,  since ANP  was unable  to  induce  ERK  1/2 phosphorylation,  intimating that 
NPR-A does not couple to the MAPK cascade and that ANP cannot activate NPR-C 
to produce an analogous effect to CNP (despite the fact that both natriuretic peptides 
bind NPR-C (Maack et a l, 1987; Matsukawa et al., 1999; Potter and Hunter, 2001)). 
This differential activity, paralleling the observed differences in vasorelaxant activity 
in  resistance  arteries,  may  be  the  result  of the  disparate  binding  characteristics  of 
ANP and CNP at NPR-C (He et al, 2006), and merits further attention.
In addition to the importance of NPR-C to the vasodilator properties of endothelium- 
derived  CNP  in  the  resistance  vasculature,  endothelial  CNP  contributes  to  the 
regulation of coronary blood flow and is a protective mechanism against ischaemia- 
reperfusion injury; these actions are also mediated via NPR-C (Hobbs et al, 2004). 
Moreover,  the  importance  of  CNP  in  the  vasculature,  particularly  during 
inflammatory disease, has been highlighted by the fact that it possesses  significant 
anti-leukocyte  and anti-platelet  effects;  again these  effects have been attributed to 
NPR-C activation (Scotland et al, 2005a).  Taken together, these observations stress 
the importance of NPR-C signalling in bringing about the anti-atherogenic properties 
of CNP and data from the present study reveal that the anti-mitogenic properties of 
CNP  are an  additional  cytoprotective property of this  endothelium-derived peptide 
that can be attributed to NPR-C.
Future studies will be required to investigate further the signalling cascade that leads 
to  CNP-induced  ERK  1/2  phosphorylation and  growth  inhibition  in  an attempt to 
elucidate  other  members  of this  signalling  pathway.  It  is  known  that  signalling 
through Gi-coupled receptors can lead to Src tyrosine kinase activation (Milligan and 
Kostenis, 2006), which lies upstream of ERK 1/2.  Furthermore, Src tyrosine kinase 
and  ERK  1/2  can  modulate  eNOS  activation  (Fulton  et  al,  2005),  which  could 
subsequently inhibit growth  (Cooney et al,  2006).  Therefore,  the  effects of CNP 
and M372049 on Src tyrosine kinase and eNOS should be investigated.  In addition, 
the effect of ANP and CNP on the third component of the MAPK family cascade, 
JNK/SAPK, might be investigated since this arm of the MAPK family is also known 
to  play  a  key  role  in  mediating  cell  differentiation  and  apoptosis  during 
atherosclerotic plaque development (Metzler et al, 2000).
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6.8.  Conclusions
In conclusion the results from the current study indicate for the first time that NPR-A 
KO  mice  are  less  susceptible  to  LPS-induced  endothelial  dysfunction.  This  is 
accompanied  by  reduced  iNOS  expression  and  plasma  NOx,  suggesting  that 
ANP/BNP, possess a pro-inflammatory role in sepsis.  Despite these observations in 
vivo,  ANP  and  CNP  were  unable  to  modulate  iNOS  expression  and  activity  in 
murine  macrophages  and  1°  RAoSMC.  Furthermore,  the  p38  MAPK  cascade 
inhibitor  SB203580  inhibits  LPS  and cytokine-induced iNOS  in  1° RAoSMC,  but 
this was not mimicked by the ERK 1/2 inhibitor PD98059, giving a role for p38 but 
not ERK 1/2 signalling in the regulation of iNOS expression in these cells.
I have also demonstrated that CNP enhances ERK  1/2 phosphorylation and inhibits 
cell  proliferation  via  NPR-C  involving  Gj-coupling.  These  data  strengthen  the 
evidence supporting NPR-C signal transduction as a principal mechanism conveying 
the anti-atherogenic actions of this peptide.  Together with previous work (Cahill and 
Hassid, 1994; Chauhan et a l, 2003b; Hobbs et al., 2004; Scotland et al., 2005a), it is 
clear that CNP has an important role to play in maintaining vascular homeostasis at a 
local level.  The NPR-C-dependent anti-proliferative properties of CNP highlighted 
in this study could prove a novel means of therapeutic intervention in the treatment 
of inflammatory cardiovascular diseases such as atherosclerosis, sepsis and coronary 
artery disease.
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Figure 59 -  Schematic of established signalling pathways involved in MAPK activation by G- 
protein  coupled  receptors  (A)  and  proposed  mechanism  by  which  CNP  may  exert  effects  on 
growth inhibition via ERK 1/2 phosphorylation (B).
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